Oesophageal Cancer: Staging, Surgery and Survival by Talsma, A.K. (Aaldert)
209846-L-os-Talsma Processed on: 9_17_2015
O
esophageal cancer  -   S
taging, S
urgery and S
urvival                                                               A
aldert K
onraad Talsm
a
Many improvements have been made in the treatment of oesophageal 
cancer. Surgical techniques have been refined, multimodality treat-
ment has become the standard of care and nationwide quality audits 
have been introduced. Nevertheless, there are some persevering chal-
lenges in the treatment of oesophageal cancer and its complications: 
1. with current staging modalities, even after radical surgery, many pa-
tients suffer from early recurrence (“challenge to stage”) ; 2. more than 
half of the patients who undergo surgery will still die from oesophageal 
cancer  (“challenge to cure”) ;  3. complications after surgery cannot 
always be treated early and appropriately (“challenge to rescue”) ; 4. 
surgery alone, without preceding neoadjuvant therapy, too often has 
the disadvantage of involved surgical resection margins (“challenge 
to resect”); 5. there is a striking rise in the incidence of oesophageal 
adenocarcinoma, especially in the Western hemisphere, which is only 
partly understood (“challenge to prevent”).
This thesis includes clinical studies that address these issues which 
are still present in treating this devastating disease.
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InTROdUCTIOn
Oesophageal cancer is a challenging malignancy of cancer for many reasons, requiring the 
interdisciplinary approach of e.g. surgeons, gastroenterologists, medical and radiation on-
cologists, intensivists, radiologists, nuclear physicians, pathologists, dieticians and special 
care nurses. Since the first successful oesophagectomy for cancer was performed in 1909 
in the United States by Franz Torek (a son of German U.S. immigrants), many improvements 
have been made in the treatment of oesophageal cancer. Postoperative mortality rates have 
decreased from 30% in the 1950s-60s to 13 % in the 1980s and less than 5 % nowadays 
in experienced hands. Surgical techniques have been refined and multimodality treatment 
has become the standard of care. Other recent developments include the introduction of 
nationwide quality audits. Although these developments have contributed to an increased 
quality of care, there are some persevering “failures” that persist in the treatment of oe-
sophageal cancer and its complications. This leaves room for ongoing research into this still 
devastating disease. 
In the first place involved physicians are faced with the  aggressive natural behaviour of 
this disease with early lymphatic and distant dissemination. Most patients present with ad-
vanced disease, leaving only 30-40% of patients suitable for potentially curative treatment. 
Even after radical surgery many patients suffer from early recurrence, suggesting a “failure 
to stage” by current staging modalities. Although long-term survival rates have improved, 
there is still a “failure to cure” in more than half of the patients who undergo surgery, which 
has led to the recent implementation of (neo-)adjuvant chemotherapy with or without radio-
therapy.
Secondly, there is the surgical resection. For many years surgery alone, without 
preceding neoadjuvant therapy, had the disadvantage of “failure to resect” leading to in-
volved surgical resection margins. The required oncological radicality in close vicinity to 
several vital anatomical structures (heart, aorta, trachea) makes an oesophagectomy proba-
bly one of the most challenging procedures in surgery. Moreover the continuity of the upper 
gastrointestinal tract has to be reconstructed, with its associated postoperative morbidity 
and even mortality, especially when complications cannot be treated early and appropriately 
(“failure to rescue”). 
In the third place there is a striking rise in the incidence of oesophageal (adeno-) car-
cinoma, especially in the Western hemisphere, which is only partly understood. This “failure 
to prevent” is beyond the scope of the present thesis.
Outline of the thesis
This thesis includes clinical studies that address the themes as mentioned above and focus 
on recent developments in surgery (Part I), staging (Part II) and survival (Part III) of oesoph-
ageal cancer patients.
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PART I – GOAlS Of SURGICAl ThERAPy fOR OESOPhAGEAl CAnCER
Although during the past decade multimodality treatment has become standard of 
care, surgery is still a crucial part in the potentially curative treatment of oesophageal cancer 
patients. In Chapter 2 an overview of the literature on goals of surgical therapy is presented 
including radical resection, appropriate lymph node retrieval, gastrointestinal reconstruction 
and the limitation of the related morbidity and mortality. Two different surgical approaches 
are discussed:  the  transthoracic oesophagectomy (TTO) with extended lymphadenectomy 
of the middle and lower mediastinal nodes versus  the less invasive  transhiatal oesophagec-
tomy (THO), in which only the perioesophageal nodes and the nodes  in the upper abdomen 
are removed. Arguments for more extensive surgery  are optimal staging, better locoregional 
control and thus potentially improved cure rates. However, four randomised controlled trials 
comparing TTO and THO have been published which have failed to demonstrate significant 
differences between the two approaches. The same debate is going on for the extent of 
lymphadenectomy: a more extended lymph node dissection contributes to the accuracy of 
staging the disease, but there is still no evidence whether it really contributes to an improved 
survival. In Chapter 2 also an overview of the optimal pretreatment workup is provided and 
a paragraph is devoted to definitive chemoradiotherapy as an alternative for potentially cu-
rative resection. Non-surgical therapies with the aim of palliation are beyond the scope of 
this thesis.
PART II - STAGInG Of OESOPhAGEAl CAnCER bASEd On lymPh nOdE 
InvOlvEmEnT
Oesophagectomy for cancer should only be undertaken when a potentially curative R0 re-
section (complete removal of all – macroscopic -  cancer) is expected. It is generally accept-
ed that there is no role for resection in the presence of proven distant metastases (e.g. liver, 
lung) no matter how localized. This makes preoperative staging of crucial importance. Long-
term outcome of oesophageal surgery is strongly stage dependent. For over 50 years the 
TNM classification has been the standard in classifying the anatomic extent of the disease, 
reflecting the depth of infiltration (T) and lymphatic (N) and haematogenous (M) spread. In 
2010 the latest, 7th edition of the Union Internationale Contre le Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC) TNM staging system was presented as the 
ratification of data-driven recommendations from a worldwide database of thousands of 
patients with predominantly squamous cell carcinoma. The most important change in this 
7th edition of the TNM staging system is that N-stage is defined as the number of involved 
nodes.  Another change in the 7th edition of the TNM staging system is that the concept 
of non-regional lymph nodes (for example celiac lymph node metastases scored as ‘M1’ in 
TNM6) has been abandoned. But although the TNM staging system has been revised from 
a site-dependent to a numerically based classification, many oesophageal cancer surgeons 
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have the impression that the location of a positive node is still important, not only for long 
term survival but also for (pre-)operative planning. In Chapter 3 a hypothesis-generating 
study is presented that investigates whether incorporation of information concerning the 
location of involved nodes besides the number of nodes refines its prediction accuracy, not 
only based on pathological staging of the surgical specimen but also on clinical staging with 
preoperative EUS.
It is unknown whether TNM-7 is also generalisable to patients who have undergone 
a transhiatal approach resulting in pathological specimens with less lymph nodes which 
potentially impairs the accuracy of staging. Therefore, in Chapter 4, the performance of the 
7th edition of the TNM staging system for oesophageal cancer is described in a study pop-
ulation of patients with adenocarcinoma who underwent a transhiatal approach. 
Besides its potential impact on staging and prognostication that will be addressed 
in Chapter 3 and 4, more extended lymph node retrieval potentially has also a genuine 
therapeutic impact on survival. However, this has remained a highly controversial issue for 
decades. The debate has regained attention especially after the broad implementation of 
neoadjuvant chemoradiotherapy (nCRT). As nCRT  is known for its ‘sterilising’ impact on 
regional nodes, it is unclear whether extended lymphadenectomy after nCRT is still indicat-
ed for prognostic and perhaps even therapeutic reasons. In Chapter 5 the impact of the 
neoadjuvant CROSS regimen on the assumed association between the number of removed 
nodes and survival is investigated. 
PART III – SURvIvAl AfTER SURGICAl RESECTIOn Of OESOPhAGEAl CAnCER
Surgical resection of oesophageal cancer is still accompanied by a wide variety of compli-
cations, inducing substantial morbidity and even mortality. There is an increasing interest 
in performance indicators because the effectivity of managing these complications varies 
substantially between institutes. Currently, it is unclear which definition of postoperative 
mortality best reflects quality of surgical care and how many additional deaths are captured 
if the time window is expanded after the traditional postoperative period of 30 days. In Chap-
ter 6 causes of death are described as a function of time after surgery and a proposal is 
made for the ideal time frame as a proxy for quality of surgical care. Additionally, a case-mix 
adjustment model is presented for comparison of postoperative mortality after oesophagec-
tomy between institutes.
Many factors have been held responsible for the improved long-term survival that have 
been achieved over the previous decades, including centralization of care, early tumor de-
tection, improved patient selection based on novel staging modalities, increased use of 
neoadjuvant therapy, better surgical and anaesthesiological techniques and detailed and 
standardised perioperative clinical pathways. There is also evidence confirming the influ-
ence of surgeon case volume on the outcome of oesophageal surgery. Each of these factors 
has been investigated separately in relation to survival after oesophagectomy in previous 
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(sometimes even randomised) studies. The combined implementation of these improve-
ments and their impact on survival on a population-based level are unknown. In Chapter 
7 patient-, tumour- and treatment- characteristics are studied contributing to the previously 
observed trend of increased survival after oesophagectomy for cancer in the Netherlands. 
Furthermore, it is analyzed whether the positive impact of multimodality therapy as shown by 
the randomised CROSS trial can be corroborated on a population-based level.
Future perspectives on oesophageal cancer surgery, staging and survival are given in 
Chapter 8 and a summary of the thesis is presented in Chapter 9.
209846-L-bw-Talsma
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Goals of surgical therapy for 
esophageal cancer
A.K.TALSMA, 
J. SHAPIRO, 
B.P.L. WIJNHOVEN, 
J.J.B. VAN LANSCHOT
Chapter in: Mimimally invasive foregut surgery for malignancy: principles and practice 
(Springer 2015, Editor: Steven N. Hochwald).
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1. InTROdUCTIOn
Operative resection of esophageal cancer is probably one of the most challenging pro-
cedures in surgery. Partly this is because it encompasses two or even three body com-
partments: chest and abdomen with or without neck. Moreover, its position immediately 
adjacent to vital structures (trachea, bronchi, aorta and heart) warrants a careful dissection. 
With the recent introduction of minimally invasive esophagectomy, the operation has be-
come technically even more demanding. This chapter describes the surgeon’s main goals 
when performing a potentially curative esophagectomy for esophageal cancer, regardless 
of the surgical approach that is chosen.  The various indicators that have been identified to 
promote oncological control in open surgery will be discussed as well as the tools that help 
to prevent complications. 
In fact, these same goals have to be set for minimally invasive esophagectomy.
2. PRETREATmEnT wORK-UP And STAGInG
multidisciplinary approach
In patients with esophageal cancer a great variety of treatment options are available. For 
proper medical decision making accurate pretreatment staging is of crucial importance. 
Early (mucosal) lesions for example can be cured with endoscopic mucosal resection, thus 
avoiding conventional surgery. At the other end of the clinical spectrum, accurate pretreat-
ment staging is also essential to avoid futile attempts at radical treatment for patients that 
are in fact incurable due to distant metastases and to guide effective palliation that can be 
achieved with endoscopic stenting or intraluminal brachytherapy. Discussion of all patients 
with esophageal malignancies in a multidisciplinary tumor board is recommended because 
it is associated with improved outcomes after surgery[1, 2]. In a considerable number of 
patients, the diagnostic work-up or treatment plan is altered after careful evaluation in a 
multidisciplinary tumor board[3]. Adenocarcinomas arising at the esophago-gastric junction 
can pose a specific problem for guiding the choice between neoadjuvant chemo- versus 
chemoradiotherapy and between subtotal esophagectomy versus extended gastrectomy. 
At present, Siewert type I and II tumors are treated as esophageal cancers while type III 
tumors are generally treated as gastric cancers.
Patient selection : does the general condition of the patient allow for extensive surgery?
The pretreatment assessment should not only focus on tumor staging but also on opti-
mization of the patient’s general condition. The success of a specific treatment modality 
does not only depend on the tumor-stage, but also on the fitness of the patient. Surgery for 
esophageal and junctional cancer has a high risk of postoperative (especially pulmonary) 
complications. Several risk scoring systems have been developed as predictors of poor 
postoperative outcome. These scoring systems can be used for the individual patient to 
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guide treatment choice. Moreover, these scoring systems can be used to correct for case-
mix differences when comparing performance between hospitals. The prognostic value of 
the available models however is generally limited. Worldwide, the most widely used and 
most simple classification is that of the American Society of Anesthesiologists[4], but has 
been criticized for being subjective. The POSSUM[5] and Charlson score [6] are more 
comprehensive but are also more cumbersome to calculate[7]. Several series have shown 
that POSSUM and Oesophageal(O)-POSSUM[8] overestimate postoperative mortality in 
gastro-esophageal cancer patients[9-11]. The Portsmouth(P)-POSSUM showed less over-
estimation and may be the most useful predictor of likely postoperative mortality in these 
types of patients[12]. Older age (e.g. >80 years) per se is not a contraindication for upper 
GI surgery, but older patients have increased postoperative mortality and decreased long-
term survival after esophageal resection for cancer[13, 14]. Substantial weight loss before 
surgery was also a negative prognostic factor in several studies [15, 16]. 
TUmOR SElECTIOn: CAn ThE TUmOR bE RAdICAlly RESECTEd And POTEnTIAlly 
CUREd?
Over the past decades, long-term survival results have substantially improved. Besides cen-
tralization of surgical procedures, early cancer detection, and use of neoadjuvant therapy, 
improved patient and tumor selection based on novel staging modalities accounts for this 
improvement[17, 18]. 
Guidelines for pretreatment staging of patients with esophageal and junctional cancer 
recommend a number of investigations, including endoscopy with biopsy, endoscopic ultra-
sonography (EUS), computed tomography (CT) of neck, chest and abdomen, and external 
ultrasonography (US) of the neck with fine needle aspiration (FNA) of suspected lymph 
nodes. In addition, positron emission tomography (PET) can also be a useful staging modal-
ity, albeit not yet mandatory in e.g. Dutch, UK and USA guidelines. In case of an advanced 
tumor above the carina bronchoscopy is advised to confirm or exclude invasion of the tra-
cheobronchial tree. Clinical and histopathological staging is generally based on the tumor/
node/metastasis (TNM) classification developed by the Union Internationale Contre le Can-
cer (UICC) and the American Joint Committee on Cancer (AJCC)[19]. The most important 
change in the latest (7th) edition is that the concept of non-regional lymph nodes has been 
abandoned and that staging of tumors in the esophagus, at the esophogastric junction and 
in stomach has been harmonized. Number of positive lymph nodes is now more important 
than their location.
EUS
EUS is superior to any current diagnostic modality for imaging of the primary tumor and its 
immediate surroundings (T- and N-stage) due to its ability to identify the component layers 
of the esophageal wall[20, 21]. The main problem with EUS is failure to pass in 1 out of 5 
209846-L-bw-Talsma
16
Chapter 2
2
patients[22]. FNA of suspected nodes is only indicated when the results will change the 
treatment plan (e.g. radiation field). EUS can identify metastatic lymph nodes at the celiac 
trunk, but is not accurate in detecting distant metastases, with the exception of  hematog-
enous metastases in the left liver lobe and left adrenal gland. FNA of the celiac nodes is 
technically feasible in 95 % of patients[23]. 
CT and external US
Spiral CT and external US are used for the detection of distant hematogenous and lymphat-
ic metastases (M-stage). Probably, PET scanning can replace US of the neck, although 
it is generally recommended to confirm suspected lymph nodes by US-FNA to exclude 
false-positivity of the PET scan (e.g. due to sarcoidosis)[24]. The ability to accurately predict 
locoregional resectability is especially important before embarking upon a thoracoscopic or 
laparoscopic surgical approach to minimize the risk of accidental damage. For this purpose, 
CT continues to play an important role. Invasion into adjacent organs is unlikely when a per-
iesophageal fat plane can be recognized, but when absent, it cannot be taken as absolute 
evidence of invasion. This accounts for the overestimation of tumor invasion into trachea, 
aorta and pericardium.  
PET
PET is a non-invasive imaging technique which is increasingly used in the staging of various 
tumor types, including esophageal cancer[25, 26]. The increased glucose metabolism of 
malignant cells is the driving force for the uptake of fluorine-18-fluorodeoxyglucose (FDG), 
which is the most common radiotracer used for oncological PET studies. In addition to 
qualitative staging (esp. detection of distant metastases), PET is able to quantify FDG-up-
take in malignant tissue by calculating the standardized uptake value (SUV) of the primary 
tumor. After extensive “conventional” diagnostic work-up, additional PET scanning yields 
a diagnosis of distant dissemination in an additional 10% of patients, especially in case of 
T3-tumors[27]. The simultaneous, combined PET- and CT-scan is able to localize and clas-
sify hotspots more accurately than PET alone.
Intraoperative staging by laparoscopy and sentinel node biopsy
Although inconsistently applied, a systematic review has recommended the use of staging 
laparoscopy in junctional cancer patients [28], especially for demonstrating low-volume peri-
toneal disease. 
The value of sentinel node (SN) sampling in esophageal cancer is less clear than for 
e.g. breast cancer and malignant melanoma. In a British study, 96% of SN biopsies accu-
rately detected lymph node metastatic disease[29]. In another study, however, so-called skip 
lesions were identified in 55% of resected two-field lymphadenectomy specimens[30-32]. 
Currently, a multicenter trial in Japan is being performed, in which the extent of lymph node 
dissection during gastric surgery is tailored depending on the SN biopsy[33].
209846-L-bw-Talsma
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Re-staging
After completion of neoadjuvant therapy patients can be restaged to evaluate response 
to treatment and to detect any progression of disease before proceeding to surgery. The 
assessment of nodal disease following chemoradiotherapy by EUS and CT is disappointing 
because viable tumor cannot be readily distinguished from fibrotic tissue[32, 34]. Studies 
with PET especially when measuring SUV before and after chemotherapy have been en-
couraging[35, 36]. Unfortunately, tumor response assessment by PET after neoadjuvant 
chemoradiotherapy is hampered by radiation-induced inflammation.
future developments
Recently, more research has focused on staging techniques that address the biological 
behavior of tumors which is important in the response to chemoradiotherapy and likelihood 
of recurrence. This can be achieved by PET scanning with novel radiotracers such as (18)
F FLT 3-deoxy-3-fluorothymidine or (11)C-choline[37, 38]. Other studies focus on MRI as a 
potential non-invasive technique for locoregional staging of esophageal cancer[39]. Encour-
aging results have been achieved in the  rapidly improving technology of in vivo intraopera-
tive imaging as well[40]. 
3. dEfInITIvE ChEmORAdIOThERAPy: An AlTERnATIvE fOR POTEnTIAlly CURA-
TIvE RESECTIOn?
In recent years two randomized controlled trials compared definitive chemoradiotherapy 
(dCRT) to neoadjuvant chemoradiotherapy plus surgery (nCRT+S). Both studies employed 
a non-inferiority design to test the chance that patients in both treatment paradigms have a 
significantly different survival.
The first study by Stahl et al. [41] included 172 patients between 1994 and 2002 from 
11 German centers. It compared dCRT (without salvage surgery) with nCRT+S for ‘locally 
advanced’ (i.e. T3-4, N0-1, M0) esophageal squamous cell carcinomas. Two-year survival 
was 35.4% and 39.9% in the dCRT arm and nCRT+S arm, respectively (P= 0.007). Free-
dom from local progression was worse in the dCRT arm (40.7% vs. 64.3% respectively; HR 
2.1 P=.003). A significant difference was found in treatment related mortality: 3.5% in the 
dCRT arm and 12.8% in the nCRT+S arm (‏2, P= .03). In summary, there was no difference 
in overall survival, however local failure was more common, and treatment-related death was 
less common in the dCRT arm.
The second randomized controlled trial (FFCD 9102) [42] compared dCRT to nCRT+S 
in patients who had an objective clinical response or an improvement of dysphagia after ne-
oadjuvant chemoradiotherapy (259/444, 58.3%). Two-year survival rates for the dCRT arm 
and nCRT+S arm were 39.8% and 33.6% respectively (P= 0.03, i.e. the chance that the 
actual difference is >10%). Three-month mortality (0.8% versus 9.3%, P=0.003) favored 
the dCRT arm, whereas locoregional relapse (43.0% versus 33.6%, HR 1.63, P= 0.03) 
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favored the nCRT+S arm. 
Both studies suffered from major drawbacks (e.g. inadequate power and lack of stand-
ardized chemoradiotherapy protocols), thus precluding more general conclusions from 
these data. This ambiguity towards dCRT is reflected in clinical practice where in most 
countries dCRT is reserved only for those patients who are deemed unfit for surgery.
4. SURGICAl PERfORmAnCE IndICATORS : On whICh PARAmETERS ShOUld mIE 
bE jUdGEd?
Resection margins
The main goal in the surgical treatment for esophageal cancer is the complete removal of the 
primary tumor and affected lymph nodes. As esophageal cancer easily spreads longitudi-
nally via the submucosal lymphatics, the incidence of intramucosal and submucosal metas-
tases is reportedly high (Figure 1). The completeness of resection of the primary tumor and 
its intramural metastases can be described with respect to the proximal, distal, and circum-
ferential resection margin and is a well-known determinant of long-term survival in several 
studies[43-46]. Previous studies have investigated the required length of macroscopic prox-
imal and distal resection margins in order to minimize anastomotic recurrence. A reasonable 
margin is 10cm for larger tumors and 4 cm for more localized tumors[47]. When only a short 
proximal resection margin can be obtained through the thoracic exposure (especially for a 
squamous cell carcinoma) a cervical extension with subtotal esophagectomy is advisable. 
An adenocarcinoma of the lower esophagus requires an extensive sleeve resection of the 
lesser curve and fundus to minimize positive distal resection margins.
An esophageal resection can be suboptimal due because of an involved circumferen-
tial margin. The definition of circumferential resection margin (CRM) involvement remains 
controversial. The College of American Pathologists (CAP) and the Royal College of Pathol-
ogists (RCP) use different definitions for CRM involvement. Microscopic tumor involvement 
(R1 resection) is defined by CAP as as tumor found at the cut circumferential resection 
margin, while it is defined by RCP as any tumor within 1 mm of the circumferential resec-
tion plane. Recently, a systematic review was published of fourteen studies involving 2,433 
patients. Rates of CRM involvement were 15.3 per cent and 36.5 per cent according to the 
CAP and RCP criteria respectively. It was shown that CRM involvement is an important 
predictor of poor prognosis and that the CAP criteria had a greater (negative) prognostic 
power than the RCP criteria[48]. It can be difficult and time-consuming to identify a positive 
circumferential resection margin in a large T3 tumor and it has been suggested that this 
should preferably be done in accordance with the CAP criteria (tumor is found at the inked 
lateral margin of resection[49]. There has been a significant decrease in CRM involvement 
especially with the introduction of neoadjuvant chemoradiotherapy[17, 50]. After neoadju-
vant chemotherapy CRM involvement still has prognostic importance[51].
209846-L-bw-Talsma
19
Goals of surgical therapy for esophageal cancer
2
lymphadenectomy
As esophageal cancer readily spreads longitudinally in the submucosal lymphatics, early 
dissemination to lymph nodes in the chest and abdomen may be involved in cancer of all 
parts of the esophagus. And even skip metastases, defined as positive distant lymph nodes 
in combination with negative regional lymph nodes, are encountered relatively frequent-
ly[52]. Lymphatic dissemination occurs not only in a chaotic pattern, but also at an early 
stage. Some 30% of the T1b tumors (with infiltration limited to the submucosa) already have 
positive lymph nodes involved[53]. Ideally, a complete resection of all locoregional nodes 
draining the esophagus should include the two or three fields (see above) in addition to the 
easily accessible periesophageal and perigastric lymph nodes (Figure 2). In a survey among 
surgeons around the world, the techniqually challenging three-field lymphadenectomy was 
performed routinely by only 12% of the responders[54]. A SEER analysis showed that the 
median number of total lymph nodes resected in over 5,600 esophagectomies was only 8 
nodes[55]. Lymphadenectomy can be performed safely during minimally invasive surgery 
and it has been shown that minimally invasive and robotic esophagectomy have similar lymph 
node retrieval compared to open techniques[56-58].
For staging purposes it is clear that an extended lymphadenectomy is superior to a 
limited dissection. It has, therefore, been suggested by the 7th edition of the TNM staging 
system that for staging purposes the total number of resected and identified lymph nodes 
should be at least 15 nodes. The therapeutic impact of an extended lymphadenectomy is 
still a matter of debate in esophageal cancer surgery[59]. Some authors state that surgery 
has reached its limit, while others believe that the course of the disease can be influenced 
positively by aggressive surgery with an extended lymphadenectomy. One of the hypotheses 
supporting the benefits of extended lympadenectomy is the clearance of micrometastases 
that can be present in up to 50% of histology-negative nodes. This hypothesis is supported 
by the correlation of micrometastases in routine lymph node-negative patients with a poor 
outcome[60, 61]. 
More skeptical authors believe that the therapeutic impact of an increased lymph node 
harvest per se is limited and it is probably not the type of operation performed that makes a 
difference but rather the stage of the disease at the time of operation[56]. According to this 
view, lymph node metastases are markers of systemic disease and removal of the primary 
lesion alone will yield the same survival[62]. The spurious effect of extended lymphadenec-
tomy might then be caused by stage migration which occurs if positive nodes in the extend-
ed field change N stage. This results in the so-called ‘Will Rogers phenomenon’ or ‘stage 
purification’ and leads to unreliable stage-by-stage comparisons of survival. For that reason 
some authors prefer to use the lymph node ratio (i.e. the number of positive nodes over the 
number of removed nodes) rather than the absolute number of positive nodes[63, 64]. 
Several prospective trials have been performed comparing survival after esophagectomy 
with or without extended lymphadenectomy. In the largest RCT (HIVEX-trial), comparing lim-
ited transhiatal esophagectomy and extended transthoracic esophagectomy with two-field 
lymphadenectomy, five-year survival was not significantly different[65, 66]. The survival ben-
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efit of an extended lymphadenectomy by a transthoracic approach was limited to a subgroup 
of patients with low burden of nodal disease (1 to 8  nodes positive on pathological exam-
ination of the resection specimen). The identification of this group makes the pretreatment 
staging very challenging. Unfortunately, unlike in breast cancer, the sentinel node concept 
has not become popular in esophageal surgery[29, 31]. Several studies have confirmed the 
higher morbidity after thoracotomy than after transhiatal apporach: more pulmonary compli-
cations, more recurrent nerve injuries and higher early mortality [67-69].
Meta-analysis of the available literature data did not show differences in survival be-
tween transhiatal and transthoracic operations. Other studies compared fields of dissection, 
for example the single-center studies by Lerut et al [70] and Altorki et al [71] that suggested 
a potential survival benefit for three-field lymphadenectomy. 
Finally, there are studies that investigated the absolute number of nodes dissected. 
This has led to different recommendations regarding the optimal extent of lymphadenectomy 
ranging from 16-30 nodes. In a population of 4,627 patients in the Worldwide Esophageal 
Cancer Collaboration (WECC), extent of lymphadenectomy was not asscociated with in-
creased survival for patients with extremes of esophageal cancer (TisN0M0 and 7 or more 
nodes positive and those with well differentiated pN0 cancer[72]. For all other cancers, five-
year survival improved with increasing extent of lymphadenectomy. Based on these WECC 
data a stage-dependent extent of lymphadenectomy was recommended. This is compa-
rable to the findings of the HIVEX trial that showed a better survival after a transthoracic 
approach in the subgroup of patients with 1-8 nodes positive[66]. Rizk et al identified 18 
nodes resected as the minimum necessary for accurate staging and for eliminating an effect 
of lymphadenectomy on survival[73]. In the study by Altorki et al effect of lymphadenectomy 
on survival was lost after 25 nodes for early stage and after 16 nodes in stage III and IV 
cancers[71]. Peyre et al investigated an international database of 2,303 esophagectomies 
in which survival was maximized with 23 nodes resected[74]. 
Nowadays, multimodality treatment of esophageal cancer has been widely accept-
ed. As neoadjuvant chemoradiotherapy (CRT) is known to ‘sterilize’ nodes, it is unclear 
whether the recommendations for number of lymph nodes from the surgery-alone era still 
stand. Extended lymphadenectomy seems to be beneficial, particularly in patients who are 
not down-staged regarding pathological tumor depth (ypT) and those with persistent nodal 
metastases (ypN+)[75, 76]. The effect of lymphadenectomy is influenced by tumor response 
after CRT and the survival benefit is stronger in patients without a complete pathological 
response (non-pCR) compared to those with pCR[77].
morbidity – Prevention of complications
The typical esophageal cancer patient suffers from several co-morbidities including obesity 
(especially in adenocarcinoma) and cardiopulmonary diseases (in both squamous and ade-
nocarcinoma) that put the patient at increased risk for postoperative complications. Serious 
intraoperative and postoperative complications can occur with minimally invasive as well as 
open techniques, also depending on the need of a thoracic phase of the operation. Overall, 
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complication rates are reported in over 50% of esophagectomy series, with incidence var-
ying between 17 and 74%[78, 79]. Postoperative complications have been directly linked 
to a variety of other outcome parameters including mortality, readmission rate, early cancer 
recurrence, survival, length of hospital stay, costs and resource utilization and quality of 
life[80-83]. The most important issues in the management of perioperative complications 
are prevention and early detection. However, a clear understanding of the relationships 
between complications, their recognition, management and how they influence subsequent 
mortality, is hampered by the lack of standardized definitions [84, 85]. Finally, early detec-
tion and proper management of postoperative complications is of crucial importance. It has 
been shown repeatedly that the so-called “failure to rescue” largely explains the difference 
in mortality rates between low-volume and high-volume hospitals for complicated surgery 
including esophagectomy[86].
The exact role for minimally invasive techniques is still not fully clear. The increased 
magnification offered by thoracoscopy might decrease complications, but lack of tactile 
control is probably a contributory factor to the increase of intraoperative injuries. It is unlikely 
that minimally invasive methods will reduce mortality rates since in experienced centers 
death after open esophagectomy is already a rare event. Minimally invasive esophagectomy 
(MIE) might be proven superior for other endpoints such as blood loss, duration of ICU 
or hospital stay, need for analgesics and pulmonary function. The best available evidence 
comes from a recently published RCT (TIME-trial) showing that MIE is accompanied by less 
pulmonary complications[87]. This trial has been criticized because of the lack of a clear 
definition of “pulmonary complications” as the primary endpoint[88]. Moreover, an unex-
plained increase of recurrent nerve injuries was present in the open group. 
Respiratory complications
Respiratory failure is a major problem after esophagectomy. Several studies have reported 
that about half of the in-hospital deaths after esophagectomy is due to pneumonia, which 
is the most frequent general complication after surgery[89]. Preventive measures include 
preoperative respiratory training, cessation of smoking and continuous postoperative pain 
control by epidural analgesia in order to avoid restrictive respiration and insufficient cough-
ing. Micro-aspiration as a consequence of impaired swallowing coordination because of 
a cervical anastomosis also plays a role in the pathophysiology of bronchopneumonias. 
Another reason for postoperative respiratory impairment is a large pleural effusion, which 
should be drained if provoking extended atelectasis. Avoiding the need for a combined thor-
acotomy and laparotomy may potentially reduce postoperative pain, ventilator dependence 
and cardiopulmonary complications[90]. In a study comparing thoracoscopic resection with 
a historical cohort the overall incidence of pulmonary complications was reduced from 33% 
to 20%[91]. Probably cardiopulmonary complications do not depend on the incision size 
only. The benefit of smaller port sites that are needed during minimally invasive surgery may 
be offset by the lengthened time of operation and single-lung ventilation. 
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Recurrent laryngeal nerve injury
More recurrent laryngeal nerve injuries when using thoracoscopy have been reported, which 
might be attributed to the use of diathermia. Others claim that the use of minimally invasive 
techniques has lowered the incidence of hoarseness because of the magnified view[87].
Anastomotic leakage
Lack of standardization of definitions is a problem when reporting on complications. In a re-
cent meta-analysis anastomotic leakage was reported in most of the publications, but it was 
defined in only a minority with 22 differing definitions [84]. Early disruption of the esophago-
gastric anastomosis is the result of a technical problem and immediate re-exploration is fre-
quently indicated for correction. Many different suturing and (semi-) mechanical techniques 
have been described. The semimechanical side-by-side technique claims a lower leakage 
rate compared to a hand-sewn anastomosis, but has not been tested in a randomized tri-
al[92, 93]. Leakage is more frequent in the neck than in the chest, but the associated mor-
tality might be lower, especially after a transhiatal approach[94]. If a transmural necrosis of 
the gastric conduit is suspected, this can be diagnosed by endoscopy and when present is 
also an indication for surgery with formation of a cervical esophagostomy, resection of the 
gastric tube and placement of a feeding jejunostomy. After rehabilitation of the patient, a 
colonic interposition can be performed at a secondary stage. Late disruptions become man-
ifest generally between postoperative day 5 and 10 and are most frequently due to ischemia. 
They can be managed non-operatively in most cases with aggressive drainage using radio-
logically guided drains or endoluminal vaccum therapy[95]. Self-expandable stents can be 
inserted in these situations but can have the disadvantage of migration or further necrosis 
due to tissue compression ultimately leading to e.g. neoesophago-tracheal fistula formation.
Chylothorax
The incidence of accidental thoracic duct leakage can be diminished by intraoperative iden-
tification and ligation of the duct. Reported incidence of chylothorax varies between 3% and 
10% and is seen more often in patients who undergo transthoracic esophagectomy and in 
patients who have more positive nodes. Patients with chyle leakage have more pulmonary 
complications. Conservative therapy (initial parenteral feeding and subsequent enteral  diet 
with medium-chain triglycerides (MCT)) is often successful, but operative therapy should be 
seriously considered in patients with a persistently high daily output of more than 2 L after 2 
days of optimal conservative therapy[96]. 
Cardiac arythmias
Cardiac arhythmias are not uncommon in the postoperative phase. Atrial fibrillation (AF) 
is seen in 15-20% of patients and requires further investigation because it can be an early 
manifestation of e.g. mediastinitis due to intra-thoracic anastomotic leakage. AF can also be 
associated with hypervolemia, pre-existent pulmonary or cardiac disease and dilation of the 
gastric conduit.
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mORTAlITy And qUAlITy COnTROl
definitions
There is an increasing interest in comparing institutional performance. For surgical proce-
dures postoperative mortality rate is generally used, because it is a relatively objective meas-
ure and reflects the summation of the most severe postoperative complications. Currently 
it is unclear which definition of postoperative mortality best reflects surgical quality of care. 
The 30-day operative mortality (30DM) and the in-hospital mortality (IHM) after esophage-
al resection are well documented and vary from 4% for specialized centers to > 10% for 
nationwide registries[97]. Few studies report on mortality beyond 30 days. Damhuis et al. 
however showed in the Dutch Cancer Registry that 43% of in-hospital deaths after surgery 
for esophageal cancer occurred 30 days or more after the operation[98]. Therefore, 90-day 
mortality (90DM) might be preferred as a performance indicator. Using a longer time period 
after the operation for defining postoperative mortality may thus provide a better definition 
of quality of surgery[99]. Extending the mortality period beyond 30 days and beyond in-hos-
pital stay has the advantage that patients who die because of surgery related complications 
outside the hospital are included as well. 
Not only short-term outcomes, but also long-term survival should be part of the bench-
mark as both aspects are relevant for comparing surgical performance. Both surgery-relat-
ed deaths and cancer recurrence related deaths are reflections of surgical quality of care. 
Less radical surgical resections will generally result in lower postoperative morbidity and 
mortality, but will generally give less favorable oncological outcomes.
Case mix correction
Even after agreement on a uniform definition of postoperative mortality, direct comparison of 
crude mortality rates between hospitals can be misleading as they do not take into account 
the case-mix difference, i.e. the differences in physiological condition and tumor stages of 
patients. Sophisticated models have been developed for prediction of 30DM and IHM [8, 
14, 67, 100-104] after esophageal surgery, but models for 90DM have been mostly based 
on large multi-institutional databases with only few parameters available[105]. 
Outcome-volume relationship and registration
Over the past decades, better long-term survival results have been presented, evolving 
from 18 % 5-year survival in the era from 1980-1990 to 48% in the most recently published 
RCT (Table 1) [17, 65, 99, 106, 107]. It is suggested that many factors are responsible for 
this positive effect, including large hospital volume, early tumor detection, improved patient 
selection based on novel staging modalities, increased use of neoadjuvant therapy, better 
surgical and anesthesiological techniques and improved standardized perioperative clinical 
pathways[18, 108]. In many countries around the world it has been decided that high-risk 
surgical procedures such as esophagectomy should be restricted to facilities with a yearly 
minimum volume [109, 110]. It has been demonstrated that the incidence of postoperative 
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complications is similar across hospitals but that the associated mortality rates are lowest 
in high volume centers, which generally show a lower “failure to rescue” [86, 111]. Cen-
tralization is currently implemented widely. Also auditing has been implemented as a way 
of improvement of care. Of course this results in an additional registration burden for the 
surgeon, but comparing individual or institutional results with the benchmark has proven val-
uable in other types of cancer surgery, such as for rectal cancer[112] [113]. For esophageal 
cancer, variables of interest are for example hospital mortality, radicality (R-status), extent of 
lymph node dissection, length of hospital stay, application of neoadjuvant therapy, availability 
of PET-CT and the presence of a well-structured MDT. The quality indicators can be divided 
in structural, process and outcome measures respectively (Table 2) [114]. Heterogeneity 
and lack of standardized definitions of the outcome of interest is a problem here as well. In 
a review of esophagectomy outcomes from 164 NSQIP (National Surgical Quality Improve-
ment Project) hospitals it was demonstrated that even following case mix adjustment, results 
between centers varied by 161 % for 30-day mortality and 84% for serious morbidity[67].
Finally, comparing the quality of infrequent operations such as esophagectomies is difficult, 
besides issues of definition and case-mix correction, because of another complex element 
in comparing surgical performance, i.e the problem of sample size [115].
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COnClUSIOn / TAKE hOmE mESSAGES
•	 Discussion of all patients with esophageal malignancies in a multidisciplinary tumor 
board is recommended and is associated with improved outcomes after surgery.
•	 ASA, (O-)POSSUM and Charlson are the preoperative risk scoring systems that are 
often used in esophageal surgery. 
•	 The most important change in the most recent 7th edition of the TNM staging system is 
that the concept of non-regional lymph nodes has been abandoned and that staging of 
esophageal cancer has been harmonized with gastric cancer.  
•	 After extensive “conventional” diagnostic work-up, additional PET scanning yields a 
diagnosis of distant dissemination in an additional 10% of patients, especially in case 
of T3-tumors.
•	 The goals that have been achieved in open esophageal surgery should also act as tar-
gets for minimally invasive esophagectomy, being a lymph node retrieval of at least 15 
nodes, R0 resection (>1mm margin) and operative mortality < 5%.
•	 Neoadjuvant chemoradiotherapy decreases the incidence of a tumor-positive circum-
ferential margin.
•	 Meta-analysis of the available literature data did not show differences in survival be-
tween transhiatal and transthoracic operations. The survival benefit of an extended 
lymphadenectomy by a transthoracic approach seems to be limited to a subgroup of 
patients with low burden of nodal disease.
•	 Overall, complication rates are reported in over 50% of esophagectomy series, with 
incidences varying between 17 and 74%. Postoperative complications have been di-
rectly linked to a variety of other outcome parameters including mortality, readmission 
rate, early cancer recurrence, survival, length of hospital stay, resource utilization and 
quality of life.
•	 It has been suggested that MIE is accompanied by less pulmonary complications. 
•	 The 30-day operative mortality (30DM) and the in-hospital mortality (IHM) after esopha-
geal resection vary from 4% for specialized centers to > 10% for nationwide registries.
•	 Many factors are responsible for the better long-term survival rates that have been 
achieved over the previous decades, including large hospital volume, early tumor de-
tection, improved patient selection based on novel staging modalities, increased use 
of neoadjuvant therapy, better surgical and anesthesiological techniques and improved 
standardized perioperative clinical pathways.
•	 The lack of standardized definitions of complications and mortality has hampered out-
come assessment after open and minimally invasive esophagectomy
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Table 1 
Several studies over previous decades showing improved long-term survival after esophageal 
resection.
Study Randomization Survival
Muller, 1990[106] N/A 5-y survival 10 %
Walsh, 1996 [107] Multimodality therapy vs surgery 3-y survival 32 %
Hulscher 2002, Omloo 2007 [65, 66] Transthoracic vs transhiatal approach 5-y survival 36 %
Van Hagen, 2013 [17] Multimodality therapy vs surgery 5-y survival 47%
Table 2 
Performance indicators that have been identified in esophageal cancer surgery[114]
quality-of-care indicators
Structural measures
    Hospital volume
    Surgeon volume
    Centralization
Process measures
    Discussion in Multidisciplinary Board
    Age
    Pre-operative quality of life
    Staging (FDG-PET versus FDG-PET)
    Lymphadenectomy
    Neoadjuvant chemoradiation
    Surgical approach
Outcome measures
    Postoperative complications
    Radicality of resection
    Number of resected lymph nodes
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figure 1
The lymphatics of the esophagus are distributed in the form of a submucosal and a paraesophageal 
plexus that can both drain directly into the periesophageal lymph nodes (copyright Elsevier; Siva Raja et 
al. Esophageal submucosa: The watershed for esophageal cancer The Journal of Thoracic and Cardio-
vascular Surgery 2011. 142(6):1403-11).
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figure 2
Extent of resection and fields of lymph node dissection routinely carried out for cancer of the esoph-
agus (previously published in Griffin S., Raimes SA. A companion to specialist surgical practice : oe-
sophagogastric surgery 4th ed. Elsevier ; 2009:97).
2
209846-L-bw-Talsma
2 9
Goals of surgical therapy for esophageal cancer
2
REfEREnCES
1. Stephens, M.R., et al., Multidisciplinary 
team management is associated with 
improved outcomes after surgery for 
esophageal cancer. Dis Esophagus, 
2006. 19(3): p. 164-71.
2. Davies, A.R., et al., The multidisciplinary 
team meeting improves staging accu-
racy and treatment selection for gas-
tro-esophageal cancer. Dis Esopha-
gus, 2006. 19(6): p. 496-503.
3. van Hagen, P., et al., Impact of a multi-
disciplinary tumour board meeting for 
upper-GI malignancies on clinical de-
cision making: a prospective cohort 
study. Int J Clin Oncol, 2013. 18(2): p. 
214-9.
4. Keats, A.S., The ASA classification of 
physical status--a recapitulation. Anes-
thesiology, 1978. 49(4): p. 233-6.
5. Prytherch, D.R., et al., POSSUM and 
Portsmouth POSSUM for predicting 
mortality. Physiological and Operative 
Severity Score for the enUmeration 
of Mortality and morbidity. Br J Surg, 
1998. 85(9): p. 1217-20.
6. Hall, W.H., et al., An electronic applica-
tion for rapidly calculating Charlson co-
morbidity score. BMC Cancer, 2004. 
4: p. 94.
7. Chandra, A., S. Mangam, and D. Mar-
zouk, A review of risk scoring systems 
utilised in patients undergoing gastro-
intestinal surgery. J Gastrointest Surg, 
2009. 13(8): p. 1529-38.
8. Tekkis, P.P., et al., Risk-adjusted predic-
tion of operative mortality in oesoph-
agogastric surgery with O-POSSUM. 
Br J Surg, 2004. 91(3): p. 288-95.
9. Lagarde, S.M., et al., Evaluation of 
O-POSSUM in predicting in-hospital 
mortality after resection for oesopha-
geal cancer. Br J Surg, 2007. 94(12): 
p. 1521-6.
10. Lai, F., et al., Evaluation of various 
POSSUM models for predicting mor-
tality in patients undergoing elective 
oesophagectomy for carcinoma. Br J 
Surg, 2007. 94(9): p. 1172-8.
11. Bosch, D.J., et al., Comparison of dif-
ferent risk-adjustment models in as-
sessing short-term surgical outcome 
after transthoracic esophagectomy in 
patients with esophageal cancer. Am J 
Surg, 2011. 202(3): p. 303-9.
12. Dutta, S., P.G. Horgan, and D.C. McMil-
lan, POSSUM and its related models 
as predictors of postoperative mortality 
and morbidity in patients undergoing 
surgery for gastro-oesophageal can-
cer: a systematic review. World J Surg, 
2010. 34(9): p. 2076-82.
13. Cijs, T.M., et al., Outcome of esophagec-
tomy for cancer in elderly patients. Ann 
Thorac Surg, 2010. 90(3): p. 900-7.
14. Koppert, L.B., et al., Impact of age and 
co-morbidity on surgical resection rate 
and survival in patients with oesoph-
ageal and gastric cancer. Br J Surg, 
2012. 99(12): p. 1693-700.
15. Polee, M.B., et al., Prognostic factors for 
survival in patients with advanced oe-
sophageal cancer treated with cispla-
tin-based combination chemotherapy. 
Br J Cancer, 2003. 89(11): p. 2045-50.
16. Masoomi, H., et al., Predictive factors of 
acute respiratory failure in esophagec-
tomy for esophageal malignancy. Am 
Surg, 2012. 78(10): p. 1024-8.
17. van Hagen, P., et al., Preoperative 
chemoradiotherapy for esophageal or 
209846-L-bw-Talsma
3 0
Chapter 2
2
junctional cancer. N Engl J Med, 2012. 
366(22): p. 2074-84.
18. Stein, H.J. and J.R. Siewert, Improved 
prognosis of resected esophageal 
cancer. World J Surg, 2004. 28(6): p. 
520-5.
19. Sobin, L.H. and C.C. Compton, TNM 
seventh edition: what’s new, what’s 
changed: communication from the In-
ternational Union Against Cancer and 
the American Joint Committee on Can-
cer. Cancer, 2010. 116(22): p. 5336-9.
20. Kelly, S., et al., A systematic review of 
the staging performance of endoscopic 
ultrasound in gastro-oesophageal car-
cinoma. Gut, 2001. 49(4): p. 534-9.
21. van Vliet, E.P., et al., Staging investiga-
tions for oesophageal cancer: a me-
ta-analysis. Br J Cancer, 2008. 98(3): 
p. 547-57.
22. Vickers, J. and D. Alderson, Influence 
of luminal obstruction on oesophageal 
cancer staging using endoscopic ultra-
sonography. Br J Surg, 1998. 85(7): p. 
999-1001.
23. Reed, C.E., et al., Esophageal cancer 
staging: improved accuracy by en-
doscopic ultrasound of celiac lymph 
nodes. Ann Thorac Surg, 1999. 67(2): 
p. 319-21; discussion 322.
24. Omloo, J.M., et al., Additional value of 
external ultrasonography of the neck 
after CT and PET scanning in the pre-
operative assessment of patients with 
esophageal cancer. Dig Surg, 2009. 
26(1): p. 43-9.
25. van Westreenen, H.L., et al., Systematic 
review of the staging performance of 
18F-fluorodeoxyglucose positron emis-
sion tomography in esophageal cancer. 
J Clin Oncol, 2004. 22(18): p. 3805-12.
26. Blom, R.L., et al., PET/CT-based met-
abolic tumour volume for response 
prediction of neoadjuvant chemoradio-
therapy in oesophageal carcinoma. Eur 
J Nucl Med Mol Imaging, 2013. 40(10): 
p. 1500-6.
27. van Westreenen, H.L., et al., Limited 
additional value of positron emission 
tomography in staging oesophageal 
cancer. Br J Surg, 2007. 94(12): p. 
1515-20.
28. Gouma, D.J., et al., Laparoscopic ultra-
sonography for staging of gastrointesti-
nal malignancy. Scand J Gastroenterol 
Suppl, 1996. 218: p. 43-9.
29. Lamb, P.J., et al., Sentinel node biopsy 
to evaluate the metastatic dissemina-
tion of oesophageal adenocarcinoma. 
Br J Surg, 2005. 92(1): p. 60-7.
30. Schroder, W., et al., Localization of iso-
lated lymph node metastases in esoph-
ageal cancer--does it influence the 
sentinel node concept? Hepatogastro-
enterology, 2007. 54(76): p. 1116-20.
31. Grotenhuis, B.A., et al., The sentinel 
node concept in adenocarcinomas of 
the distal esophagus and gastroesoph-
ageal junction. J Thorac Cardiovasc 
Surg, 2009. 138(3): p. 608-12.
32. Kalha, I., et al., The accuracy of endo-
scopic ultrasound for restaging esoph-
ageal carcinoma after chemoradiation 
therapy. Cancer, 2004. 101(5): p. 940-
7.
33. Kitagawa, Y., et al., Sentinel node map-
ping for gastric cancer: a prospective 
multicenter trial in Japan. J Clin Oncol, 
2013. 31(29): p. 3704-10.
34. Ribeiro, A., et al., Endoscopic ultra-
sound restaging after neoadjuvant 
chemotherapy in esophageal cancer. 
209846-L-bw-Talsma
31
Goals of surgical therapy for esophageal cancer
2
Am J Gastroenterol, 2006. 101(6): p. 
1216-21.
35. Westerterp, M., et al., Esophageal can-
cer: CT, endoscopic US, and FDG PET 
for assessment of response to neoad-
juvant therapy--systematic review. Ra-
diology, 2005. 236(3): p. 841-51.
36. Swisher, S.G., et al., 2-Fluoro-2-de-
oxy-D-glucose positron emission to-
mography imaging is predictive of 
pathologic response and survival af-
ter preoperative chemoradiation in 
patients with esophageal carcinoma. 
Cancer, 2004. 101(8): p. 1776-85.
37. Smyth, E.C. and M.A. Shah, Role of (1)
(8)F 2-fluoro-2-deoxyglucose positron 
emission tomography in upper gastro-
intestinal malignancies. World J Gas-
troenterol, 2011. 17(46): p. 5059-74.
38. Han, D., et al., Comparison of the diag-
nostic value of 3-deoxy-3-18F-fluoro-
thymidine and 18F-fluorodeoxyglucose 
positron emission tomography/comput-
ed tomography in the assessment of 
regional lymph node in thoracic esoph-
ageal squamous cell carcinoma: a pilot 
study. Dis Esophagus, 2012. 25(5): p. 
416-26.
39. Riddell, A.M., et al., The appearances of 
oesophageal carcinoma demonstrated 
on high-resolution, T2-weighted MRI, 
with histopathological correlation. Eur 
Radiol, 2007. 17(2): p. 391-9.
40. Kijanka, M., et al., Rapid optical imag-
ing of human breast tumour xenografts 
using anti-HER2 VHHs site-directly 
conjugated to IRDye 800CW for im-
age-guided surgery. Eur J Nucl Med 
Mol Imaging, 2013. 40(11): p. 1718-29.
41. Stahl, M., et al., Chemoradiation With 
and Without Surgery in Patients With 
Locally Advanced Squamous Cell 
Carcinoma of the Esophagus. Journal 
of Clinical Oncology, 2005. 23(10): p. 
2310-2317.
42. Bedenne, L., et al., Chemoradiation 
Followed by Surgery Compared With 
Chemoradiation Alone in Squamous 
Cancer of the Esophagus: FFCD 
9102. Journal of Clinical Oncology, 
2007. 25(10): p. 1160-1168.
43. Dexter, S.P., et al., Circumferential re-
section margin involvement: an inde-
pendent predictor of survival following 
surgery for oesophageal cancer. Gut, 
2001. 48(5): p. 667-70.
44. Scheepers, J.J., et al., Influence of 
circumferential resection margin on 
prognosis in distal esophageal and 
gastroesophageal cancer approached 
through the transhiatal route. Dis 
Esophagus, 2009. 22(1): p. 42-8.
45. Rao, V.S., et al., Comparison of circum-
ferential resection margin clearance 
criteria with survival after surgery for 
cancer of esophagus. J Surg Oncol, 
2012. 105(8): p. 745-9.
46. O’Neill, J.R., et al., Defining a positive 
circumferential resection margin in 
oesophageal cancer and its implica-
tions for adjuvant treatment. Br J Surg, 
2013. 100(8): p. 1055-63.
47. Skinner, D.B., En bloc resection for neo-
plasms of the esophagus and cardia. J 
Thorac Cardiovasc Surg, 1983. 85(1): 
p. 59-71.
48. Chan, D.S., et al., Systematic review 
and meta-analysis of the influence of 
circumferential resection margin in-
volvement on survival in patients with 
operable oesophageal cancer. Br J 
Surg, 2013. 100(4): p. 456-64.
209846-L-bw-Talsma
32
Chapter 2
2
49. Verhage, R.J., et al., How to define 
a positive circumferential resection 
margin in T3 adenocarcinoma of the 
esophagus. Am J Surg Pathol, 2011. 
35(6): p. 919-26.
50. Sujendran, V., et al., Effect of neoad-
juvant chemotherapy on circumferen-
tial margin positivity and its impact on 
prognosis in patients with resectable 
oesophageal cancer. Br J Surg, 2008. 
95(2): p. 191-4.
51. Khan, O.A., D. Cruttenden-Wood, and 
S.K. Toh, Is an involved circumferential 
resection margin following oesphagec-
tomy for cancer an important prognos-
tic indicator? Interact Cardiovasc Tho-
rac Surg, 2010. 11(5): p. 645-8.
52. Prenzel, K.L., et al., Prognostic rele-
vance of skip metastases in esopha-
geal cancer. Ann Thorac Surg, 2010. 
90(5): p. 1662-7.
53. Westerterp, M., et al., Outcome of surgi-
cal treatment for early adenocarcinoma 
of the esophagus or gastro-esopha-
geal junction. Virchows Arch, 2005. 
446(5): p. 497-504.
54. Boone, J., et al., International survey 
on esophageal cancer: part I surgical 
techniques. Dis Esophagus, 2009. 
22(3): p. 195-202.
55. Schwarz, R.E. and D.D. Smith, Clinical 
impact of lymphadenectomy extent in 
resectable esophageal cancer. J Gas-
trointest Surg, 2007. 11(11): p. 1384-
93; discussion 1393-4.
56. Herbella, F.A. and M.G. Patti, Minimally 
invasive esophagectomy. World J Gas-
troenterol, 2010. 16(30): p. 3811-5.
57. Weksler, B., et al., Robot-assisted mini-
mally invasive esophagectomy is equiv-
alent to thoracoscopic minimally inva-
sive esophagectomy. Dis Esophagus, 
2012. 25(5): p. 403-9.
58. Pennathur, A. and J.D. Luketich, Mini-
mally invasive esophagectomy: short-
term outcomes appear comparable 
to open esophagectomy. Ann Surg, 
2012. 255(2): p. 206-7.
59. Hulscher, J.B., et al., Transthoracic ver-
sus transhiatal resection for carcinoma 
of the esophagus: a meta-analysis. Ann 
Thorac Surg, 2001. 72(1): p. 306-13.
60. Lagarde, S.M., et al., Prognostic factors 
in adenocarcinoma of the esophagus 
or gastroesophageal junction. J Clin 
Oncol, 2006. 24(26): p. 4347-55.
61. Izbicki, J.R., et al., Prognostic value of 
immunohistochemically identifiable tu-
mor cells in lymph nodes of patients 
with completely resected esophageal 
cancer. N Engl J Med, 1997. 337(17): 
p. 1188-94.
62. Orringer, M.B., B. Marshall, and M.D. 
Iannettoni, Transhiatal esophagectomy 
for treatment of benign and malignant 
esophageal disease. World J Surg, 
2001. 25(2): p. 196-203.
63. Siewert, J.R., et al., Histologic tumor 
type is an independent prognostic pa-
rameter in esophageal cancer: lessons 
from more than 1,000 consecutive re-
sections at a single center in the West-
ern world. Ann Surg, 2001. 234(3): p. 
360-7; discussion 368-9.
64. van Sandick, J.W., et al., Indicators of 
prognosis after transhiatal esophageal 
resection without thoracotomy for can-
cer. J Am Coll Surg, 2002. 194(1): p. 
28-36.
65. Hulscher, J.B., et al., Extended transtho-
racic resection compared with limited 
transhiatal resection for adenocarcino-
209846-L-bw-Talsma
33
Goals of surgical therapy for esophageal cancer
2
ma of the esophagus. N Engl J Med, 
2002. 347(21): p. 1662-9.
66. Omloo, J.M., et al., Extended transtho-
racic resection compared with limited 
transhiatal resection for adenocarcino-
ma of the mid/distal esophagus: five-
year survival of a randomized clinical 
trial. Ann Surg, 2007. 246(6): p. 992-
1000; discussion 1000-1.
67. Merkow, R.P., et al., Short-term Out-
comes After Esophagectomy at 164 
American College of Surgeons Na-
tional Surgical Quality Improvement 
Program Hospitals: Effect of Operative 
Approach and Hospital-Level Variation. 
Arch Surg, 2012. 147(11): p. 1009-16.
68. Boshier, P.R., O. Anderson, and G.B. 
Hanna, Transthoracic versus transhia-
tal esophagectomy for the treatment of 
esophagogastric cancer: a meta-anal-
ysis. Ann Surg, 2011. 254(6): p. 894-
906.
69. Fujita, H., et al., Mortality and morbidi-
ty rates, postoperative course, quality 
of life, and prognosis after extended 
radical lymphadenectomy for esoph-
ageal cancer. Comparison of three-
field lymphadenectomy with two-field 
lymphadenectomy. Ann Surg, 1995. 
222(5): p. 654-62.
70. Lerut, T., et al., Three-field lymphadenec-
tomy for carcinoma of the esophagus 
and gastroesophageal junction in 174 
R0 resections: impact on staging, dis-
ease-free survival, and outcome: a plea 
for adaptation of TNM classification in 
upper-half esophageal carcinoma. Ann 
Surg, 2004. 240(6): p. 962-72; discus-
sion 972-4.
71. Altorki, N.K., et al., Total number of re-
sected lymph nodes predicts survival in 
esophageal cancer. Ann Surg, 2008. 
248(2): p. 221-6.
72. Rizk, N.P., et al., Optimum lymphadenec-
tomy for esophageal cancer. Ann Surg, 
2010. 251(1): p. 46-50.
73. Rizk, N., et al., The prognostic impor-
tance of the number of involved lymph 
nodes in esophageal cancer: implica-
tions for revisions of the American Joint 
Committee on Cancer staging sys-
tem. J Thorac Cardiovasc Surg, 2006. 
132(6): p. 1374-81.
74. Peyre, C.G., et al., The number of lymph 
nodes removed predicts survival in 
esophageal cancer: an international 
study on the impact of extent of surgi-
cal resection. Ann Surg, 2008. 248(4): 
p. 549-56.
75. Stiles, B.M., et al., Worldwide Oesoph-
ageal Cancer Collaboration guidelines 
for lymphadenectomy predict surviv-
al following neoadjuvant therapy. Eur 
J Cardiothorac Surg, 2012. 42(4): p. 
659-64.
76. Torgersen, Z., et al., Prognostic implica-
tions of lymphadenectomy in esopha-
geal cancer after neo-adjuvant therapy: 
a single center experience. J Gastroin-
test Surg, 2011. 15(10): p. 1769-76.
77. Chao, Y.K., et al., Lymph node dissec-
tion after chemoradiation in esopha-
geal cancer: a subgroup analysis of 
patients with and without pathological 
response. Ann Surg Oncol, 2012. 
19(11): p. 3500-5.
78. Dunst, C.M. and L.L. Swanstrom, Min-
imally invasive esophagectomy. J Gas-
trointest Surg, 2010. 14 Suppl 1: p. 
S108-14.
79. Courrech Staal, E.F., et al., Systematic 
review of the benefits and risks of neo-
209846-L-bw-Talsma
3 4
Chapter 2
2
adjuvant chemoradiation for oesopha-
geal cancer. Br J Surg, 2010. 97(10): 
p. 1482-96.
80. Kassin, M.T., et al., Risk factors for 30-
day hospital readmission among gen-
eral surgery patients. J Am Coll Surg, 
2012. 215(3): p. 322-30.
81. Hii, M.W., et al., Impact of postopera-
tive morbidity on long-term survival af-
ter oesophagectomy. Br J Surg, 2013. 
100(1): p. 95-104.
82. Derogar, M., et al., Influence of ma-
jor postoperative complications on 
health-related quality of life among 
long-term survivors of esophageal 
cancer surgery. J Clin Oncol, 2012. 
30(14): p. 1615-9.
83. Lagarde, S.M., et al., Postoperative 
complications after esophagectomy 
for adenocarcinoma of the esophagus 
are related to timing of death due to re-
currence. Ann Surg, 2008. 247(1): p. 
71-6.
84. Blencowe, N.S., et al., Reporting of 
short-term clinical outcomes after 
esophagectomy: a systematic review. 
Ann Surg, 2012. 255(4): p. 658-66.
85. Koch, C.G., et al., What are the real 
rates of postoperative complications: 
elucidating inconsistencies between 
administrative and clinical data sourc-
es. J Am Coll Surg, 2012. 214(5): p. 
798-805.
86. Ghaferi, A.A., J.D. Birkmeyer, and J.B. 
Dimick, Variation in hospital mortality 
associated with inpatient surgery. N 
Engl J Med, 2009. 361(14): p. 1368-
75.
87. Biere, S.S., et al., Minimally invasive 
versus open oesophagectomy for pa-
tients with oesophageal cancer: a mul-
ticentre, open-label, randomised con-
trolled trial. Lancet, 2012. 379(9829): 
p. 1887-92.
88. Law, S., Is minimally invasive prefera-
ble to open oesophagectomy? Lancet, 
2012. 379(9829): p. 1856-8.
89. Tandon, S., et al., Peri-operative risk fac-
tors for acute lung injury after elective 
oesophagectomy. Br J Anaesth, 2001. 
86(5): p. 633-8.
90. Law, S., et al., Predictive factors for 
postoperative pulmonary complications 
and mortality after esophagectomy for 
cancer. Ann Surg, 2004. 240(5): p. 
791-800.
91. Akaishi, T., et al., Thoracoscopic en 
bloc total esophagectomy with radical 
mediastinal lymphadenectomy. J Tho-
rac Cardiovasc Surg, 1996. 112(6): p. 
1533-40; discussion 1540-1.
92. Orringer, M.B., B. Marshall, and M.D. 
Iannettoni, Eliminating the cervical 
esophagogastric anastomotic leak 
with a side-to-side stapled anastomo-
sis. J Thorac Cardiovasc Surg, 2000. 
119(2): p. 277-88.
93. Collard, J.M., et al., Terminalized semi-
mechanical side-to-side suture tech-
nique for cervical esophagogastrosto-
my. Ann Thorac Surg, 1998. 65(3): p. 
814-7.
94. van Heijl, M., et al., Intrathoracic mani-
festations of cervical anastomotic leaks 
after transhiatal and transthoracic oe-
sophagectomy. Br J Surg, 2010. 97(5): 
p. 726-31.
95. Weidenhagen, R., et al., Anastomotic 
leakage after esophageal resection: 
new treatment options by endoluminal 
vacuum therapy. Ann Thorac Surg, 
2010. 90(5): p. 1674-81.
209846-L-bw-Talsma
35
Goals of surgical therapy for esophageal cancer
2
96. Lagarde, S.M., et al., Incidence and 
management of chyle leakage after 
esophagectomy. Ann Thorac Surg, 
2005. 80(2): p. 449-54.
97. Dikken, J.L., et al., Effect of hospital 
volume on postoperative mortality and 
survival after oesophageal and gastric 
cancer surgery in the Netherlands be-
tween 1989 and 2009. Eur J Cancer, 
2012. 48(7): p. 1004-13.
98. Damhuis, R.A., et al., Comparison of 
30-day, 90-day and in-hospital post-
operative mortality for eight different 
cancer types. Br J Surg, 2012. 99(8): 
p. 1149-54.
99. Jamieson, G.G., et al., Postoperative 
mortality following oesophagectomy 
and problems in reporting its rate. Br J 
Surg, 2004. 91(8): p. 943-7.
100. Wright, C.D., et al., Predictors of 
major morbidity and mortality after 
esophagectomy for esophageal can-
cer: a Society of Thoracic Surgeons 
General Thoracic Surgery Database 
risk adjustment model. J Thorac Car-
diovasc Surg, 2009. 137(3): p. 587-95; 
discussion 596.
101. Morita, M., et al., In-hospital mortality 
after a surgical resection for esopha-
geal cancer: analyses of the associat-
ed factors and historical changes. Ann 
Surg Oncol, 2011. 18(6): p. 1757-65.
102. Lagarde, S.M., et al., Prognostic no-
mogram for patients undergoing oe-
sophagectomy for adenocarcinoma of 
the oesophagus or gastro-oesopha-
geal junction. Br J Surg, 2007. 94(11): 
p. 1361-8.
103. Lagarde, S.M., et al., Preoperative pre-
diction of the occurrence and severity 
of complications after esophagectomy 
for cancer with use of a nomogram. 
Ann Thorac Surg, 2008. 85(6): p. 
1938-45.
104. Grotenhuis, B.A., et al., Validation of 
a nomogram predicting complications 
after esophagectomy for cancer. Ann 
Thorac Surg, 2010. 90(3): p. 920-5.
105. Dikken, J.L., et al., Influence of hospital 
type on outcomes after oesophageal 
and gastric cancer surgery. Br J Surg, 
2012. 99(7): p. 954-63.
106. Muller, J.M., et al., Surgical therapy of 
oesophageal carcinoma. Br J Surg, 
1990. 77(8): p. 845-57.
107. Walsh, T.N., et al., A comparison of 
multimodal therapy and surgery for 
esophageal adenocarcinoma. N Engl J 
Med, 1996. 335(7): p. 462-7.
108. Low, D.E., et al., Esophagectomy--it’s 
not just about mortality anymore: stan-
dardized perioperative clinical path-
ways improve outcomes in patients 
with esophageal cancer. J Gastrointest 
Surg, 2007. 11(11): p. 1395-402; dis-
cussion 1402.
109. Dikken, J.L., et al., Differences in out-
comes of oesophageal and gastric 
cancer surgery across Europe. Br J 
Surg, 2013. 100(1): p. 83-94.
110. Markar, S.R., et al., Volume-outcome 
relationship in surgery for esophageal 
malignancy: systematic review and me-
ta-analysis 2000-2011. J Gastrointest 
Surg, 2012. 16(5): p. 1055-63.
111. Patti, M.G., et al., A hospital’s annual 
rate of esophagectomy influences the 
operative mortality rate. J Gastrointest 
Surg, 1998. 2(2): p. 186-92.
112. van Gijn, W., et al., Nationwide out-
come registrations to improve quality 
of care in rectal surgery. An initiative of 
209846-L-bw-Talsma
3 6
Chapter 2
2
the European Society of Surgical On-
cology. J Surg Oncol, 2009. 99(8): p. 
491-6.
113. Birgisson, H., et al., Improved surviv-
al in cancer of the colon and rectum 
in Sweden. Eur J Surg Oncol, 2005. 
31(8): p. 845-53.
114. Courrech Staal, E.F., et al., Quali-
ty-of-care indicators for oesophageal 
cancer surgery: A review. Eur J Surg 
Oncol, 2010. 36(11): p. 1035-43.
115. Dimick, J.B., H.G. Welch, and J.D. 
Birkmeyer, Surgical mortality as an in-
dicator of hospital quality: the problem 
with small sample size. JAMA, 2004. 
292(7): p. 847-51.
209846-L-bw-Talsma
37
Goals of surgical therapy for esophageal cancer
2
209846-L-bw-Talsma
209846-L-bw-Talsma
Chapter 3
Location of lymph node 
involvement in patients with 
esophageal adenocarcinoma 
predicts survival
AALDERT K. TALSMA1, MD MSC, 
CHIN-ANN J. ONG2, MD, 
XINXUE LIU2, PHD, 
PIETER VAN HAGEN1, MD, 
JAN J.B. VAN LANSCHOT1, MD PHD, 
HUUG W.TILANUS, MD PHD1, 
RICHARD H. HARDWICK3, MD FRCS, 
NICHOLAS R. CARROLL, MD3, 
MANON C.W.SPAANDER4, MD PHD, 
REBECCA C. FITZGERALD2, MD MB BCHIR, 
BAS P.L.WIJNHOVEN1, MD PHD
1 Department of Surgery and Gastroenterology4,  
Erasmus Medical Center, Rotterdam, The Netherlands
2 Medical Research Council (MRC) Cancer Cell Unit,  
Hutchinson/MRC Research Center, Cambridge, UK
3 Cambridge Oesophago-gastric Center,  
Addenbrookes Hospital, Cambridge, UK
World J Surg. 2014 
Jan;38(1):106-13
209846-L-bw-Talsma
4 0
Chapter 3
3
AbSTRACT
background
Location of positive lymph nodes has been abandoned in the 7th classification of the 
TNM-staging system for esophageal adenocarcinoma. The present study evaluates whether 
distribution of involved nodes relative to the diaphragm in addition to TNM 7 further refines 
prediction.  
methods
Pathology reports of patients who underwent esophagectomy between 2000 and 2008 for 
adenocarcinoma of the esophagus were reviewed and staging was performed according to 
the 7th UICC-AJCC staging system. In addition, lymph node involvement of nodal stations 
above and below the diaphragm was investigated by endoscopic ultrasonography (EUS) in 
a separate cohort of patients who were scheduled for esophagectomy between 2008 and 
2009 at two institutions. Survival was calculated by the Kaplan-Meier method, and multivar-
iate analysis was performed with a Cox-regression model.
Results
Some 327 patients after esophagectomy for cancer were included. Multivariate analysis re-
vealed that patients with 3-6 involved lymph nodes in the resection specimen on both sides 
of the diaphragm had a twofold higher chance of dying compared to patients with the same 
number of lymph nodes on one side of the diaphragm. 
EUS assessment of lymph node metastases relative to diaphragm in 102 patient showed 
that nodal involvement at both sides of the diaphragm was associated with worse sur-
vival as compared to patients with nodes on one side or no involved nodes (HR and 
95%CI:2.38[1.15-4.90]).
Conclusions
A combined staging system that incorporates distribution of lymph nodes relative to the 
diaphragm refines prognostication after esophagectomy as assessed in the resection spec-
imen and pre-treatment as assessed by EUS. This improved staging has potentially a great 
impact on clinical decision making as to whether to embark upon potentially curative or 
palliative treatments.
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InTROdUCTIOn
Surgery with neoadjuvant chemo(radio)therapy for resectable esophageal cancer offers the 
best chance for long term survival [1]. Following esophagectomy, prognosis is largely deter-
mined by the depth of infiltration of the primary tumor and the lymphatic or hematogenous 
spread, traditionally reflected in the histopathological TNM classification [2]. Lymphatic dis-
semination in adenocarcinomas of the distal esophagus and gastro-esophageal junction is 
frequenty seen in the lymph nodes located in the middle-lower mediastinum and in the upper 
abdomen around the celiac axis.
Driven by several large retrospective studies, the 7th edition of the UICC-AJCC esoph-
ageal TNM staging system (TNM 7) has acknowledged the prognostic importance of the 
number of involved nodes on survival by subdividing the N-classification into N0-N3 [3]. 
However, this system does not take into account the location of involved nodes. Peters et al. 
[4] have demonstrated that a revised N-classification that incorporates both burden and dis-
tribution of involved nodes relative to the diaphragm provided improved prognostic power. 
It is unclear whether location of positive lymph nodes in relation to the diaphragm can refine 
the latest TNM-staging system for esophageal cancer patients.
Although histopathological staging does reflect patient’s prognosis after esophagec-
tomy, accurate pre-treatment clinical staging is important for deciding whether to embark 
upon potentially curative or palliative treatment and for informing patients about their prog-
nosis. Endoscopic ultrasound with fine needle aspiration (EUS-FNA) has the highest accu-
racy for the assessment of the T- and N-stage [5]. However, clinicians struggle to put EUS 
findings into clinical practice as TNM 7 has abandoned M1a metastases. Also assessment 
of the number of involved nodes using EUS in a busy clinical practice is time consuming, dif-
ficult and inaccurate [6].  In contrast, determination of the ‘bulk’ of nodal involvement relative 
to the diaphragm regardless of the exact number of involved nodes might be a more easily 
adopted and clinically useful approach.    
The first aim of the study was to evaluate if number and distribution of involved lymph 
nodes relative to the diaphragm, as determined in the resection specimen, can accurately 
prognosticate patients with esophageal adenocarcinoma. The second aim was to assess if 
preoperative EUS staging of lymph node distribution relative to the diaphragm can predict 
prognosis of patients. 
mEThOdS
To address the first study objective, patients who underwent esophagectomy with cura-
tive intent between January 2000 and September 2008 at the Erasmus University Medical 
Center  Rotterdam, the Netherlands, for adenocarcinoma of the esophagus or esopha-
go-gastric junction (EGJ; Siewert type 1 and 2) were identified from a prospective data-
base. All patients underwent the standard diagnostic work-up including endoscopic ultra-
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sound (EUS), CT-scan of chest and abdomen and ultrasonography of the neck. A PET scan 
was not routinely performed during the study period. Some patients received neoadjuvant 
chemo(radio)therapy in the context of randomized controlled trials [7,8]. Induction chemo-
radio- or chemotherapy was given to patients with either a cT4-tumor without distant me-
tastases or in patients with gross involvement of celiac trunk lymph nodes who were not 
considered candidates for primary surgical therapy. Pathology reports were reviewed and 
pN-stage was scored according to TNM 7. The sites of lymph nodes were classified accord-
ing to the nomenclature and code number of the Japanese Society for Esophageal Diseases 
[9]. Patients were further classified as having involved nodes on one side or on both sides 
of the diaphragm. Lymph node metastases designated in the report as 'peri-esophageal', 
‘subcarinal’, ‘paratracheal’ or ‘aortopulmonary window’ were considered to be above the 
diaphragm whereas ‘perigastric’, ‘paracardiac’, ‘left gastric artery’, ‘splenic artery’, ‘com-
mon hepatic artery’ or ‘celiac trunk’ nodes were considered as being below the diaphragm. 
In particular, the subcarinal, paratracheal, aortopulmonary, celiac trunk, left gastric, splenic 
artery and common hepatic artery lymph node stations were mainly designated by the sur-
geons during surgery and placed in separate containers.  The nodal stations which can be 
identified anatomically from the specimen (peri-esophageal, perigastric and paracardiac) 
were present with the specimen en-bloc and were removed by the pathologist.   When the 
pathologist identified nodes that could have been sterilized in patients who received neoad-
juvant therapy, these were counted as negative. 
To evaluate the prognostic value of EUS in detecting nodes above and below the dia-
phragm, consecutive patients who were scheduled for an esophagectomy for adenocarci-
noma of the esophagus or EGJ at the Erasmus MC or Addenbrooke’s Hospital (Cambridge, 
UK) between 2008 and 2009 were identified. Experienced endoscopists performing the 
EUS were specifically prompted by the study team to look for the relationship of involved 
lymph node stations with the diaphragm (cN-stage) and to include this into the formal report 
since 2008. On EUS a lymph node was considered malignant based on morphological cri-
teria [10]. FNA sampling was not so much driven by these criteria but rather by the presence 
of suspected nodes outside the surgical and radiation field which positivity would change 
the treatment plan. In case FNA of lymph nodes was performed, the initial endoscopic clas-
sification was not changed when the cytology results were disclosed. 
Surgery
Transhiatal esophagectomy encompassed the en bloc dissection of the distal es-
ophagus and its adjacent lymph nodes under direct vision through the widened hi-
atus of the diaphragm up to the level of the inferior pulmonary vein. The paracar-
dial, lesser curvature, left gastric artery, celiac trunk, common hepatic artery, and 
splenic artery nodes were dissected and a gastric tube was created. After mobilization 
and transection of the cervical esophagus, the intrathoracic part was bluntly dissect-
ed in an antegrade fashion with a vein stripper. Esophagogastrostomy was performed 
in the neck. The left gastric artery was marked in the operation specimen with a suture. 
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In Rotterdam, a transthoracic esophagectomy was mainly done during the study period in 
the context of a randomized controlled trial [11]. The thoracic duct, azygos vein, ipsilateral 
pleura, and all peri-esophageal tissue in the posterior mediastinum were dissected en bloc 
via a right-sided thoracotomy. The resection specimen included the lower and middle medi-
astinal, subcarinal, and right-sided paratracheal lymph nodes, that were collected as sepa-
rate samples as well as nodes in the aortopulmonary window. The abdominal and cervical 
phase of the transthoracic procedure were identical to the transhiatal procedure. 
follow-up
Surviving patients were followed at regular intervals at the outpatient clinic until five years 
after the operation. Overall survival was defined as the time between date of operation and 
date of death. Surviving patients were censored on the day of last follow-up. Patient survival 
status was calculated after contacting the general practitioners or the municipal mortality 
registers by a trained data manager. Last follow-up checkpoint was July 31st 2011. 
Statistical Analysis
Univariable and multivariable Cox regression analyses were performed to assess the as-
sociations between overall survival and histopathological and clinical lymph node staging 
systems. Hazard ratios were reported for each variable analyzed. Overall survival rates were 
estimated by the method of Kaplan–Meier and log rank test was used to determine statisti-
cal significance. Two-tailed P<0.05 was considered statistically significant. All the analyses 
were performed using SPSS version 19.0 (SPSS Inc, Chicago, IL, USA).
RESUlTS
Importance of lymph node number and location
From the database 392 patients were identified. Two patients were excluded because of 
missing information on the number of positive lymph nodes and date of last follow up. In 
addition, 63 patients with squamous cell cancers were excluded. The clinical characteristics 
and univariate analysis of the 327 patients are shown in Table 1. The overall 5-year survival 
rate was 34.6%. Overall survival according to TNM 7 is shown in Figure 1A. Patients with 
involved lymph node metastases on both sides of the diaphragm had a significantly poorer 
survival as compared to patients with nodal disease on one side of the diaphragm or N0 
disease (p<0.001; Figure 1B).  
Adjusting for all significant variables from the univariable analysis, multivariable analysis 
showed that nodal involvement on both sides of the diaphragm is associated with a higher 
hazard for death as compared to nodal involvement on one side of the diaphragm.  Analysis 
of the number of lymph nodes sampled in each group showed that there was no difference 
in the number of lymph nodes sampled which could account for the prognostic effect ob-
served (Supplementary figure 1).  Location of the primary tumor did not have impact on 
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prognostic significance of positive lymph nodes found above and below the diaphragm. 
In addition, subset analysis performed on patients who underwent transhiatal resection 
(n=313) or did not receive neoadjuvant chemoradiotherapy (n=220) consistently showed 
that involvement of lymph nodes of both sides of the diaphragm was a significant prognostic 
factor (Supplementary Table 1).  Lastly, in view that location of nodal involvement should be 
combined with current staging criteria with the possibility of N3 status (>6 involved lymph 
nodes), we performed a subset analysis on patients with at least 7 lymph nodes sampled. 
Patients with nodal involvement on both side had the highest hazard ration of death (2.88; 
95% CI:1.68-4.94; supplementary Table 1). Combining the nodal categories as dictated by 
TNM 7 with the location relative to the diaphragm in a Cox regression analysis model result-
ed in the hazard ratios for each group, as summarized in Table 2.  Notably, after adjusting 
for covariates, patients with 3 to 6 involved lymph nodes distributed on both sides of the di-
aphragm had a markedly increased risk of death (HR=2.93;95%CI:1.79-4.79) as compared 
to patients with 3-6 involved lymph nodes that resided on one side of the diaphragm (1.74; 
95%CI:0.94-3.21). 
From the finding in the Cox regression analysis that location only affects prognosis in 
the group of patients with 3-6 lymph nodes involved (N2), two survival curves for N2 were 
calculated and drawn in Figure 1C. Patients with 3 to 6 involved lymph nodes on one side 
of the diaphragm have a similar prognosis (5-year survival rate 29.7%) when compared to 
patients with 1-2 involved lymph nodes (5-year survival rate 27.0%) while the 5-year sur-
vival rate is 10.4% for patients with 3-6 involved nodes on both sides of the diaphragm. 
Prediction of survival with EUS
One hundred and twenty two patients (55 from Rotterdam and 67 from Cambridge) un-
derwent pretreatment EUS for esophageal adenocarcinoma between 2008 and 2009 to 
determine the number and location of involved lymph nodes. Patients with missing informa-
tion on EUS location, because the endoscope could not pass the tumor (n=14), incomplete 
follow-up (n=1) or who were irresectable intraoperatively (n=5) were excluded, leaving 102 
patients for analysis. 
Lymph node metastases were detected by EUS in 66.7% of patients. Positive lymph 
nodes on both sides of the diaphragm were seen in 15.7 % of patients. Patients with sus-
pected lymph nodes on both sides of the diaphragm had a significantly worse overall survival 
as compared to patients with nodal disease on one side of the diaphragm or with no positive 
lymph nodes identified at all (cN0) with 2-year survival rates of 34.7 % and  61.1% respec-
tively (p = 0.027; Figure 2). 
After adjusting for age, sex, chemoradiotherapy and study center, patients with node pos-
itivity on both sides of the diaphragm had a higher risk of death as compared to patients with-
out node positivity on EUS (Table 3). However, no significant difference was found between 
patients with one-sided nodal disease and those without node positivity.  With the latter two 
categories combined, a statistically significant difference was found when compared to pa-
tients with positive nodes on both sides of the diaphragm (HR and 95%CI: 2.38[1.15-4.90]).
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dISCUSSIOn
Surgical resection margin, depth of tumor invasion and lymph node status are the most im-
portant predictors of outcome in patients with esophageal cancer. The lymphatic drainage 
pattern of the esophagus is complex with abundant lymph-capillary networks especially in 
the submucosa [12]. This results in a longitudinal lymphatic drainage as opposed to seg-
mental drainage as is the case in colorectal cancer [13].  Lymphoscintigraphy indicates that 
the main lymphatic pathways originating from the distal esophagus preferentially drain into 
the lymph node stations in the upper abdomen but also upwards into the mediastinum [14]. 
From previous studies we know that intra-thoracic lymph node metastases in patients with 
cardiac tumors are associated with a poor prognosis [15-18]. 
Identification of patients who will not benefit from surgical therapy is an important issue. 
Despite a great need for accurate staging prior to treatment of esophageal cancer, pro-
posed modifications of TNM staging are mostly based on post-surgery pathological staging. 
Moreover, location of positive lymph nodes has been abandoned in the 7th classification of 
the TNM. The present study shows that besides the number also the distribution of involved 
lymph nodes in relation to the diaphragm refines prediction of prognosis. A combined lymph 
node staging system is proposed in which patients currently staged as N2 (3 to 6 lymph 
nodes involved) comprises 2 groups of patients that can be distinguished by the distribution 
of the involved lymph nodes relative to the diaphragm. Multivariable analysis demonstrated 
that N2 disease distributed at both sides of the diaphragm was associated with a worse 
outcome compared to patients with the same number of lymph nodes involved but one side 
of the diaphragm. Subgroup analysis showed the same prognostic effect of lymph node 
metastases located at both sides of the diaphragam after stratification for location of primary 
tumor in the distal esophagus versus a tumour located at the gastroesophageal junction.  In 
addition, after adjusting for number of positive lymph nodes and other covariates in our co-
hort, nodal involvement on both sides of the diaphragm still confers a poorer prognosis than 
nodal involvement on one side of the diaphragm. It should be noted that the determination of 
location of nodal involvement on esophagectomy samples requires careful coordination be-
tween the surgical and pathological services.  In our experience, nodal stations that cannot 
be identified from anatomical landmarks of the specimen (eg subcarinal) should be identified 
as separate stations by the surgeon whereas nodal stations resected en-bloc with the stom-
ach can easily identified by the pathologist.    
More importantly, we have demonstrated that, before surgery, assessment of location 
by EUS was able to identify a subset of patients at high risk for early death. This study 
shows that  EUS is useful in dichotomizing patients’ preoperative nodal stage into locore-
gionally early (one-sided disease) or advanced (both-sided disease), which is very hard to 
do by counting individual nodes. It is the adequate pre-operative assessment of clinical 
TNM stage that largely determines whether a patient will benefits from surgery at all or 
whether surgery will not cure the disease [19,20]. Other studies have examined the value 
of EUS as a predictor of long-term survival in esophageal cancer patients [21-24] but no 
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study has examined the prognostic significance of the location of lymph node metastases 
on ultrasonography before. 
A surprising finding was that location of involved lymph nodes was able to predict sur-
vival during clinical staging by EUS, but lost its statistical significance after surgery in the 
assessment of the resection specimen. An explanation could be that post surgery effect of 
nodal status was diluted by stage migration secondary to neoadjuvant therapy with involved 
lymph nodes sterilized in the final surgical specimen. Sensitivity analysis in which patients 
who underwent neoadjuvant treatment were excluded did not change the hazard ratios in 
multivariable analysis and hence neoadjuvant therapy did not introduce selection bias.
The present study has limitations. Because the overall accuracy for EUS in predicting the 
N-stage per nodal station is moderate, mainly because of a high false-negative rate, this 
might give rise to an underestimation of the number of patients with nodal involvement on 
both sides of the diaphragm. In the absence of FNA, accuracy is 80% [25]. In an earli-
er study from Rotterdam, EUS predicted nodal status correctly in 137 out of 202 lymph 
node stations[6]. The accuracy was better for those stations located high in the chest 
(paratracheal and aortopulmonary window nodes) than for the peritumoral lymph nodes 
(subcarinal, paraesophageal and lesser curvature nodes). The lack of FNA sampling is not 
so much an issue in this paper that considers prognostication before surgery. If a lymph 
node would have been proved positive at a defined metastatic site, there would be no need 
to prognosticate anymore as the patient would go down the palliative pathway. Moreover, 
FNA adds considerable time to EUS and in the real world is often not done routinely. So 
the lack of FNA could also be considered a strength of the study and the results are likely 
to be external valid. 
Secondly, transhiatal esophagectomy, which was the predominant surgical approach in 
this study, may have affected the completeness of mediastinal lymph node dissection. How 
extensive a lymph node dissection should be for proper staging is unknown. In the pres-
ent study a transhiatal approach was associated with a better outcome. This is probably a 
biased effect due to ‘confounding by indication’: patients clinically staged as having more 
advanced disease were more often offered a transthoracic approach. A transthoracic ap-
proach yields more lymph nodes and thus a more robust nodal staging. It should therefore 
be noted that in the present study there is a risk of understaging - especially for lymph nodes 
above the diaphragm – and hence underestimation of the shown effect. We don’t feel that 
distribution of lymph nodes relative to the diaphragm is a surrogate of the number of nodes 
involved. Indeed there is a mean difference of 0.85 lymph node (4.39 positive lymph nodes 
in “3-6 LN both sides group” versus 3.54 positive lymph nodes in “3-6 LN one side group”; 
data not shown) but this difference is too small to explain the effect. Moreover, both mean 
number of nodes would be categorized as N2 by the 7th edition of the TNM staging system 
and apparently distribution relative to the diaphragm further stratifies prognosis.
Thirdly, the determination of nodal location following resection was left up to the pathol-
ogists. It is the experience of many surgeons that especially nodes around the esophago-
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gastric junction will be difficult to accurately localize unless the pathologist is directed by 
immediate feedback from the operating surgeon.  
Fourth, the EUS examinations were all performed by experienced endosonographers. 
While this may be considered a relative strength of the study, it may also be a potential 
weakness, because the results may not be applicable to centers with lower case loads, or 
without expert endosonographers. 
Finally, during the study period, only thirty-five percent of patients underwent neoad-
juvant therapy. This number is different from current Dutch and worldwide practice and 
might influence generalizability to the worldwide population of patients with esophageal 
adenocarcinoma. 
In conclusion, this retrospective study supports a subclassification of N-stage based on 
both number and location of lymph node metastases relative to the diaphragm, from both 
a clinical and a histopathological perspective. Because of the retrospective design and its 
intrinsic limitations, the study is only hypothesis generating. It supports the feeling of many 
surgeons that survival is related not only to the number of nodes involved, but also their 
anatomical location. It has to be validated whether a ‘hybrid’ staging system that is similar 
to TNM 7, but incorporates both number and location of involved lymph nodes, still stands 
using promising staging modalities such as contrast enhanced EUS or MRI with different 
types of contrast [26], preferably in association with CT (FDG) PET imaging.
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figure 1
Kaplan Meier overall survival curves of 327 patients stratified by (a) N-stage according to 7th edition 
TNM staging system, (b) by location of involved lymph nodes relative to the diaphragm and (c) by 
proposed combined lymph node staging system. Data are based on pathological findings as asses-
sed in the resection specimens.
figure 1 (a)
No. of patient at risk
years 0 2 4
N0 122 90 70
N1 85 49 22
N2 62 24 11
N3 58 10 2
Log Rank test: P<0.001
figure 1 (b) 
No. of patient at risk
years 0 2 4
No positive LN 122 90 70
Positive LN on  
one side
109 57 27
Positive LNs on  
both sides
96 26 8
Log Rank test: P<0.001
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figure 1 (c)
No. of patient at risk
years 0 2 4
No positive LN 122 90 70
1-2 LNs 85 49 22
3-6 LNs on one side 24 11 6
3-6 LNs on both sides 38 13 5
>6 LNs 58 10 2
Log Rank test: P<0.001
No. of patient at risk
years 0 1 2 3
No positive LNs 
or positive LNs 
on one side
86 65 37 11
Positive LNs on 
both sides
16 11 4 1
Log Rank test: P=0.027
figure 2
Kaplan Meier overall survival curves for 102 
patients stratified by location of involved nodes 
relative to the diaphragm as assessed by preop-
erative EUS (Log Rank test: P=0.027)
figure 2
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Supplementary figure 1
Number of lymph nodes harvested in surgical samples of patients with lymph node involvement on 
one side of the diaphragm versus both sides of the diaphragm.
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AbSTRACT
background
The new 7th edition of the Union for International Cancer Control–American Joint Commit-
tee on Cancer (UICC-AJCC) tumor, node, metastasis (TNM) staging system is the ratifica-
tion of data-driven recommendations from the Worldwide Esophageal Cancer Collaboration 
database. Generalizability remains questionable for single institutions. The present study 
serves as a validation of the 7th edition of the TNM system in a prospective cohort of pa-
tients with pre-dominantly adenocarcinomas from a single institution.
methods
Included were patients who underwent transhiatal esophagectomy with curative intent be-
tween 1991 and 2008 for invasive carcinoma of the esophagus or gastro-esophageal junc-
tion. Excluded were patients who had received neoadjuvant chemo(radio)therapy, patients 
after a noncurative resection and patients who died in the hospital. Tumors were staged 
according to both the 6th and the 7th editions of the UICC-AJCC staging systems. Survival 
was calculated by the Kaplan–Meier method, and multivariate analysis was performed with 
a Cox regression model. The likelihood ratio chi-square test related to the Cox regression 
model and the Akaike information criterion were used for measuring goodness of fit.
Results
A study population of 358 patients was identified. All patients underwent transhiatal eso-
phagectomy for ade-nocarcinoma. Overall 5-year survival rate was 38%. Univariate analysis 
revealed that pT stage, pN stage, and pM stage significantly predicted overall survival. Pre-
diction was best for the 7th edition, stratifying for all substages.
Conclusions
The application of the 7th UICC-AJCC staging system results in a better prognostic stratifi-
cation of overall survival compared to the 6th edition. The fact that the 7th edition performs 
better predominantly in patients with adenocarcinomas who underwent a transhiatal sur-
gical approach, in addition to findings from earlier research in other cohorts, supports its 
generalizability for different esophageal cancer practices.
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InTROdUCTIOn
Accurate staging of cancer is important for stage-specific treatment, thus minimizing inap-
propriate treatment. Moreover, it allows for interinstitutional comparisons and disclosure of 
prognosis to patients.[1] The staging system for cancer in the esophagus and esophago-
gastric junction has been revised as outlined in the 7th edition of the Union for Internation-
al Cancer Control/Union Internationale Contre le Cancer (UICC) and the American Joint 
Committee on Cancer (AJCC), Cancer Staging Manual.[2]
Retrospective studies suggested that the number of involved lymph nodes is a better 
predictor of outcome than classifying lymph node involvement as either present or absent.
[3,4] Peyre et al. showed that patients with 3 or more lymph nodes involved have a risk of 
systemic disease that exceeds 50%. When > 8 nodes are involved, the risk of dying is al-
most 100%.[5] Indeed, the latest 7th edition of the UICC-AJCC esophageal tumor, node, 
metastasis (TNM) staging system has acknowledged the importance of the number of in-
volved nodes by revising the N category from site-dependent staging to a numerically based 
classification into N0 to N3. Another major change is the definition of regional lymph nodes.
The new UICC-AJCC staging system is the ratification of data-driven recommenda-
tions from a database of [7800 esophageal cancer patients created from a large multi-in-
stitutional collaboration involving 13 institutions.[6,7] This Worldwide Esophageal Cancer 
Collaboration (WECC) database overcomes problems of rarity of this cancer, but generaliz-
ability remains questionable for single institutions. WECC incorporates high-volume centers 
both from the West (where adenocarcinomas prevail) and from the East (where most tumors 
are squamous cell carcinomas). Moreover, the extent of intrathoracic lymph node dissection 
can vary greatly between different institutions, leading to potential bias.
The present study serves as a validation of the WECC-based 7th edition of the TNM 
system in a cohort of patients with both squamous cell carcinomas and adenocarcinomas 
from a single Western high-volume institution. Two studies already showed that the 7th 
edition criteria resulted in better prognostic stratification than the 6th edition.[8,9] However, 
both study cohorts consisted of squamous cell carcinomas or junctional tumors, respective-
ly. Moreover, Gaur et al. included patients who received (neo)adjuvant therapy.[9]
The aim of this study was to assess the predictive ability of the 7th edition of the AJCC 
TNM staging system for overall survival and to compare this with the 6th edition in a cohort 
of patients who underwent transhiatal esophagectomy for adenocarcinomas without (neo)
adjuvant therapy.
PATIEnTS And mEThOdS
Study Population
Included were all patients who underwent a transhiatal esophagectomy with curative intent 
between January 1991 and September 2008 at the Erasmus Medical Center (Rotterdam, 
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The Netherlands) for invasive squamous cell carcinoma and adenocarcinoma of the esoph-
agus or gastroesophageal junction. Excluded were patients who had received neoadjuvant 
chemo(radio)therapy, patients after a noncurative (R1) resection (tumor-free margin\1 mm) 
and patients who died in the hospital. Clinicopathologic data of all patients had been rou-
tinely collected in an ongoing prospective registry.
Surgery
Transhiatal esophagectomy with cervical anastomosis was the chosen surgical approach 
in the present study. This encompasses the en-bloc dissection of the primary tumor and 
its adjacent lymph nodes under direct vision through the widened hiatus of the diaphragm 
up to the level of the inferior pulmonary vein. Subsequently, a 3–4-cm-wide gastric tube is 
created. The left gastric artery is transected at its origin with resection of celiac trunk lymph 
nodes. After mobilization and transection of the cervical esophagus, the intrathoracic mid-
dle and upper esophagus is bluntly dissected in an antegrade fashion with a vein stripper. 
Esophagogastrostomy is performed in the neck without a formal cervical lymphadenectomy.
follow-up
Surviving patients were followed at regular intervals at the outpatient clinic until 5 years after 
surgery. Outpatient clinic visits encompassed history taking and physical examination. No 
routine imaging was performed. Recurrences were sought afterward, only when clinically 
indicated, by CT scan or ultrasound and proven by histology and cytology whenever possi-
ble. Overall survival was defined as the time between date of operation and date of death. 
Surviving patients were censored on the day of last follow-up. Patient survival status was 
calculated after contacting the general practitioners (performed by a trained data manager). 
The last follow-up checkpoint was July 2010. If follow-up was incomplete, survival was veri-
fied in the municipal mortality registers.
Statistical Analysis
Tumors were staged according to both the 6th and 7th editions of the UICC-AJCC staging 
systems. Survival was calculated by the Kaplan–Meier method, and differences between 
curves were assessed by the log rank test. Two multivariable models were built, one with the 
6th edition and one with the 7th edition of the TNM staging system as categorical variables. 
The performance was tested for the model in which the stages were combined into four 
categories (I–IV) as well as for the model with all substages included (IA, IB, IIA, IIB, IIIA, 
IIIB, IIIC, IV). A multivariable model with both 6th and 7th edition criteria included was used 
to assess the remaining value of the 6th edition when the 7th edition information was known.
The likelihood ratio chi-square test related to the Cox regression model was used for 
measuring goodness of fit. The Akaike information criterion (AIC) was applied to correct for 
the potential bias in comparing prognostic systems with different number of stages.[10,11] 
The -2 log likelihood (which is the parameter in the Cox regression) of the 6th edition was 
compared to that of the 7th edition; the smaller the value of this statistic, the better the model.
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AIC was defined as: AIC = -2 log maximum likelihood + 2 x (the number of parameters in 
the model). A smaller AIC value indicates a more desirable model for predicting outcome. A 
value of P<0.05 was considered statistically significant. Statistical analysis was performed 
with SPSS 10 for Windows (SPSS, Chicago, IL).
RESUlTS
Patient Characteristics
A consecutive series of 766 patients underwent esophagectomy with curative intent. In total, 
221 patients were excluded because they had received neoadjuvant chemo(radio)therapy 
in the context of a randomized, controlled trial.[12] Another 165 patients were excluded be-
cause of a noncurative (R1) resection, and 20 patients were excluded because of in-hospital 
mortality. Two patients had an in situ carcinoma and were also excluded from the current 
analysis. This resulted in a final study population of 358 patients. Mean follow-up was 51 
months (median 37 months). Overall 5-year survival rate was 38%. Most recurrences of 
disease occurred within 2 years after surgery.
Patient characteristics and overall survival rates are summarized in Table 1. All patients 
underwent transhiatal esophagectomy for adenocarcinoma. Eight patients seemed to have 
distant metastasis during the operation; their disease was scored as M1.
Univariate analysis revealed that parameters pT stage, pN stage, and pM stage all 
significantly predicted overall survival. Except for histologic grade, no other significant pre-
dictors of survival were detected in this univariate analysis. The median number of dissected 
nodes per patient was 11. In patients with negative lymph nodes (pN0), the survival rates 
did not differ between patients with <=11 nodes and > 11 nodes dissected: 65% vs. 69%, 
respectively; P = 0.65; data not shown).
Stratification of Prognosis According to 6th and 7th Editions of Tnm Staging Systems
The overall survival curves according to the N classifications of the 6th and 7th editions are 
shown in Fig. 1a and b, respectively.
Patient stage migration for reclassifying patients from the 6th to the 7th staging sys-
tem and their survival rates are listed in Table  2. In 58% of the 358 esophageal cancer 
patients, stage did not differ in these two classification systems. Reassignment of disease 
stage occurred in all other patients, either to a higher or to a lower tier. According to the 
6th edition staging system, 56 (87%) of 64 stage IV patients were staged as such be-
cause of a celiac lymph node metastasis. These patients were reclassified to a lower tier 
in the 7th edition: 6 of 64 were staged as stage IIB, 15 as stage IIIA, 19 as IIIB, and 16 
as IIIC (Table 2).
The Kaplan–Meier curves of esophageal cancer patients based on the 6th and 7th 
editions of the TNM staging systems are depicted in Fig. 2. Both systems show a relatively 
ordered monotone distribution of survival. However, according to the 6th edition staging 
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system, the Kaplan– Meier plot shows overlapping curves for stage III and IV. In the 7th 
edition, no important overlapping occurs among stages I through IV.
Subgroup analysis among selected patients who had been considered to have stage 
IV disease according to the UICC-AJCC 6th edition scoring system showed that patients 
reclassified from stage IV disease to a lower tier in the UICC-AJCC 7th edition had a signifi-
cantly better survival compared to patients still classified as stage IV according to the UICC-
AJCC 7th edition. Moreover, the UICC-AJCC 7th edition was able to make further signifi-
cant stratification of survival rates of these reclassified patients (Fig. 3; log rank P = 0.43).
The UICC-AJCC 7th edition staging system defines patients with positive paraesoph-
ageal cervical lymph nodes (n = 10) as having stage IIIA or IIIB disease. These patients, 
however, had a prognosis as bad as that of patients with distant metastasis (1-year overall 
survival rate 30% vs. 33%).
The performance of the 7th edition staging systems won quantified by the likelihood 
ratio chi-square and AIC (Table 3). Predictive ability was best for the full 7th edition criteria 
stratifying for all substages (highest likelihood ratio X2). AIC value was smaller for the 7th 
edition compared to the 6th edition staging system, indicating that it has a better prognostic 
stratification. The AIC value was lowest when patients with cervical lymph node metastasis 
at a large distance from the primary tumor (i.e., the lower third of the esophagus) were also 
classified as having stage IV disease. When the 6th and 7th edition staging systems are 
both included in one Cox regression model, the 6th edition no longer significantly predict-
ed survival, whereas the 7th edition remained a significant stratifier of prognosis (data not 
shown).
dISCUSSIOn
This study shows that both the 6th and 7th UICC-AJCC TNM staging systems have a dis-
tinctive and monotone (ordered) relationship of stage group to overall survival for esopha-
geal cancer patients who have undergone potentially curative surgery without (neo)adjuvant 
therapy. Distribution of patients among different stages is in line with that described in the 
literature. All groups are large enough for proper statistical analysis, except for stage IIA in 
the 7th edition.
Further testing of both systems on the present data shows that the 7th edition has the 
best performance because of the lowest AIC (i.e., a better fit) when Cox regression models 
are used. Survival curves stratified according to the UICC-AJCC 7th edition TNM staging 
system did not overlap, which is in contrast to the curves of the 6th edition. Moreover, further 
stratification of N stage according to number of positive lymph nodes in the 7th edition is 
indeed valuable, as shown in Fig. 1.
A major change in the new TNM staging system is the definition of regional lymph 
nodes. There has always been debate regarding the prognostic importance of positive ce-
liac nodes, which were considered distant metastases in earlier editions.[13] In the 6th 
209846-L-bw-Talsma
6 5
Comparison of the 6th and 7th editions of the UICC-AJCC TNM classification for esophageal cancer
4
edition staging system, the Kaplan–Meier plot showed overlapping curves for stage III and 
IV. According to the UICC-AJCC 7th edition, only patients with distant metastasis can be 
categorized as having stage IV disease. In contrast, according to the 6th edition, most stage 
IV disease was due to nonregional celiac lymph node metastasis, whereas stage IIB and III 
consisted of regional lymph node metastasis. Hence, 87% (56 of 64) of the patients with 
stage IV disease who were assessed according to the 6th edition criteria were reclassified 
as having stage IIB, IIIA, IIIB, and IIIC disease according to 7th edition criteria. Because 
these stages all had different survivals (Fig. 3), the present results support the new con-
cept that it is unnecessary to identify nonregional lymph node metastasis and to label these 
nodes as M1A or M1B.
Two previous studies have compared the performance of 6th with the 7th editions 
of the TNM staging system in predicting survival. Hsu et al. evaluated 392 patients who 
underwent primary surgical resection through a tri-incisional approach in Taiwan during 
1995–2006 [8] In the other study, nearly two-thirds of the patients received neoadjuvant 
therapy.[9] Both Hsu et al. and Gaur et al. concluded  that the 7th edition of the staging sys-
tem was a better model for pre-dicting outcome.[8,9] The most important difference with the 
present study is tumor histology; the vast majority of our patients had an adenocarcinoma, 
and almost all patients underwent a transhiatal resection.
The WECC-based 7th edition of the TNM staging sys-tem was built on data from pa-
tients without neoadjuvant treatment in a squamous cell carcinoma predominant database. 
Our sample population from a single institution is of course small compared with the world-
wide esophageal cancer collaboration database, but the surgical procedures were highly 
uniform throughout the entire study period. The previous studies of Hsu et al. and Gaur et 
al., as well as the present study, underline the generalizability of the 7th edition and make it 
broadly applicable for daily clinical practice of esophageal cancer surgery around the world.
[8,9]
The 7th edition of the UICC-AJCC esophageal TNM staging system has acknowl-
edged the importance of the number of involved nodes by subdividing the N classification 
into N0 to N3. The transhiatal approach may profoundly affect the completeness of lymph 
node dissection and, accordingly, proper nodal staging. On the basis of data from a Dutch 
trial, nowadays, tumors proximal of esophagogastric junction (Siewert type 1) are preferably 
offered a transthoracic approach in our institution.[14,15] The latter approach will result in 
the collection of more lymph nodes and might give a more valid node sampling for staging. 
To which extent lymph nodes should be sampled for proper staging remains an important 
issue.[16] In a study performed by Peyre et al., the number of lymph nodes removed was an 
independent predictor of survival and a minimum number of 23 regional lymph nodes was 
pro-posed.[17] In the present study, the median number of nodes removed in a transhiatal 
approach was 11. This relatively scarce lymph node collection result can be seen as a 
drawback of our study, but it also gives rise to a remarkable finding. Although all patients 
underwent a transhiatal esophagectomy, the survival curves of different N stages (N0–N3; 
Fig. 1) do not overlap in our data, which probably indicates that there has been a valid and 
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robust node sampling. On the other hand, there seems to be a relatively large difference in 
survival rate between N0 and N1. We know from previous studies that there is a dichotomy 
in survival rate between tumors that did and did not lymphatically disseminate.[18] Early 
tumors (pT1) with lymph node invasion have prognosis comparable to tumors with more 
advanced T stage. Lymphatic dissemination is an independent indication of the biological 
aggressiveness of the tumor.
However, the large step in survival rate between N0 and N1 might also be due to a 
stage migrational effect. This, the so-called Will Rogers effect, means that stage N1 disease 
might actually include N2 or even N3 disease as a result of invalid node sampling.[19] The 
WECC group has indicated a resection of a minimum of 10 nodes for T1, 20 for T2, and 
>=30 nodes for T3–4 to be resected to obtain optimal results.[20] In N0 patients, such an 
effect does not occur; we found no significant difference in survival rates according to the 
number of resected lymph nodes in lymph node–negative patients. However, a median of 11 
nodes definitely entails the risk of a stage migration effect in the patient group with positive 
nodes.
Finally, an important question remains: does a better predictive staging system have 
consequences for preoperative decision making? Medical decision making in terms of ad-
ministering neoadjuvant chemotherapy and choosing the optimal surgical approach for es-
ophagectomy is often based on clinical N staging. Lack of accurate preoperative staging 
is a major problem in allocating treatment modalities in these patients. It has been recently 
shown that further stratification according to the position of the positive node relative to the 
diaphragm can effectively discriminate between node-positive patients.[21] The overall ac-
curacy for endoscopic ultrasound and CT in predicting the N stage per station is moderate, 
however. When the therapeutic approach depends on the status of a specific lymph node 
station, a more objective and reliable assessment of lymph nodal involvement (e.g., endo-
scopic ultrasound–fine-needle aspiration) should be considered.[22]
This study indicates that the application of the 7th UICC-AJCC staging system re-
sults in a better prognostic stratification of overall survival compared to the 6th edition. The 
fact that the 7th edition also has a superior prognostic ability in this study population from 
a single high-volume institution with predominantly adenocarcinomas and a two-incisional 
surgical approach supports its generalizability for different esophageal cancer practices.
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Table 1
Patient demographics and results of univariate analysis for overall survival (N = 358)
Characteristic Value 5-y survival, % P
No. of patients 358
Age, year, mean (range) 62.6 (28–83) 38.8
Gender
Male 293 (82%) 37.2 0.664
Female 65 (18%) 45.9
pT
1 78 (22%) 68.7 <0.001
2 79 (22%) 51.1 <0.001
3 201 (56%) 22.7
pN
0 146 (41%) 65.9 <0.001
1 90 (25%) 28.4 <0.001
2 81 (23%) 17.5 <0.001
3 41 (11%) 3.0
pM
0 350 39.7 <0.001
1 8 0.0
Grade
Well differentiated (G1) 31 (9%) 75.3 <0.001
Moderately differentiated (G2) 177 (49%) 39.4 <0.053
Poorly differentiated (G3) 150 (42%) 30.9
Histology
Squamous cell carcinoma 47 (13%) 41.9 0.752
Adenocarcinoma 311 (87%) 38.3
Location
Upper third 6 (2%) 30.4 0.352
Middle third 14 (4%) 42.6 0.325
Lower third (distal ? EGJ) 338 (94%) 36.9
Type of surgical approach
Transhiatal esophagectomy 358 (100%)
Transthoracic esophagectomy
T tumor stage (depth of invasion), N lymphatic dissemination stage (according to 7th edition of UICC-
AJCC TNM staging system: N0 no positive lymph nodes, N1 1–2 positive lymph nodes, N2 3–6 
positive lymph nodes, N3 C6 positive lymph nodes), M distant metastasis stage (according to 7th 
edition of UICC-AJCC TNM staging system: M0 no metastasis, M1 distant metastasis present), EGJ 
esophagogastric junction
4
209846-L-bw-Talsma
Tables and figures
68
Chapter 4
Table 2 
Cross table of staging esophageal cancer patients according to the 6th and 7th editions of UICC-
AJCC TNM staging
6th editiona 5 year-survival 
according to 
7th edition 
(%)
I IIA IIB III IV
7th editionb
IA 43 0 0 0 0 87.7
IB 13 28 0 0 0 73.3
IIA 0 19 0 0 0 55.3
IIB 0 41 24 0 6 40.1
IIIA 0 0 21 50 15 24.3
IIIB 0 0 0 31 19 11.9
IIIC 0 0 4 20 16 3.1
IV 0 0 0 0 8 0.0
5 year-survival 
according to 6th 
edition (%)
81.9 56.8 38.3 14.1 12.4
M1a celiac nodes involved in lower esophageal cancer or cervical nodes involved in upper esophageal 
cancer, M1b beyond locoregional node involvement (i.e., cervical nodes in lower esophageal cancer 
and celiac nodes in upper esophageal cancer; metastatic involvement of visceral organs, pleura, 
peritoneum)
a The 6th edition AJCC-UICC TNM staging system: stage I T1N0, stage IIA T2,3N0, stage IIB T1,2N1, 
stage III T3N1 or T4N0, stage IVA TanyNanyM1a, stage IVB TanyNanyM1b. The 7th edition AJCC-UICC TNM 
staging system (for adenocarcinoma): stage IA T1N0G1,2, stage IB T1N0G3 or T2N0G1,2, stage IIA T2N0, 
stage IIB T3N0 or T1,2N1, stage IIIA T4N0 or T3N1 or T1,2N2, stage IIIB T3N2, stage IIIC TanyN3 or T4aN1–3 or 
T4bNany, stage IV Tany,Nany,M1
Table 3
Prognostic stratification of the 6th and 7th editions of the UICC-AJCC TNM staging systems
Model Figure Subgroups LR v2 AIC valuea
6th edition 2a I, II, III, IV 96.9 2607.1
7th edition, full 2b IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV 128.6 2592.9
7th edition, collapsed I, II, III, IV 99.0 2605.4
AIC Akaike information criteria, LR likelihood ratio
a  A lower AIC value represents a better discriminatory model
4
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figure 1
Kaplan–Meier overall survival curves for 358 patients stratified by N stage according to a: 7th edition 
and b: 6th edition UICC-AJCC TNM staging systems (overall log rank P\0.01)
figure 1 (a)                                                               figure 1 (b)
figure 2
Kaplan–Meier curves of overall survival for 358patients stratified according to a: 6th edition and b: 
7th edition UICC-AJCC TNM staging systems
figure 2 (a)                                                               figure 2 (b)
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figure 3
Kaplan–Meier overall survival curves for 64 UICC-AJCC 6th stage IV patients who were reclassified 
according to UICC-AJCC 7th edition TNM staging (log rank P = 0.43)
4
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AbSTRACT
Objectives
We aimed to examine the association between total number of resected nodes and survival 
in patients after esophagectomy with and without neoadjuvant chemoradiotherapy (nCRT). 
background data
Most studies concerning the potentially positive effect of extended lymphadenectomy on 
survival have been performed in patients who underwent surgery alone. As nCRT is known 
to frequently ‘sterilize’ regional nodes, it is unclear whether extended lymphadenectomy 
after nCRT is still useful.
methods
Patients from the randomized CROSS-trial who completed the entire protocol (i.e. surgery 
alone or chemoradiotherapy plus surgery) were included. With Cox regression models we 
compared the impact of number of resected nodes as well as resected positive nodes on 
survival in both groups.
Results
161 patients underwent surgery alone and 159 patients received multimodality treatment. 
Median (interquartile range) number of resected nodes was 18(12-27) and 14(9-21), with 
2(1-6) and 0(0-1) resected positive nodes respectively. Persistent lymph node positivity after 
nCRT had a greater negative prognostic impact on survival as compared to lymph node pos-
itivity after surgery alone. Total number of resected nodes was significantly associated with 
survival for patients in the surgery alone arm (hazard ratio (HR) per 10 additionally resected 
nodes, 0.76; p=0.007), but not in the multimodality arm (HR 1.00; p=0.98). 
Conclusions
The number of resected nodes had a prognostic impact on survival in patients after surgery 
alone, but its therapeutic value is still controversial. After nCRT, number of resected nodes 
was not associated with survival. These data question the indication for maximization of 
lymphadenectomy after nCRT.
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InTROdUCTIOn
Esophageal cancer is associated with early and chaotic lymphatic dissemination to both 
the neck, chest and abdomen [1, 2]. The lymphadenectomy accompanying esophagectomy 
is the main oncological factor that can be influenced by the surgeon, besides a complete 
resection of the primary tumor. Many investigators have previously attempted to explore the 
potential benefits of extended lymphadenectomy which include more accurate disease stag-
ing, better locoregional disease control, and perhaps even improved long-term survival. For 
staging purposes a more extended lymphadenectomy is intuitively superior to a more limited 
nodal dissection [3, 4]. The therapeutic impact of extended lymphadenectomy in esopha-
geal cancer surgery, however, has remained controversial. Some authors state that surgery 
has reached its maximum therapeutic impact with limited lymphadenectomy, while others 
believe that the course of the disease can be influenced favorably by aggressive surgery 
with a more extended lymphadenectomy [5, 6]. Although most studies have concluded that 
lymph node retrieval is associated with improved survival, the majority of these studies have 
been performed in patients undergoing surgery alone, which has led to recommendations 
regarding the optimal extent of lymphadenectomy ranging from 6-30 nodes [7, 8]. Oth-
er studies investigated designated fields of dissection [3, 4]. Prospective trials have been 
performed comparing survival after transhiatal and transthoracic esophagectomy [9], but a 
recent meta-analysis did not show any difference in survival between limited transhiatal and 
extended transthoracic operations [10]. 
Especially after publication of the randomized controlled CROSS trial [11], neoad-
juvant chemoradiotherapy (nCRT) has become standard of care for esophageal cancer 
patients in many countries. As nCRT is known to frequently ‘sterilize’ regional nodes, it is 
unclear whether extended lymphadenectomy after nCRT is still indicated for prognostic and 
therapeutic reasons. The aim of the present study was, therefore, to examine the association 
between the total number of resected nodes and survival in patients with esophageal cancer 
undergoing surgical resection with and without nCRT.
mEThOdS
Study population and follow-up 
The study population consisted of patients who participated in the randomized CROSS-tri-
al from March 2004 through December 2008 [11]. Patients with histologically confirmed, 
potentially curable carcinoma of the esophagus or esophagogastric junction were randomly 
assigned to receive surgery alone or neoadjuvant chemoradiotherapy followed by surgery. 
The randomization process was stratified for histological tumor type, center and clinical 
N-stage. Patients were excluded who underwent exploratory thoracotomy or laparotomy 
only. Follow-up took place at regular intervals with a minimal follow-up of 24 months. 
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Clinical and pathological staging
Pretreatment clinical staging included endoscopy (and ultrasonography) with biopsy and 
CT of the neck, chest, and upper abdomen; and external ultrasonography of the neck, with 
fine-needle aspiration of suspected cervical lymph nodes. The surgical resection specimen 
was processed according to a standardized protocol. The clinical and pathological staging 
were based on the 6th and 7th edition of the TNM staging system respectively [12]. Tumor 
regression after nCRT was classified in the resection specimen as major response: ≤10% 
viable tumor cells  and minor response: >10% viable tumor cells.
neoadjuvant treatment and surgical approach
Patients randomized to neoadjuvant treatment underwent weekly administration of carbo-
platin (doses titrated to achieve an area under the curve of 2 mg/ml/min) and paclitaxel (50 
mg/m2) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days/week), 
followed by surgery. 
For esophageal carcinomas at or above the level of the carina a transthoracic eso-
phagectomy (TTE) with two-field lymph node dissection was performed. For carcinomas lo-
cated well below the level of the carina, either a TTE with two-field lymph node dissection or 
a transhiatal esophagectomy(THE) was performed. THE encompassed en bloc dissection 
of the primary tumor and its adjacent lymph nodes under direct vision through the widened 
diaphragmatic hiatus up to the level of the inferior pulmonary vein. Dissected lymph nodes 
in the upper abdomen included the paracardial, lesser curvature, left gastric artery, celiac 
trunk, common hepatic artery, and splenic artery nodes. TTE included en bloc dissection 
of the azygos vein, thoracic duct, ipsilateral pleura, and all peri-esophageal tissue in the 
posterior mediastinum. Compared to THE, the resection specimen after TTE additionally in-
cluded the middle mediastinal, subcarinal, paratracheal and aortopulmonary window lymph 
nodes. In the present study, ‘extended’ lymphadenectomy was defined in terms of numbers 
of lymph nodes retrieved.
Statistical analysis
Descriptive statistics included median and interquartile range for continuous variables and 
percentages for categorical variables. Mann-Whitney, Chi-square, and log-rank tests were 
used to assess statistical significance (p<0.05, two-sided). Overall survival was defined as 
the time interval between day of randomization and day of censoring or death and analysed 
with Kaplan-Meier and Cox regression analysis. Scatter plots of number of resected nodes 
versus number of resected positive nodes were constructed separately for both randomiza-
tion arms. In these scatter plots, lines were fitted representing equal probabilities of death 
as calculated with Cox regression models. All analyses were performed using SPSS ver-
sion 19.0 (SPSS Inc, Chicago, IL, USA) and R (version 2.14, R foundation for statistical 
computing, Vienna, Austria).
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RESUlTS
Patient and tumor characteristics
Of 368 patients enrolled in the original CROSS trial, 180 were randomly assigned to 
nCRT+surgery, and 188 to surgery alone. In the nCRT+surgery group 161 patients actu-
ally underwent resection, of whom two patients were excluded from the present analysis 
because of missing values on the exact number of resected nodes. In the surgery alone 
group 161 actually underwent resection. In both groups, two out of three patients had signs 
of lymph node involvement during pretreatment investigations (Table 1). Both groups were 
similar in the surgical approaches that were chosen. nCRT resulted in clear downstaging; 
in almost forty percent of patients no vital tumor cells were identified in the esophageal wall 
after nCRT (ypT0). R0 resection rate increased from 69% in the surgery alone group to 
93% in the nCRT+surgery group (p<0.01).
Impact of nCRT on number of resected nodes and number of resected positive 
nodes 
The distribution of the number of resected nodes for both randomization groups is present-
ed in Figure 1, showing a leftward shift (i.e. fewer resected nodes) in the nCRT+surgery 
group. Median number (interquartile range) of resected nodes was 18(12-27) for the surgery 
alone group and 14(9-21) for the nCRT+surgery group (Table 1).  Mean difference in number 
of resected nodes between the surgery alone and nCRT+surgery group was 4.3 (p<0.001). 
Number of resected nodes was not associated with radicality of resection in both groups 
(data not shown).
Median number (interquartile range) of resected positive nodes for the surgery alone 
and nCRT +surgery group was 2(1-6) and 0(0-1) respectively (Table 1), resulting in a left-
ward shift in the 7th TNM N-stage distribution of the nCRT+surgery group (Supplementary 
figure 1). Fewer positive nodes (mean difference, 3.4 nodes; p<0.001), but a compara-
ble number of negative nodes (mean difference, 1.0 nodes; p=0.37) were resected in the 
nCRT+surgery group as compared to the surgery alone group (Supplementary figure 2).
Impact of number of resected nodes on number of resected positive nodes 
In the surgery alone group a positive association was identified between number of re-
sected nodes and number of resected positive nodes. This association was absent in the 
nCRT+surgery group (Figure 2). The mean number of resected positive nodes in patients 
who underwent surgery alone ranged from 2.4 in patients with 0-10 resected nodes to 5.9 
in patients *25 resected nodes. 
Impact of number of resected (positive) nodes on survival 
For surviving patients, the median follow-up was 48.7 months (range 25.5-80.9). The overall 
survival rate at 5 year was 44%, with 37% in the surgery alone group as compared to 50% 
in the nCRT+surgery group (p=0.004). 
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At univariable analysis, age, ypT-stage, resection margin involvement and number of 
resected positive nodes tended to be associated with survival in both groups (Table 2). In 
multivariable Cox regression analysis, the number of resected nodes was significantly asso-
ciated with survival (HR 0.76 per every 10 additionally resected nodes; p<0.01) in patients 
who underwent surgery alone. However, in the nCRT+surgery group, number of resected 
nodes was not associated with survival (HR 1.00, p=0.87), nor was it associated with sur-
vival within ypN0, ypN1 or ypN1-ypN3 patients (data not shown). The number of resected 
positive nodes was associated with survival in both groups, but lymph node positivity after 
nCRT was associated with a more negative impact on survival compared to lymph node 
positivity after surgery alone (HR 1.18 vs HR 1.12 per every additionally resected positive 
node, respectively), especially in combination with a minor pathological response to nCRT 
(HR 1.38, p<0.05; data not shown).  Additionally, a stratified analysis for histological tumor 
type showed that the significant impact of number of resected nodes observed in adenocar-
cinoma patients treated by surgery alone (every 10 additionally resected nodes HR=0.71; 
p<0.05) disappeared after nCRT (HR=1.06; n.s.). In the group of squamous cell carcinoma 
patients there was a similar (smaller) effect after nCRT, but sample sizes were probably too 
small to reach significance (surgery alone: HR=0.73; n.s. vs. nCRT+surgery: HR=0.84; n.s.). 
In Figure 3 scatter plots are shown that depict the same correlation between number 
of resected nodes and number of resected positive nodes as is visualized in Figure 2, but 
now for all individual patients. At a given number of resected positive nodes, the probability 
of death in the surgery alone group will become lower when the number of resected nodes 
increases (Figure 3A), but will remain unchanged and will even tend to become higher in the 
nCRT+surgery group (Figure 3B).
dISCUSSIOn
After nCRT, the number of resected nodes and number of resected positive nodes were 
significantly decreased, as compared to the surgery alone group. Also, the positive corre-
lation between number of resected nodes and number of resected positive nodes, which 
was significant in the surgery alone group, was not present in the nCRT+surgery group. The 
number of resected nodes was an independent prognostic factor for survival in patients who 
underwent surgery alone, but not in patients treated with nCRT followed by surgery. The 
addition of nCRT to surgery resulted in a significantly reduced number of resected positive 
nodes, but after this multimodality treatment node positivity was more strongly inversely 
associated with survival than after surgery alone.
Prognostic implications of number of resected nodes
Identifying positive nodes is informative for a patient’s prognosis. In the present study, the 
decreased number of nodes retrieved in the nCRT+surgery group resulted exclusively from 
a reduction in number of resected positive nodes, while the number of resected negative 
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nodes was similar in both groups (Supplementary figure 2). This might be because many 
positive nodes are sterilized by nCRT [13]. Therefore, many initially positive nodes will con-
tribute to the node negative category in the resection specimen after nCRT. The overall de-
crease in nodes resected after nCRT might therefore be compensated in the node negative 
category by the addition of formerly positive (i.e. sterilized) nodes. Interestingly, not only did 
the number of resected nodes and number of resected positive nodes decrease upon addi-
tion of nCRT to surgery, also the “upstaging” effect of number of resected nodes on number 
of resected positive nodes disappeared (Figure 2). This (absent) correlation suggests that 
the number of resected positive nodes found after nCRT is less dependent on sampling 
compared to resected positive nodes found after surgery alone. 
In patients treated with surgery alone, the number of resected nodes was not correlat-
ed with overall survival in univariable analysis. However, in multivariable analysis, after cor-
rection for the number of resected positive nodes, the number of resected nodes did show 
an independent association with overall survival (Table 2). The difference in association from 
univariable to multivariable analysis is most likely caused by the dominant and confounding 
effect of resected positive nodes. Thus, after correction for the number of resected positive 
nodes, the smaller but significant prognostic effect of number of resected nodes is revealed. 
For patients undergoing nCRT plus surgery, however, neither in univariable analysis, 
nor in multivariable analysis an association was found between the number of resected 
nodes and overall survival. Apparently, the prognostic value of the total number of resected 
nodes for survival is lost in patients treated with nCRT +surgery, even after correction for 
the number of resected positive nodes.
In the CROSS trial, the favorable effect of nCRT on lymph node positivity has been 
clearly shown: in the surgery alone group 76% of patients were pathologically node positive, 
versus 32% in the nCRT+surgery group. However, lymph node positivity in the nCRT+sur-
gery group in itself tended to have a stronger negative prognostic impact on survival as 
compared to that in the surgery alone group. Apparently, persistent lymph node positivity 
after nCRT reflects a biologically unfavorable tumor biology, which is in line with previous 
publications [14-17]. 
Therapeutic considerations
After correction for the number of resected positive nodes, the number of resected nodes 
was significantly associated with survival in the surgery alone group (Table 2). Removal of 
negative nodes might hence have not only a prognostic impact, but also a therapeutic impact 
in this group. The most important hypothesis supporting such genuine survival benefit of an 
extended lymphadenectomy is the clearance of micrometastases that can be present in up 
to 50% of histology-negative nodes and are associated with a poor outcome [18-20]. 
Some previous studies have shown that increasing the number of resected nodes is 
still relevant after nCRT [21-23], while other studies have concluded that it is not. [16, 24-
26] In the present data, within the nCRT+surgery group, no such prognostic impact of the 
number of resected nodes could be identified, let alone any therapeutic impact on survival. 
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This could possibly be explained by the sterilization of micrometastases after chemoradio-
therapy.[27] 
Some authors question any therapeutic impact of extended lymphadenectomy. In their 
view, lymph node metastases are simply markers of systemic disease and removal of the 
primary lesion plus the easily accessible peritumoral nodes alone will yield a similar survival 
[28]. Their alternative explanation is that the suggested therapeutic effect is based on stage 
migration. Stage migration occurs when positive nodes in the extended part of the dissec-
tion change N-stage to a higher category (surgery alone group in Figure 2), but at the same 
time have a more favorable prognosis than patients with a similar number of positive nodes 
from a more limited dissection (the so-called ‘Will Rogers phenomenon’ [29]). This ‘stage 
purification’ leads to unreliable stage-by-stage comparisons of survival. 
In the present study, ‘extended lymphadenectomy’ was defined in terms of numbers 
of lymph nodes retrieved, which is a more reliable variable to study compared to surgical 
approach, which is not always synonymous with extent of lymph node stations sampling. 
Unfortunately, data on the exact location of lymph node stations from which individual lymph 
nodes were retrieved were not available. The strength of the present study is that patients 
were randomized. Therefore, the described difference in impact of the number of resected 
nodes on survival between both arms can be attributed to neoadjuvant chemoradiotherapy 
specifically. The multicenter design is both a strength (because of great variability and there-
fore generalizability) and a limitation (since there was no strict protocol for surgical approach 
nor for extent of lymph node stations sampling). To properly address the impact of surgical 
approach on lymph node retrieval and survival, a new randomized trial should be performed 
comparing a transhiatal and transthoracic approach after nCRT. Finally, the relatively small 
number of patients per randomization arm limited the statistical power.  
In conclusion, lymph node positivity, especially if persistent after nCRT, is a strong 
negative prognostic factor for overall survival. The number of resected lymph nodes has an 
independent prognostic impact on survival in patients who undergo surgery alone. The ther-
apeutic value of extended lymphadenectomy, however, remains questionable in this group. 
After nCRT, the number of resected nodes is not associated with survival. These data ques-
tion the indication for maximization of lymph node dissection after nCRT for staging purpos-
es as well as for therapeutic reasons.
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figure 1
Distribution of number of resected lymph nodes as assessed in the resection specimen of patients 
who underwent surgery alone (n=161) or neoadjuvant chemoradiotherapy (nCRT) followed by sur-
gery (n=159). Compared to the surgery alone group, a leftward shift (i.e. fewer resected nodes) was 
observed in the nCRT+surgery group.
figure 2
Correlation between number of resected nodes (quartiles) and mean number (95% confidence 
interval) of resected positive nodes in patients who underwent surgery alone (n=161) or chemora-
diotherapy (nCRT) followed by surgery (n=159). 
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FIGURE 1. Distribution of number of resected lymph nodes as
assessed in the resection specimen of patients who underwent
surgery alone (n = 161) or nCRT followed by surgery (n =
159). Compared with the surgery-alone group, a leftward shift
(ie, fewer resected nodes) was observed in the nCRT + surgery
group.
FIGURE 2. Correlation between number of resected nodes
(quartiles) and mean number (95% confidence interval) of re-
sected positive nodes in patients who underwent surgery-alone
(n = 161) or chemoradiotherapy (nCRT) followed by surgery
(n = 159).
in the number of resected positive nodes whereas the number of re-
sected negative nodes was similar in both groups (see Supplemental
Digital Content Fig. 2, available at http://links.lww.com/SLA/A643).
This might be because many positive nodes are sterilized by nCRT.13
Therefore, many initially positive nodes will contribute to the node
negative category in the resection specimen after nCRT. The overall
decrease in nodes resected after nCRT might therefore be compen-
sated in the node negative category by the addition of formerly pos-
itive (ie, sterilized) nodes. Interestingly, not only did the number of
resected nodes and the number of resected positive nodes decrease
upon addition of nCRT to surgery, also the “upstaging” effect of the
number of resected nodes on the number of resected positive nodes
disappeared (Fig. 2). This (absent) correlation suggests that the num-
ber of resected positive nodes found after nCRT is less dependent on
sampling compared with resected positive nodes found after surgery
alone.
In patients treated with surgery alone, the number of resected
nodes was not correlated with overall survival in univariable analysis.
However, in multivariable analysis, after correction for the number
of resected positive nodes, the number of resected nodes did show an
independent association with overall survival (Table 2). The differ-
ence in association from univariable to multivariable analysis is most
likely caused by the dominant and confounding effect of resected pos-
itive nodes. Thus, after correction for the number of resected positive
nodes, the smaller but significant prognostic effect of the number of
resected nodes is revealed.
For patients undergoing nCRT + surgery, however, neither in
univariable analysis nor in multivariable analysis an association was
found between the number of resected nodes and overall survival.
Apparently, the prognostic value of the total number of resected nodes
for survival is lost in patients treated with nCRT+ surgery, even after
correction for the number of resected positive nodes.
In the CROSS trial, the favorable effect of nCRT on lymph
node positivity has been clearly shown: In the surgery-alone group,
76% of patients were pathologically node positive versus 32% in
the nCRT + surgery group. However, lymph node positivity in the
nCRT + surgery group in itself tended to have a stronger negative
prognostic impact on survival as compared with that in the surgery-
alone group. Apparently, persistent lymph node positivity after nCRT
reflects a biologically unfavorable tumor biology, which is in line with
previous publications.14–17
Therapeutic Considerations
After correction for the number of resected positive nodes, the
number of resected nodes was significantly associated with survival
in the surgery-alone group (Table 2). The removal of negative nodes
might hence have not only a prognostic impact but also a therapeu-
tic impact in this group. The most important hypothesis supporting
such genuine survival benefit of an extended lymphadenectomy is
the clearance of micrometastases that can be present in up to 50% of
histology-negative nodes and are associatedwith a poor outcome.18–20
Some previous studies have shown that increasing the number
of resected nodes is still relevant after nCRT,21–23 whereas other stud-
ies have concluded that it is not.16,24–26 In the present data, within the
nCRT + surgery group, no such prognostic impact of the number of
resected nodes could be identified, let alone any therapeutic impact
on survival. This could possibly be explained by the sterilization of
micrometastases after chemoradiotherapy.27
Some authors question any therapeutic impact of extended
lymphadenectomy. In their view, lymph node metastases are simply
markers of systemic disease and the removal of the primary lesion
and the easily accessible peritumoral nodes alone will yield a similar
survival.28 Their alternative explanation is that the suggested ther-
apeutic effect is based on stage migration. Stage migration occurs
when positive nodes in the extended part of the dissection change
N-stage to a higher category (surgery-alone group in Fig. 2) but at
the same time have a more favorable prognosis than patients with a
similar number of positive nodes from a more limited dissection (the
so-called “Will Rogers phenomenon”).29 This “stage purification”
leads to unreliable stage-by-stage comparisons of survival.
In the present study, “extended lymphadenectomy” was de-
fined in terms of numbers of lymph nodes retrieved, which is a more
reliable variable to study compared with a surgical approach, which
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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FIGURE 1. Distribution of number of resected lymph nodes as
assessed in the resection specim n f patients who underwent
surgery alone (n = 161) or nCRT followed by surgery (n =
159). Compared with the surgery-alone group, a leftward shift
(ie, fewer resected nodes) was observed in the nCRT + surgery
group.
FIGURE 2. Correlation between number of resected nodes
(quartiles) and me n number (95% confidence interval) of r -
sected positive nodes in pati nts who u derwent surgery-alone
(n = 161) or chemoradioth rapy (nCRT) followed by surgery
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c rection for the number of resected positive nodes.
In the CROSS trial, th favorable eff ct of nCRT on lymph
node positivity has been clearly sh wn: In the surgery-alone group,
76% of patients wer pathologically node po itiv versus 32% in
the nCRT + surgery group. However, lymph node positivity in the
nCRT + surgery group in itself t nded to have a str nger negativ
prognostic impact on survival as compared with that in the surgery-
al ne group. Appare tly, persistent lymph node positivity after nCRT
reflects a biologic lly unfavorable tumor biology, which is in line with
previous publications.14–17
Therapeutic Considerations
After correction for the number of resected positive nodes, the
number of esected nodes was significantly associated with survival
in the surgery-alone group (Table 2). The removal of negative nodes
might hence h ve not nly a prognostic impact but also th rapeu-
tic impact in this gr up. The m st important hypothe is supporting
such genuine survival benefit of an extended lymphadenectomy is
the clearanc of micrometastases that can be present in up to 50% of
histology-negative nodes and ar associ ted with a poor outc me.18–20
Som pre ious studies have hown that increasing the number
of resected nod s is still rel vant after nCRT,21–23 whereas other stud-
ies have concluded that it is not.16,24–26 In the present data, within the
nCRT + surgery group, no such prognostic impact of the number of
resected nodes could be identified, let alone any therap utic impact
on survival. This could possibly be xplai d b t sterilization of
micromet stases after chemoradioth rapy.27
Some authors qu sti n any therapeutic impact of extended
lymphaden ctomy. In th ir view, lymph node metastases are simply
markers of systemic dis ase and the rem val of the primary lesion
and the easil accessible peritumoral nodes alone will yield a similar
survival.28 Their alternative explanati n i that the suggested ther-
apeutic effect is based on stage migration. Stage migration occu s
when positive node in the ext nded part of the dissection change
N-stage to a higher category (surg ry-alone group in Fig. 2) but at
the same time have a more favorable prog osis than patients with a
simil r numb r of positive nodes from a more limited dissection (the
o-called “Will Rogers phenomen n”).29 This “stage purification”
leads to unreliable stage-by-stage c mparisons of survival.
In th present stud , “extended lymphadenectomy” was de-
fined in terms of numbers of lymph nodes retrieved, which is a more
reliable variable to study c mpared with a su gical approach, which
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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TABLE 2. Hazard Ratios for Overall Survival From Univariable and Multivariable Cox-Regression Analysis in 320 Esophageal or
Junctional Cancer Patients Who Underwent Surgical Resection With or Without nCRT in the CROSS Trial11
Univariable Analysis,
HR (95% CI)
Multivariable Analysis,
HR (95% CI)
Category Surgery Alone nCRT + Surgery Surgery Alone nCRT + Surgery
Age Every 10 additional years 1.28 (1.03–1.60) 1.16 (0.90–1.51) 1.20 (0.94–1.52) 1.26 (0.93–1.70)
(y)pT stage 0/in situ n/a 0.48 (0.29–0.81) n/a 0.55 (0.32–0.95)
ypT1 0.12 (0.03–0.50) 0.64 (0.28–1.44) 0.14 (0.03–0.59) 0.64 (0.28–1.51)
ypT2 0.56 (0.30–1.06) 0.55 (0.31–1.01) 0.80 (0.42–1.54) 0.44 (0.23–0.85)
ypT3 1 (ref) – – –
ypT4 0.28 (0.04–2.04) 7.11 (0.92–54.84) 0.25 (0.03–1.69) 5.44 (0.62–47.74)
Resection margin involvement R0 1 (ref) – – –
R1 1.34 (0.90–2.00) 1.62 (0.78–3.38) 1.42 (0.93–2.10) 1.20 (0.53–2.73)
Number of resected nodes Every 10 additionally
resected nodes
0.95 (0.79–1.14) 1.02 (0.84–1.25) 0.76 (0.61–0.95) 1.00 (0.84–1.25)
Number of resected positive nodes Every additionally
resected positive node
1.11 (1.08–1.15) 1.15 (1.06–1.25) 1.12 (1.08–1.16) 1.18 (1.07–1.29)
n/a indicates not available.
FIGURE 3. Correlation between the number of resected nodes and the number of resected positive nodes in individual patients
who underwent surgery-alone (A: n = 161) or nCRT followed by surgery (B: n = 159). Open circles indicate patients who were
alive at end of follow-up; closed circles indicate patients who had died at end of follow-up. Lines represent equal probabilities of
death as can be calculated by the proportion of closed (dead) and open (alive) circles. In both groups (A and B), an increase in the
number of resected positive nodes results in a higher probability of death. In the patients who underwent surgery alone, lines are
sloped, that is, at a given number of resected positive nodes more resected nodes in the specimen are associated with a decreased
probability of death (A). In patients in the nCRT + surgery group, the probability lines have a more horizontal course, that is at a
given number of resected positive nodes more resected nodes are not associated (and even tend to be positively associated) with
probability of death (B).
is not always synonymous with the extent of lymph node stations
sampling. Unfortunately, data on the exact location of lymph node
stations from which individual lymph nodes were retrieved were not
available. The strength of the present study is that patients were ran-
domized. Therefore, the described difference in impact of the number
of resected nodes on survival between both arms can be attributed to
nCRT specifically. The multicenter design is both a strength (because
of great variability and therefore generalizability) and a limitation
(since there was no strict protocol for the surgical approach, nor for
the extent of lymph node stations sampling). To properly address the
impact of surgical approach on lymph node retrieval and survival,
a new randomized trial should be performed comparing a transhi-
atal and transthoracic approach after nCRT. Finally, the relatively
small number of patients per randomization arm limited statistical
power.
In conclusion, lymph node positivity, especially if persistent
after nCRT, is a strong negative prognostic factor for overall survival.
The number of resected lymph nodes has an independent prognos-
tic impact on survival in patients who undergo surgery alone. The
therapeutic value of extended lymphadenectomy, however, remains
questionable in this group. After nCRT, the number of resected nodes
is not associated with survival. These data question the indication
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790 | www.annalsofsurgery.com C� 2014 Lippincott Williams & Wilkins
figure 3
Correlation between  number of resected nodes and number of resected positive nodes in individ-
ual patients who underwent surgery alone (A: n=161) or neoadjuvant chemoradiotherapy (nCRT) 
followed by surgery (B: n=159). Open circles indicate patients who were alive at end of follow-up; 
closed circles indicate patients who had died at end of follow-up.
figure 3 (a)
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is not always synonymous with the extent of lymph node stations
sampling. Unfortunately, data on the exact location of lymph node
stations from which individual lymph nodes were retrieved were not
available. The strength of the present study is that patients were ran-
domized. Therefore, the described difference in impact of the number
of resected nodes on survival between both arms can be attributed to
nCRT specifically. The multicenter design is both a strength (because
of great variability and therefore generalizability) and a limitation
(since there was no strict protocol for the surgical approach, nor for
the extent of lymph node stations sampling). To properly address the
impact of surgical approach on lymph node retrieval and survival,
a new randomized trial should be performed comparing a transhi-
atal and transthoracic approach after nCRT. Finally, the relatively
small number of patients per randomization arm limited statistical
power.
In conclusion, lymph node positivity, especially if persistent
after nCRT, is a strong negative prognostic factor for overall survival.
The number of resected lymph nodes has an independent prognos-
tic impact on survival in patients who undergo surgery alone. The
therapeutic value of extended lymphadenectomy, however, remains
questionable in this group. After nCRT, the number of resected nodes
is not associated with survival. These data question the indication
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legend figure 3
Lines represent equal probabilities of death as can be calculated by the proportion of closed (dead) 
and open (alive) circles. In both groups (A and B), an increase in the number of resected positive 
nodes results in a higher probability of death. In the patients who underwent surgery alone, lines 
are sloped i.e. at a given number of resected positive nodes more resected nodes in the specimen 
are associated with a decreased probability of death (A). In patients in the nCRT+surgery group, 
the probability lines have a more horizontal course, i.e. at a given number of resected positive nodes 
more resected nodes are not associated (and even tend to be positively associated) with probability 
of death (B). 
figure 3 (b)
209846-L-bw-Talsma
Chapter 3 Tables and figures
90
Supplementary figure 1
Pathological N-stage according to 7th edition of TNM staging system as assessed in patients who 
underwent surgery alone (n=161) or neoadjuvant chemoradiotherapy (nCRT) followed by surgery 
(n=159). Data indicate a leftward shift (i.e. fewer resected positive nodes) in the nCRT+surgery 
group.
N0 = no positive lymph nodes; N1 = 1-2 positive lymph nodes; N2 =3-6 positive lymph nodes; N3 = 
more than 6 positive lymph nodes.
Supplementary figure 2
Comparison of mean number of positive and negative lymph nodes as assessed in the resection 
specimen of patients who underwent surgery alone (n=161)or neoadjuvant chemoradiotherapy 
(nCRT) followed by surgery(n=159).
5
209846-L-bw-Talsma
91
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy
5
REfEREnCES
1. Rice TW, Zuccaro G, Jr., Adelstein DJ, 
et al. Esophageal carcinoma: depth of 
tumor invasion is predictive of regional 
lymph node status. Ann Thorac Surg 
1998; 65(3):787-92.
2. Prenzel KL, Bollschweiler E, Schroder 
W, et al. Prognostic relevance of skip 
metastases in esophageal cancer. Ann 
Thorac Surg 2010; 90(5):1662-7.
3. Altorki N, Kent M, Ferrara C, Port J. 
Three-field lymph node dissection for 
squamous cell and adenocarcinoma 
of the esophagus. Ann Surg 2002; 
236(2):177-83.
4. Lerut T, Nafteux P, Moons J, et al. Three-
field lymphadenectomy for carcinoma 
of the esophagus and gastroesopha-
geal junction in 174 R0 resections: im-
pact on staging, disease-free survival, 
and outcome: a plea for adaptation of 
TNM classification in upper-half eso-
phageal carcinoma. Ann Surg 2004; 
240(6):962-72.
5. Jamieson GG, Lamb PJ, Thompson SK. 
The role of lymphadenectomy in es-
ophageal cancer. Ann Surg 2009; 
250(2):206-9.
6. Tong D, Law S. Extended lymphadenec-
tomy in esophageal cancer is crucial. 
World J Surg 2013; 37(8):1751-6.
7. Peyre CG, Hagen JA, DeMeester SR, 
et al. The number of lymph nodes re-
moved predicts survival in esophageal 
cancer: an international study on the 
impact of extent of surgical resection. 
Ann Surg 2008; 248(4):549-56.
8. Rizk NP, Ishwaran H, Rice TW, et al. Opti-
mum lymphadenectomy for esophageal 
cancer. Ann Surg 2010; 251(1):46-50.
9. Hulscher JBF, van Sandick JW, de Boer 
AGEM, et al. Extended Transthorac-
ic Resection Compared with Limited 
Transhiatal Resection for Adenocarci-
noma of the Esophagus. N Engl J Med 
2002; 347(21):1662-1669.
10. Boshier PR, Anderson O, Hanna GB. 
Transthoracic versus transhiatal eso-
phagectomy for the treatment of eso-
phagogastric cancer: a meta-analysis. 
Ann Surg 2011; 254(6):894-906.
11. van Hagen P, Hulshof MC, van Lanschot 
JJ, et al. Preoperative chemoradiother-
apy for esophageal or junctional can-
cer. N Engl J Med 2012; 366(22):2074-
84.
12. Edge SB BD, Compton CC, et al., eds. 
American Joint Committee on Cancer 
Staging Manual, 7th ed. New York: 
Springer-Verlag, 2009.
13. Shapiro J, ten Kate FJ, van Hagen P, et al. 
Residual esophageal cancer after neo-
adjuvant chemoradiotherapy frequently 
involves the mucosa and submucosa. 
Ann Surg 2013; 258(5):678-88.
14. Chirieac LR, Swisher SG, Ajani JA, et 
al. Posttherapy pathologic stage pre-
dicts survival in patients with esoph-
ageal carcinoma receiving preoper-
ative chemoradiation. Cancer 2005; 
103(7):1347-55.
15. Schneider PM, Baldus SE, Metzger R, 
et al. Histomorphologic tumor regres-
sion and lymph node metastases deter-
mine prognosis following neoadjuvant 
radiochemotherapy for esophageal 
cancer: implications for response clas-
sification. Ann Surg 2005; 242(5):684-
92.
16. Vallböhmer D, Hölscher AH, DeMeester 
S, et al. A multicenter study of survival 
209846-L-bw-Talsma
9 2
Chapter 5
5
after neoadjuvant radiotherapy/chemo-
therapy and esophagectomy for ypT-
0N0M0R0 esophageal cancer. Ann 
Surg 2010; 252(5):744-749.
17. Donohoe CL, O’Farrell NJ, Grant T, et al. 
Classification of pathologic response 
to neoadjuvant therapy in esophage-
al and junctional cancer: assessment 
of existing measures and proposal of 
a novel 3-point standard. Ann Surg 
2013; 258(5):784-92.
18. Izbicki JR, Hosch SB, Pichlmeier U, et 
al. Prognostic value of immunohisto-
chemically identifiable tumor cells in 
lymph nodes of patients with complete-
ly resected esophageal cancer. N Engl 
J Med 1997; 337(17):1188-94.
19. Waterman TA, Hagen JA, Peters JH, et 
al. The prognostic importance of immu-
nohistochemically detected node me-
tastases in resected esophageal ade-
nocarcinoma. Ann Thorac Surg 2004; 
78(4):1161-9.
20. Bilchik AJ, Hoon DS, Saha S, et al. 
Prognostic impact of micrometastases 
in colon cancer: interim results of a 
prospective multicenter trial. Ann Surg 
2007; 246(4):568-75.
21. Mariette C, Piessen G, Briez N, Tribou-
let JP. The number of metastatic lymph 
nodes and the ratio between metastat-
ic and examined lymph nodes are inde-
pendent prognostic factors in esopha-
geal cancer regardless of neoadjuvant 
chemoradiation or lymphadenectomy 
extent. Ann Surg 2008; 247(2):365-71.
22. Solomon N, Zhuge Y, Cheung M, et al. 
The roles of neoadjuvant radiotherapy 
and lymphadenectomy in the treatment 
of esophageal adenocarcinoma. Ann 
Surg Oncol 2010; 17(3):791-803.
23. Torgersen Z, Sundaram A, Hoshino M, 
et al. Prognostic implications of lym-
phadenectomy in esophageal cancer 
after neo-adjuvant therapy: a single 
center experience. J Gastrointest Surg 
2011; 15(10):1769-76.
24. Chao YK, Liu HP, Hsieh MJ, et al. Impact 
of the number of lymph nodes sampled 
on outcome in ypT0N0 esophageal 
squamous cell carcinoma patients. J 
Surg Oncol 2012; 106(4):436-40.
25. Sisic L, Blank S, Weichert W, et al. 
Prognostic impact of lymph node in-
volvement and the extent of lymphad-
enectomy (LAD) in adenocarcino-
ma of the esophagogastric junction 
(AEG). Langenbecks Arch Surg 2013; 
398(7):973-81.
26. Shridhar R, Hoffe SE, Almhanna K, et 
al. Lymph node harvest in esophage-
al cancer after neoadjuvant chemo-
radiotherapy. Ann Surg Oncol 2013; 
20(9):3038-43.
27. Wang D, Smit JK, Zwaan E, et al. Neoad-
juvant therapy reduces the incidence of 
nodal micrometastases in esophageal 
adenocarcinoma. Am J Surg 2013; 
206(5):732-8.
28. Herbella FA, Laurino Neto RM, Allaix 
ME, Patti MG. Extended lymphadenec-
tomy in esophageal cancer is debata-
ble. World J Surg 2013; 37(8):1757-67.
29. Feinstein AR, Sosin DM, Wells CK. The 
Will Rogers phenomenon. Stage mi-
gration and new diagnostic techniques 
as a source of misleading statistics for 
survival in cancer. N Engl J Med 1985; 
312(25):1604-8.
209846-L-bw-Talsma
9 3
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy
5
209846-L-bw-Talsma
94
Chapter 5 Letters of correspondence
L
E
T
T
E
R
T
O
T
H
E
E
D
IT
O
R
N
eo
ad
ju
va
nt
Th
er
ap
y
an
d
Ly
m
p
ha
de
ne
ct
om
y
in
Es
op
ha
ge
al
C
an
ce
r:
Bo
th
A
re
Es
se
nt
ia
lt
o
M
ax
im
iz
e
Su
rv
iv
al
Be
ne
fit
To
th
e
E
di
to
r:
W
e
re
ad
w
it
h
gr
ea
ti
nt
er
es
tt
he
ar
ti
cl
e
by
Ta
ls
m
a
et
al
.1
T
he
au
th
or
s
ad
dr
es
se
d
th
e
ro
le
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
af
-
te
rn
eo
ad
ju
va
nt
ch
em
or
ad
io
th
er
ap
y
(C
R
T
)f
or
es
op
ha
ge
al
ca
nc
er
.
T
he
st
ud
y
po
pu
la
ti
on
in
th
is
ar
ti
cl
e
co
ns
is
te
d
of
th
e
pa
ti
en
ts
w
ho
pa
r-
ti
ci
pa
te
d
in
th
e
C
R
O
S
S
tr
ia
l.2
T
he
C
R
O
S
S
tr
ia
l,
pu
bl
is
he
d
in
20
12
,p
ro
ve
d
co
nv
in
ci
ng
ly
th
e
su
rv
iv
al
be
ne
fi
t
of
ne
oa
dj
uv
an
t
C
R
T,
fo
l-
lo
w
ed
by
su
rg
er
y
ov
er
su
rg
er
y
al
on
e
fo
r
es
op
ha
ge
al
ca
nc
er
[m
ed
ia
n
ov
er
al
l
su
rv
iv
al
of
49
.4
m
on
th
s
in
th
e
C
R
T
su
rg
er
y
gr
ou
p
vs
24
.0
m
on
th
s
in
th
e
su
rg
er
y
gr
ou
p;
ha
za
rd
ra
-
ti
o
(H
R
)
=
0.
65
7;
95
%
co
nfi
de
nc
e
in
te
rv
al
,
0.
49
5–
0.
87
1;
P
=
0.
00
3]
.T
hi
s
si
gn
ifi
ca
nt
su
r-
vi
va
lb
en
efi
ti
n
C
R
T
su
rg
er
y
gr
ou
ps
ha
s
be
en
at
tr
ib
ut
ed
to
st
er
il
iz
at
io
n
of
su
rg
ic
al
m
ar
gi
ns
(r
efl
ec
te
d
by
a
hi
gh
er
fr
eq
ue
nc
y
of
R
0
re
se
c-
ti
on
in
th
e
C
R
T
su
rg
er
y
gr
ou
p
th
an
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p,
92
%
vs
69
%
;P
<
0.
00
1)
an
d
st
er
il
iz
at
io
n
of
po
si
tiv
e
ly
m
ph
no
de
s.
O
n
th
e
ba
si
s
of
th
is
pr
em
is
e,
Ta
ls
m
a
et
al
1
qu
es
-
ti
on
ed
th
e
ap
pl
ic
ab
il
it
y
of
ly
m
ph
ad
en
ec
to
m
y
in
th
e
C
R
T
su
rg
er
y
gr
ou
p.
T
he
au
th
or
s
ev
al
ua
te
d
th
e
ro
le
of
ly
m
-
ph
ad
en
ec
to
m
y
in
bo
th
gr
ou
ps
—
C
R
T
su
rg
er
y
an
d
su
rg
er
y
al
on
e.
T
he
au
th
or
s
op
in
ed
,b
as
ed
on
st
at
is
ti
ca
la
na
ly
si
s,
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
w
as
si
gn
ifi
ca
nt
ly
as
so
ci
at
ed
w
it
h
su
r-
vi
va
l
(H
R
=
0.
76
pe
r
ev
er
y
10
ad
di
ti
on
al
ly
re
se
ct
ed
no
de
s;
P
<
0.
01
)
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p;
m
or
eo
ve
r,
a
po
si
tiv
e
as
so
ci
at
io
n
ex
is
ts
be
tw
ee
n
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
an
d
th
e
nu
m
be
r
of
re
se
ct
ed
po
si
tiv
e
no
de
s.
T
hi
s
co
nc
lu
si
on
sh
ed
s
li
gh
to
n
th
e
ro
le
of
ad
-
eq
ua
te
ly
m
ph
ad
en
ec
to
m
y
in
es
op
ha
ge
al
ca
n-
ce
r
an
d
st
re
ng
th
en
s
it
s
th
er
ap
eu
ti
c
po
te
nt
ia
l
in
ad
di
ti
on
to
it
s
ro
le
in
be
tt
er
fi
na
l
di
se
as
e
st
ag
in
g.
T
he
au
th
or
s
fu
rt
he
r
cl
ar
ifi
ed
th
at
th
e
ad
eq
ua
te
ly
m
ph
ad
en
ec
to
m
y
fa
il
ed
to
pr
ov
id
e
th
er
ap
eu
ti
c
be
ne
fi
ti
n
th
e
C
R
T
su
rg
er
y
gr
ou
p,
as
th
e
nu
m
be
ro
fr
es
ec
te
d
po
si
tiv
e
no
de
s
w
er
e
in
de
pe
nd
en
t
of
to
ta
l
re
se
ct
ed
no
de
s
an
d
so
qu
es
ti
on
ed
th
e
ro
le
of
ly
m
ph
ad
en
ec
to
m
y
in
D
is
cl
os
ur
e:
T
he
au
th
or
s
de
cl
ar
e
no
co
nfl
ic
ts
of
in
te
re
st
.
C
op
yr
ig
ht
C�
20
15
W
ol
te
rs
K
lu
w
er
H
ea
lt
h,
In
c.
A
ll
ri
gh
ts
re
se
rv
ed
.
IS
S
N
:0
00
3-
49
32
/1
5/
00
00
0-
00
01
D
O
I:
10
.1
09
7/
S
L
A
.0
00
00
00
00
00
01
16
0
es
op
ha
ge
al
ca
nc
er
.T
he
y
w
er
e
of
th
e
op
in
io
n
th
at
th
is
di
sc
re
pa
nc
y
ca
n
be
at
tr
ib
ut
ed
to
st
er
-
il
iz
at
io
n
of
m
an
y
in
it
ia
lp
os
it
iv
e
no
de
s
ca
rr
ie
d
ou
tb
y
ne
oa
dj
uv
an
tC
R
T.
W
e
be
li
ev
e
th
at
th
is
is
ov
er
si
m
pl
ifi
ca
-
ti
on
of
a
co
m
pl
ex
is
su
e.
A
lt
ho
ug
h
th
e
nu
m
-
be
r
of
ly
m
ph
no
de
s
m
ig
ht
be
m
or
e
re
li
ab
le
an
d
ro
bu
st
th
an
su
rg
ic
al
ap
pr
oa
ch
al
on
e
fo
r
th
e
pu
rp
os
e
of
st
at
is
ti
ca
la
na
ly
si
s,
th
e
co
nc
ep
t
of
sy
st
em
at
ic
ly
m
ph
ad
en
ec
to
m
y
is
ba
se
d
on
th
e
ca
re
fu
l
di
ss
ec
ti
on
of
an
at
om
ic
al
ly
w
el
l-
de
fi
ne
d
no
da
l
st
at
io
ns
.2
It
al
so
ne
ed
s
to
be
hi
gh
li
gh
te
d
th
at
th
e
nu
m
be
ro
fr
es
ec
te
d
ly
m
ph
no
de
s
is
a
su
rr
og
at
e
m
ar
ke
r
fo
r
th
e
qu
al
it
y
of
ly
m
ph
ad
en
ec
to
m
y
fo
r
th
e
pu
rp
os
e
of
st
at
is
-
ti
ca
l
an
al
ys
is
in
vi
ew
of
w
id
e
va
ri
at
io
ns
in
su
rg
ic
al
ph
il
os
op
hy
an
d
pr
ac
ti
ce
be
tw
ee
n
in
-
st
it
ut
io
ns
an
d
in
di
vi
du
al
su
rg
eo
ns
;
ho
w
ev
er
,
th
e
ef
fe
ct
of
th
e
su
rr
og
at
e
fa
ct
or
(t
he
nu
m
be
r
of
re
se
ct
ed
ly
m
ph
no
de
s)
ca
nn
ot
be
pl
ac
ed
ab
ov
e
th
at
of
th
e
re
al
fa
ct
or
,
th
at
is
,
su
rg
ic
al
di
li
ge
nc
e
in
ly
m
ph
no
de
di
ss
ec
ti
on
.
W
e
be
li
ev
e
th
at
th
e
is
su
e
of
st
ag
e
m
i-
gr
at
io
n
is
ov
er
st
at
ed
in
th
e
co
nt
ex
t
of
ex
-
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
rs
ev
er
al
ca
nc
er
s.
S
ta
ge
m
ig
ra
ti
on
(W
il
l-
R
og
er
s
ph
en
om
en
on
)
ca
n
po
ss
ib
ly
ex
pl
ai
n
th
e
st
ag
e
fo
r
st
ag
e
su
r-
vi
va
l
be
ne
fi
t
ow
in
g
to
a
be
tt
er
st
ag
in
g
by
a
m
or
e
th
or
ou
gh
ly
m
ph
ad
en
ec
to
m
y,
bu
ti
tc
an
-
no
t
ex
pl
ai
n
th
e
su
rv
iv
al
be
ne
fi
t
of
th
e
en
ti
re
co
ho
rt
of
pa
ti
en
ts
in
cl
ud
in
g
al
ls
ta
ge
s.
A
n
im
-
pe
cc
ab
le
tr
ia
ld
es
ig
n
to
ad
dr
es
st
he
qu
es
ti
on
of
su
rv
iv
al
be
ne
fi
t(
th
er
ap
eu
ti
c
po
te
nt
ia
l)
of
ly
m
-
ph
ad
en
ec
to
m
y
in
es
op
ha
ge
al
ca
nc
er
w
ou
ld
be
to
co
m
pa
re
sy
st
em
at
ic
ly
m
ph
ad
en
ec
to
m
y
ve
r-
su
s
no
ly
m
ph
ad
en
ec
to
m
y,
he
ad
to
he
ad
,i
rr
e-
sp
ec
tiv
e
of
th
e
st
ag
e
(t
o
av
oi
d
th
e
co
nf
ou
nd
in
g
ef
fe
ct
of
st
ag
e
m
ig
ra
ti
on
).
A
s
w
e
do
no
th
av
e
su
ch
a
ra
nd
om
iz
ed
tr
ia
l,
th
e
st
ud
ie
s
fo
cu
s-
in
g
on
th
e
re
su
lt
s
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
-
to
m
y
fo
r
es
op
ha
ge
al
ca
nc
er
be
co
m
e
im
po
r-
ta
nt
so
ur
ce
s
of
da
ta
to
un
de
rs
ta
nd
th
e
va
lu
e
of
su
ch
pr
oc
ed
ur
e.
M
os
t
of
th
e
su
rg
ic
al
se
-
ri
es
in
es
op
ha
ge
al
ca
nc
er
th
at
do
no
t
fo
cu
s
on
ly
m
ph
no
de
di
ss
ec
ti
on
sh
ow
5-
ye
ar
ov
er
al
l
su
rv
iv
al
ra
te
s
be
tw
ee
n
20
%
an
d
25
%
.I
n
co
n-
tr
as
t,
A
ki
ya
m
a
et
al
3
de
m
on
st
ra
te
d
a
5-
ye
ar
su
rv
iv
al
ra
te
of
55
%
fo
r3
-fi
el
d
ly
m
ph
ad
en
ec
-
to
m
y
an
d
38
.3
%
fo
r
2-
fi
el
d
ly
m
ph
ad
en
ec
-
to
m
y.
O
th
er
st
ud
ie
s
fr
om
Ja
pa
n4
,5
an
d
la
te
ly
fr
om
th
e
W
es
t6
,7
sh
ow
si
m
il
ar
re
su
lt
s
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
r
es
op
ha
ge
al
ca
nc
er
. F
in
al
ly
,t
he
de
ba
te
be
tw
ee
n
tr
an
sh
ia
ta
l
an
d
tr
an
st
ho
ra
ci
c
es
op
ha
ge
ct
om
y
is
fu
ti
le
un
-
le
ss
th
e
tr
an
st
ho
ra
ci
c
ap
pr
oa
ch
is
ac
co
m
pa
-
ni
ed
by
m
ed
ia
st
in
al
ly
m
ph
ad
en
ec
to
m
y
w
it
h
a
w
id
er
pe
ri
es
op
ha
ge
al
m
ar
gi
n.
In
th
e
ab
se
nc
e
of
a
sy
st
em
at
ic
m
ed
ia
st
in
al
ly
m
ph
ad
en
ec
-
to
m
y,
2
di
ff
er
en
ta
pp
ro
ac
he
s
(t
ra
ns
th
or
ac
ic
vs
tr
an
sh
ia
ta
l)
fo
r
th
e
sa
m
e
pr
oc
ed
ur
e,
th
at
is
,
m
ob
il
iz
at
io
n
of
es
op
ha
gu
s,
ar
e
un
li
ke
ly
to
be
di
ff
er
en
t
fr
om
ea
ch
ot
he
r
in
te
rm
s
of
on
co
-
lo
gi
c
ou
tc
om
e;
it
is
pe
rh
ap
s
be
tt
er
to
av
oi
d
th
or
ac
ot
om
y
an
d
to
ad
op
t
a
tr
an
sh
ia
ta
l
ap
-
pr
oa
ch
in
su
ch
a
sc
en
ar
io
.T
he
re
al
be
ne
fi
to
f
th
e
tr
an
st
ho
ra
ci
c
ap
pr
oa
ch
is
th
e
op
po
rt
un
it
y
fo
r
a
th
or
ou
gh
an
d
sy
st
em
at
ic
ly
m
ph
ad
en
ec
-
to
m
y
in
th
e
m
ed
ia
st
in
um
.
T
hi
s
be
ne
fi
t,
in
ou
r
op
in
io
n,
w
il
l
co
nt
in
ue
to
ho
ld
ev
en
af
te
r
ne
oa
dj
uv
an
t
C
R
T.
S
ol
om
on
et
al
8
re
it
er
at
ed
th
at
su
rv
iv
al
be
ne
fi
t
of
ne
oa
dj
uv
an
t
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
is
ad
di
tiv
e
as
bo
th
ar
e
in
de
pe
nd
en
tp
re
di
ct
or
s
of
im
pr
ov
ed
su
rv
iv
al
.
W
e
be
li
ev
e
th
at
th
e
ad
di
ti
on
of
ne
oa
dj
uv
an
t
th
er
ap
y
in
es
op
ha
ge
al
ca
nc
er
m
us
tn
ot
be
as
a
co
m
pe
ns
at
or
y
sa
fe
gu
ar
d
to
di
sg
ui
se
th
e
in
ad
-
eq
ua
ci
es
of
a
su
bo
pt
im
al
su
rg
er
y;
ra
th
er
,b
ot
h
th
es
e
m
od
al
it
ie
s
m
us
tb
e
ad
di
tiv
e
to
m
ax
im
iz
e
th
e
su
rv
iv
al
be
ne
fi
t.
D
ur
ga
to
sh
P
an
de
y,
M
S,
D
N
B
,M
C
h
D
ep
ar
tm
en
to
f
S
ur
gi
ca
lO
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
R
am
bh
a
P
an
de
y,
M
D
D
ep
ar
tm
en
to
f
R
ad
ia
ti
on
O
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
P
an
ka
j
K
um
ar
G
ar
g,
M
S
D
ep
ar
tm
en
to
f
S
ur
gi
ca
lO
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
du
rg
at
os
h@
gm
ai
l.c
om
R
EF
ER
EN
C
ES
1.
Ta
ls
m
a
A
K
,S
ha
pi
ro
J,
L
oo
m
an
C
W
N
,e
ta
l.
Ly
m
ph
no
de
re
tr
ie
va
l
du
ri
ng
es
op
ha
ge
ct
om
y
w
it
h
an
d
w
it
ho
ut
ne
oa
dj
uv
an
t
ch
em
or
ad
io
th
er
ap
y.
P
ro
gn
os
-
ti
c
an
d
th
er
ap
eu
ti
c
im
pa
ct
on
su
rv
iv
al
.
A
nn
Su
rg
.
20
14
;2
60
:7
86
–7
93
.
2.
va
n
H
ag
en
P
,
H
ul
sh
of
M
C
,
va
n
L
an
sc
ho
t
JJ
,
et
al
.
P
re
op
er
at
iv
e
ch
em
or
ad
io
th
er
ap
y
fo
r
es
op
ha
ge
al
or
ju
nc
ti
on
al
ca
nc
er
.
N
E
ng
l
J
M
ed
.
20
12
;3
66
:2
07
4–
20
84
.
3.
A
ki
ya
m
a
H
,T
su
ru
m
ar
u
M
,U
da
ga
w
a
H
,e
ta
l.
R
ad
i-
ca
ll
ym
ph
no
de
di
ss
ec
ti
on
fo
rc
an
ce
ro
ft
he
th
or
ac
ic
es
op
ha
gu
s.
A
nn
Su
rg
.1
99
4;
22
0:
36
4–
37
3.
4.
U
da
ga
w
a
H
,
A
ki
ya
m
a
H
.
S
ur
gi
ca
l
tr
ea
tm
en
t
of
es
op
ha
ge
al
ca
nc
er
:
To
ky
o
ex
pe
ri
en
ce
of
th
e
th
re
e-
fi
el
d
te
ch
ni
qu
e.
D
is
E
so
ph
ag
us
.2
00
1;
14
:1
10
–1
14
.
5.
O
za
w
a
S
,T
ac
hi
m
or
iY
,B
ab
a
H
,e
ta
l.
C
om
pr
eh
en
-
si
ve
re
gi
st
ry
of
es
op
ha
ge
al
ca
nc
er
in
Ja
pa
n.
E
so
ph
-
ag
us
.2
01
1;
8:
9–
29
.
6.
A
lt
or
ki
N
,K
en
t
M
,P
or
t
J.
T
hr
ee
fi
el
d
ly
m
ph
no
de
di
ss
ec
ti
on
fo
r
sq
ua
m
ou
s
ce
ll
an
d
ad
en
oc
ar
ci
no
m
a
of
th
e
es
op
ha
gu
s.
A
nn
Su
rg
.2
00
2;
23
6:
17
7–
18
3.
7.
Po
rt
al
e
G
,H
ag
en
JA
,P
et
er
s
JH
,e
ta
l.
M
od
er
n
5-
ye
ar
su
rv
iv
al
of
re
se
ct
ab
le
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a:
si
ng
le
in
st
it
ut
io
n
ex
pe
ri
en
ce
w
it
h
26
3
pa
ti
en
ts
.J
A
m
C
ol
lS
ur
g.
20
06
;2
02
:5
88
–5
96
.
8.
S
ol
om
on
N
,Z
hu
ge
Y
,C
he
un
g
M
,e
ta
l.
T
he
ro
le
s
of
ne
oa
dj
uv
an
tr
ad
io
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
in
th
e
tr
ea
tm
en
t
of
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a.
A
nn
Su
rg
O
nc
ol
.2
01
0;
17
:7
91
–8
03
.
Co
py
rig
ht
©
20
15
W
o
lte
rs
Kl
uw
e
r
H
ea
lth
,I
nc
.U
na
ut
ho
riz
e
d
re
pr
od
uc
tio
n
o
ft
hi
s
a
rti
cl
e
is
pr
oh
ib
ite
d.
An
na
ls
of
Su
rg
er
y
 Volu
m
e
00
,N
um
be
r
00
,
20
15
w
w
w
.a
nn
al
so
fs
ur
ge
ry
.c
om
|
1
5
209846-L-bw-Talsma
95
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy
L
E
T
T
E
R
T
O
T
H
E
E
D
IT
O
R
N
eo
ad
ju
va
nt
Th
er
ap
y
an
d
Ly
m
p
ha
de
ne
ct
om
y
in
Es
op
ha
ge
al
C
an
ce
r:
Bo
th
A
re
Es
se
nt
ia
lt
o
M
ax
im
iz
e
Su
rv
iv
al
Be
ne
fit
To
th
e
E
di
to
r:
W
e
re
ad
w
it
h
gr
ea
ti
nt
er
es
tt
he
ar
ti
cl
e
by
Ta
ls
m
a
et
al
.1
T
he
au
th
or
s
ad
dr
es
se
d
th
e
ro
le
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
af
-
te
rn
eo
ad
ju
va
nt
ch
em
or
ad
io
th
er
ap
y
(C
R
T
)f
or
es
op
ha
ge
al
ca
nc
er
.
T
he
st
ud
y
po
pu
la
ti
on
in
th
is
ar
ti
cl
e
co
ns
is
te
d
of
th
e
pa
ti
en
ts
w
ho
pa
r-
ti
ci
pa
te
d
in
th
e
C
R
O
S
S
tr
ia
l.2
T
he
C
R
O
S
S
tr
ia
l,
pu
bl
is
he
d
in
20
12
,p
ro
ve
d
co
nv
in
ci
ng
ly
th
e
su
rv
iv
al
be
ne
fi
t
of
ne
oa
dj
uv
an
t
C
R
T,
fo
l-
lo
w
ed
by
su
rg
er
y
ov
er
su
rg
er
y
al
on
e
fo
r
es
op
ha
ge
al
ca
nc
er
[m
ed
ia
n
ov
er
al
l
su
rv
iv
al
of
49
.4
m
on
th
s
in
th
e
C
R
T
su
rg
er
y
gr
ou
p
vs
24
.0
m
on
th
s
in
th
e
su
rg
er
y
gr
ou
p;
ha
za
rd
ra
-
ti
o
(H
R
)
=
0.
65
7;
95
%
co
nfi
de
nc
e
in
te
rv
al
,
0.
49
5–
0.
87
1;
P
=
0.
00
3]
.T
hi
s
si
gn
ifi
ca
nt
su
r-
vi
va
lb
en
efi
ti
n
C
R
T
su
rg
er
y
gr
ou
ps
ha
s
be
en
at
tr
ib
ut
ed
to
st
er
il
iz
at
io
n
of
su
rg
ic
al
m
ar
gi
ns
(r
efl
ec
te
d
by
a
hi
gh
er
fr
eq
ue
nc
y
of
R
0
re
se
c-
ti
on
in
th
e
C
R
T
su
rg
er
y
gr
ou
p
th
an
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p,
92
%
vs
69
%
;P
<
0.
00
1)
an
d
st
er
il
iz
at
io
n
of
po
si
tiv
e
ly
m
ph
no
de
s.
O
n
th
e
ba
si
s
of
th
is
pr
em
is
e,
Ta
ls
m
a
et
al
1
qu
es
-
ti
on
ed
th
e
ap
pl
ic
ab
il
it
y
of
ly
m
ph
ad
en
ec
to
m
y
in
th
e
C
R
T
su
rg
er
y
gr
ou
p.
T
he
au
th
or
s
ev
al
ua
te
d
th
e
ro
le
of
ly
m
-
ph
ad
en
ec
to
m
y
in
bo
th
gr
ou
ps
—
C
R
T
su
rg
er
y
an
d
su
rg
er
y
al
on
e.
T
he
au
th
or
s
op
in
ed
,b
as
ed
on
st
at
is
ti
ca
la
na
ly
si
s,
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
w
as
si
gn
ifi
ca
nt
ly
as
so
ci
at
ed
w
it
h
su
r-
vi
va
l
(H
R
=
0.
76
pe
r
ev
er
y
10
ad
di
ti
on
al
ly
re
se
ct
ed
no
de
s;
P
<
0.
01
)
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p;
m
or
eo
ve
r,
a
po
si
tiv
e
as
so
ci
at
io
n
ex
is
ts
be
tw
ee
n
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
an
d
th
e
nu
m
be
r
of
re
se
ct
ed
po
si
tiv
e
no
de
s.
T
hi
s
co
nc
lu
si
on
sh
ed
s
li
gh
to
n
th
e
ro
le
of
ad
-
eq
ua
te
ly
m
ph
ad
en
ec
to
m
y
in
es
op
ha
ge
al
ca
n-
ce
r
an
d
st
re
ng
th
en
s
it
s
th
er
ap
eu
ti
c
po
te
nt
ia
l
in
ad
di
ti
on
to
it
s
ro
le
in
be
tt
er
fi
na
l
di
se
as
e
st
ag
in
g.
T
he
au
th
or
s
fu
rt
he
r
cl
ar
ifi
ed
th
at
th
e
ad
eq
ua
te
ly
m
ph
ad
en
ec
to
m
y
fa
il
ed
to
pr
ov
id
e
th
er
ap
eu
ti
c
be
ne
fi
ti
n
th
e
C
R
T
su
rg
er
y
gr
ou
p,
as
th
e
nu
m
be
ro
fr
es
ec
te
d
po
si
tiv
e
no
de
s
w
er
e
in
de
pe
nd
en
t
of
to
ta
l
re
se
ct
ed
no
de
s
an
d
so
qu
es
ti
on
ed
th
e
ro
le
of
ly
m
ph
ad
en
ec
to
m
y
in
D
is
cl
os
ur
e:
T
he
au
th
or
s
de
cl
ar
e
no
co
nfl
ic
ts
of
in
te
re
st
.
C
op
yr
ig
ht
C�
20
15
W
ol
te
rs
K
lu
w
er
H
ea
lt
h,
In
c.
A
ll
ri
gh
ts
re
se
rv
ed
.
IS
S
N
:0
00
3-
49
32
/1
5/
00
00
0-
00
01
D
O
I:
10
.1
09
7/
S
L
A
.0
00
00
00
00
00
01
16
0
es
op
ha
ge
al
ca
nc
er
.T
he
y
w
er
e
of
th
e
op
in
io
n
th
at
th
is
di
sc
re
pa
nc
y
ca
n
be
at
tr
ib
ut
ed
to
st
er
-
il
iz
at
io
n
of
m
an
y
in
it
ia
lp
os
it
iv
e
no
de
s
ca
rr
ie
d
ou
tb
y
ne
oa
dj
uv
an
tC
R
T.
W
e
be
li
ev
e
th
at
th
is
is
ov
er
si
m
pl
ifi
ca
-
ti
on
of
a
co
m
pl
ex
is
su
e.
A
lt
ho
ug
h
th
e
nu
m
-
be
r
of
ly
m
ph
no
de
s
m
ig
ht
be
m
or
e
re
li
ab
le
an
d
ro
bu
st
th
an
su
rg
ic
al
ap
pr
oa
ch
al
on
e
fo
r
th
e
pu
rp
os
e
of
st
at
is
ti
ca
la
na
ly
si
s,
th
e
co
nc
ep
t
of
sy
st
em
at
ic
ly
m
ph
ad
en
ec
to
m
y
is
ba
se
d
on
th
e
ca
re
fu
l
di
ss
ec
ti
on
of
an
at
om
ic
al
ly
w
el
l-
de
fi
ne
d
no
da
l
st
at
io
ns
.2
It
al
so
ne
ed
s
to
be
hi
gh
li
gh
te
d
th
at
th
e
nu
m
be
ro
fr
es
ec
te
d
ly
m
ph
no
de
s
is
a
su
rr
og
at
e
m
ar
ke
r
fo
r
th
e
qu
al
it
y
of
ly
m
ph
ad
en
ec
to
m
y
fo
r
th
e
pu
rp
os
e
of
st
at
is
-
ti
ca
l
an
al
ys
is
in
vi
ew
of
w
id
e
va
ri
at
io
ns
in
su
rg
ic
al
ph
il
os
op
hy
an
d
pr
ac
ti
ce
be
tw
ee
n
in
-
st
it
ut
io
ns
an
d
in
di
vi
du
al
su
rg
eo
ns
;
ho
w
ev
er
,
th
e
ef
fe
ct
of
th
e
su
rr
og
at
e
fa
ct
or
(t
he
nu
m
be
r
of
re
se
ct
ed
ly
m
ph
no
de
s)
ca
nn
ot
be
pl
ac
ed
ab
ov
e
th
at
of
th
e
re
al
fa
ct
or
,
th
at
is
,
su
rg
ic
al
di
li
ge
nc
e
in
ly
m
ph
no
de
di
ss
ec
ti
on
.
W
e
be
li
ev
e
th
at
th
e
is
su
e
of
st
ag
e
m
i-
gr
at
io
n
is
ov
er
st
at
ed
in
th
e
co
nt
ex
t
of
ex
-
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
rs
ev
er
al
ca
nc
er
s.
S
ta
ge
m
ig
ra
ti
on
(W
il
l-
R
og
er
s
ph
en
om
en
on
)
ca
n
po
ss
ib
ly
ex
pl
ai
n
th
e
st
ag
e
fo
r
st
ag
e
su
r-
vi
va
l
be
ne
fi
t
ow
in
g
to
a
be
tt
er
st
ag
in
g
by
a
m
or
e
th
or
ou
gh
ly
m
ph
ad
en
ec
to
m
y,
bu
ti
tc
an
-
no
t
ex
pl
ai
n
th
e
su
rv
iv
al
be
ne
fi
t
of
th
e
en
ti
re
co
ho
rt
of
pa
ti
en
ts
in
cl
ud
in
g
al
ls
ta
ge
s.
A
n
im
-
pe
cc
ab
le
tr
ia
ld
es
ig
n
to
ad
dr
es
st
he
qu
es
ti
on
of
su
rv
iv
al
be
ne
fi
t(
th
er
ap
eu
ti
c
po
te
nt
ia
l)
of
ly
m
-
ph
ad
en
ec
to
m
y
in
es
op
ha
ge
al
ca
nc
er
w
ou
ld
be
to
co
m
pa
re
sy
st
em
at
ic
ly
m
ph
ad
en
ec
to
m
y
ve
r-
su
s
no
ly
m
ph
ad
en
ec
to
m
y,
he
ad
to
he
ad
,i
rr
e-
sp
ec
tiv
e
of
th
e
st
ag
e
(t
o
av
oi
d
th
e
co
nf
ou
nd
in
g
ef
fe
ct
of
st
ag
e
m
ig
ra
ti
on
).
A
s
w
e
do
no
th
av
e
su
ch
a
ra
nd
om
iz
ed
tr
ia
l,
th
e
st
ud
ie
s
fo
cu
s-
in
g
on
th
e
re
su
lt
s
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
-
to
m
y
fo
r
es
op
ha
ge
al
ca
nc
er
be
co
m
e
im
po
r-
ta
nt
so
ur
ce
s
of
da
ta
to
un
de
rs
ta
nd
th
e
va
lu
e
of
su
ch
pr
oc
ed
ur
e.
M
os
t
of
th
e
su
rg
ic
al
se
-
ri
es
in
es
op
ha
ge
al
ca
nc
er
th
at
do
no
t
fo
cu
s
on
ly
m
ph
no
de
di
ss
ec
ti
on
sh
ow
5-
ye
ar
ov
er
al
l
su
rv
iv
al
ra
te
s
be
tw
ee
n
20
%
an
d
25
%
.I
n
co
n-
tr
as
t,
A
ki
ya
m
a
et
al
3
de
m
on
st
ra
te
d
a
5-
ye
ar
su
rv
iv
al
ra
te
of
55
%
fo
r3
-fi
el
d
ly
m
ph
ad
en
ec
-
to
m
y
an
d
38
.3
%
fo
r
2-
fi
el
d
ly
m
ph
ad
en
ec
-
to
m
y.
O
th
er
st
ud
ie
s
fr
om
Ja
pa
n4
,5
an
d
la
te
ly
fr
om
th
e
W
es
t6
,7
sh
ow
si
m
il
ar
re
su
lt
s
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
r
es
op
ha
ge
al
ca
nc
er
. F
in
al
ly
,t
he
de
ba
te
be
tw
ee
n
tr
an
sh
ia
ta
l
an
d
tr
an
st
ho
ra
ci
c
es
op
ha
ge
ct
om
y
is
fu
ti
le
un
-
le
ss
th
e
tr
an
st
ho
ra
ci
c
ap
pr
oa
ch
is
ac
co
m
pa
-
ni
ed
by
m
ed
ia
st
in
al
ly
m
ph
ad
en
ec
to
m
y
w
it
h
a
w
id
er
pe
ri
es
op
ha
ge
al
m
ar
gi
n.
In
th
e
ab
se
nc
e
of
a
sy
st
em
at
ic
m
ed
ia
st
in
al
ly
m
ph
ad
en
ec
-
to
m
y,
2
di
ff
er
en
ta
pp
ro
ac
he
s
(t
ra
ns
th
or
ac
ic
vs
tr
an
sh
ia
ta
l)
fo
r
th
e
sa
m
e
pr
oc
ed
ur
e,
th
at
is
,
m
ob
il
iz
at
io
n
of
es
op
ha
gu
s,
ar
e
un
li
ke
ly
to
be
di
ff
er
en
t
fr
om
ea
ch
ot
he
r
in
te
rm
s
of
on
co
-
lo
gi
c
ou
tc
om
e;
it
is
pe
rh
ap
s
be
tt
er
to
av
oi
d
th
or
ac
ot
om
y
an
d
to
ad
op
t
a
tr
an
sh
ia
ta
l
ap
-
pr
oa
ch
in
su
ch
a
sc
en
ar
io
.T
he
re
al
be
ne
fi
to
f
th
e
tr
an
st
ho
ra
ci
c
ap
pr
oa
ch
is
th
e
op
po
rt
un
it
y
fo
r
a
th
or
ou
gh
an
d
sy
st
em
at
ic
ly
m
ph
ad
en
ec
-
to
m
y
in
th
e
m
ed
ia
st
in
um
.
T
hi
s
be
ne
fi
t,
in
ou
r
op
in
io
n,
w
il
l
co
nt
in
ue
to
ho
ld
ev
en
af
te
r
ne
oa
dj
uv
an
t
C
R
T.
S
ol
om
on
et
al
8
re
it
er
at
ed
th
at
su
rv
iv
al
be
ne
fi
t
of
ne
oa
dj
uv
an
t
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
is
ad
di
tiv
e
as
bo
th
ar
e
in
de
pe
nd
en
tp
re
di
ct
or
s
of
im
pr
ov
ed
su
rv
iv
al
.
W
e
be
li
ev
e
th
at
th
e
ad
di
ti
on
of
ne
oa
dj
uv
an
t
th
er
ap
y
in
es
op
ha
ge
al
ca
nc
er
m
us
tn
ot
be
as
a
co
m
pe
ns
at
or
y
sa
fe
gu
ar
d
to
di
sg
ui
se
th
e
in
ad
-
eq
ua
ci
es
of
a
su
bo
pt
im
al
su
rg
er
y;
ra
th
er
,b
ot
h
th
es
e
m
od
al
it
ie
s
m
us
tb
e
ad
di
tiv
e
to
m
ax
im
iz
e
th
e
su
rv
iv
al
be
ne
fi
t.
D
ur
ga
to
sh
P
an
de
y,
M
S,
D
N
B
,M
C
h
D
ep
ar
tm
en
to
f
S
ur
gi
ca
lO
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
R
am
bh
a
P
an
de
y,
M
D
D
ep
ar
tm
en
to
f
R
ad
ia
ti
on
O
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
P
an
ka
j
K
um
ar
G
ar
g,
M
S
D
ep
ar
tm
en
to
f
S
ur
gi
ca
lO
nc
ol
og
y
A
ll
In
di
a
In
st
it
ut
e
of
M
ed
ic
al
S
ci
en
ce
s
N
ew
D
el
hi
,I
nd
ia
du
rg
at
os
h@
gm
ai
l.c
om
R
EF
ER
EN
C
ES
1.
Ta
ls
m
a
A
K
,S
ha
pi
ro
J,
L
oo
m
an
C
W
N
,e
ta
l.
Ly
m
ph
no
de
re
tr
ie
va
l
du
ri
ng
es
op
ha
ge
ct
om
y
w
it
h
an
d
w
it
ho
ut
ne
oa
dj
uv
an
t
ch
em
or
ad
io
th
er
ap
y.
P
ro
gn
os
-
ti
c
an
d
th
er
ap
eu
ti
c
im
pa
ct
on
su
rv
iv
al
.
A
nn
Su
rg
.
20
14
;2
60
:7
86
–7
93
.
2.
va
n
H
ag
en
P
,
H
ul
sh
of
M
C
,
va
n
L
an
sc
ho
t
JJ
,
et
al
.
P
re
op
er
at
iv
e
ch
em
or
ad
io
th
er
ap
y
fo
r
es
op
ha
ge
al
or
ju
nc
ti
on
al
ca
nc
er
.
N
E
ng
l
J
M
ed
.
20
12
;3
66
:2
07
4–
20
84
.
3.
A
ki
ya
m
a
H
,T
su
ru
m
ar
u
M
,U
da
ga
w
a
H
,e
ta
l.
R
ad
i-
ca
ll
ym
ph
no
de
di
ss
ec
ti
on
fo
rc
an
ce
ro
ft
he
th
or
ac
ic
es
op
ha
gu
s.
A
nn
Su
rg
.1
99
4;
22
0:
36
4–
37
3.
4.
U
da
ga
w
a
H
,
A
ki
ya
m
a
H
.
S
ur
gi
ca
l
tr
ea
tm
en
t
of
es
op
ha
ge
al
ca
nc
er
:
To
ky
o
ex
pe
ri
en
ce
of
th
e
th
re
e-
fi
el
d
te
ch
ni
qu
e.
D
is
E
so
ph
ag
us
.2
00
1;
14
:1
10
–1
14
.
5.
O
za
w
a
S
,T
ac
hi
m
or
iY
,B
ab
a
H
,e
ta
l.
C
om
pr
eh
en
-
si
ve
re
gi
st
ry
of
es
op
ha
ge
al
ca
nc
er
in
Ja
pa
n.
E
so
ph
-
ag
us
.2
01
1;
8:
9–
29
.
6.
A
lt
or
ki
N
,K
en
t
M
,P
or
t
J.
T
hr
ee
fi
el
d
ly
m
ph
no
de
di
ss
ec
ti
on
fo
r
sq
ua
m
ou
s
ce
ll
an
d
ad
en
oc
ar
ci
no
m
a
of
th
e
es
op
ha
gu
s.
A
nn
Su
rg
.2
00
2;
23
6:
17
7–
18
3.
7.
Po
rt
al
e
G
,H
ag
en
JA
,P
et
er
s
JH
,e
ta
l.
M
od
er
n
5-
ye
ar
su
rv
iv
al
of
re
se
ct
ab
le
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a:
si
ng
le
in
st
it
ut
io
n
ex
pe
ri
en
ce
w
it
h
26
3
pa
ti
en
ts
.J
A
m
C
ol
lS
ur
g.
20
06
;2
02
:5
88
–5
96
.
8.
S
ol
om
on
N
,Z
hu
ge
Y
,C
he
un
g
M
,e
ta
l.
T
he
ro
le
s
of
ne
oa
dj
uv
an
tr
ad
io
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
in
th
e
tr
ea
tm
en
t
of
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a.
A
nn
Su
rg
O
nc
ol
.2
01
0;
17
:7
91
–8
03
.
Co
py
rig
ht
©
20
15
W
o
lte
rs
Kl
uw
e
r
H
ea
lth
,I
nc
.U
na
ut
ho
riz
e
d
re
pr
od
uc
tio
n
o
ft
hi
s
a
rti
cl
e
is
pr
oh
ib
ite
d.
An
na
ls
of
Su
rg
er
y
 Volu
m
e
00
,N
um
be
r
00
,
20
15
w
w
w
.a
nn
al
so
fs
ur
ge
ry
.c
om
|
1
5
209846-L-bw-Talsma
96
Letters of correspondenceChapter 5
5
R
E
S
P
O
N
S
E
T
O
L
E
T
T
E
R
Re
p
ly
to
Le
tt
er
:
“N
eo
ad
ju
va
nt
Th
er
ap
y
an
d
Ly
m
p
ha
de
ne
ct
om
y
in
Es
op
ha
ge
al
C
an
ce
r
Bo
th
A
re
Es
se
nt
ia
lt
o
M
ax
im
iz
e
Su
rv
iv
al
Be
ne
fit
”
R
ep
ly
:
W
e
th
an
k
D
r
Pa
nd
ey
an
d
co
ll
ea
gu
es
fo
r
th
ei
r
in
si
gh
tf
ul
co
m
m
en
ts
an
d
th
e
op
-
po
rt
un
it
y
to
cl
ar
if
y
a
nu
m
be
r
of
po
in
ts
fr
om
ou
r
ar
ti
cl
e.
1
T
he
ir
m
ai
n
po
in
t
of
cr
it
ic
is
m
is
th
at
th
e
nu
m
be
r
of
re
m
ov
ed
ly
m
ph
no
de
s
is
on
ly
a
su
rr
og
at
e
m
ar
ke
r
fo
r
sy
st
em
at
ic
ly
m
-
ph
ad
en
ec
to
m
y.
In
de
ed
,w
e
ha
ve
ad
dr
es
se
d
th
is
is
su
e
in
th
e
di
sc
us
si
on
.
A
n
ad
eq
ua
te
ly
m
-
ph
ad
en
ec
to
m
y
is
al
so
de
te
rm
in
ed
by
th
e
re
l-
ev
an
ce
of
th
e
re
m
ov
ed
ly
m
ph
no
de
st
at
io
ns
an
d
he
nc
e
th
e
su
rg
ic
al
ap
pr
oa
ch
.
O
ne
ha
s
to
re
m
ov
e
th
e
re
le
va
nt
ly
m
ph
no
de
s
to
ha
ve
an
im
pa
ct
on
su
rv
iv
al
.
O
ur
st
ud
y
ha
s
a
st
ro
ng
de
si
gn
be
-
ca
us
e
it
is
ba
se
d
on
th
e
C
R
O
S
S
tr
ia
l.2
In
th
e
C
R
O
S
S
tr
ia
l,
pa
ti
en
ts
w
er
e
ra
nd
om
-
iz
ed
be
tw
ee
n
su
rg
er
y
al
on
e
an
d
ne
oa
dj
u-
va
nt
ch
em
or
ad
io
th
er
ap
y
(n
C
R
T
)p
lu
s
su
rg
er
y.
T
he
re
fo
re
,w
e
ca
n
co
nc
lu
de
th
at
af
te
r
su
rg
er
y
al
on
e
a
hi
gh
er
nu
m
be
ro
fr
es
ec
te
d
no
de
s
w
er
e
as
so
ci
at
ed
w
it
h
su
rv
iv
al
w
he
re
as
th
is
as
so
-
ci
at
io
n
w
as
lo
st
in
a
co
m
pa
ra
bl
e
gr
ou
p
of
pa
ti
en
ts
w
ho
un
de
rw
en
t
su
rg
er
y
af
te
r
nC
R
T.
T
he
ra
nd
om
iz
at
io
n
w
as
st
ra
ti
fi
ed
fo
r
tr
ea
t-
m
en
t
ce
nt
er
,
cl
in
ic
al
N
-s
ta
ge
an
d
hi
st
ol
og
y,
w
hi
ch
m
ak
es
as
ym
m
et
ry
be
tw
ee
n
bo
th
tr
ea
t-
m
en
ta
rm
s
in
,f
or
ex
am
pl
e,
di
se
as
e
ex
te
ns
io
n
at
ba
se
li
ne
,s
ur
gi
ca
lt
ec
hn
iq
ue
or
ly
m
ph
no
de
ex
am
in
at
io
n
by
th
e
pa
th
ol
og
y
de
pa
rt
m
en
tu
n-
li
ke
ly
.
M
or
eo
ve
r,
st
at
is
ti
ca
l
ad
ju
st
m
en
ts
ex
-
cl
ud
ed
th
es
e
ch
ar
ac
te
ri
st
ic
s
as
an
ex
pl
an
at
io
n
of
th
e
ob
se
rv
ed
as
so
ci
at
io
ns
.
D
is
cl
os
ur
e:
T
he
au
th
or
s
de
cl
ar
e
no
co
nfl
ic
ts
of
in
te
re
st
.
C
op
yr
ig
ht
C�
20
15
W
ol
te
rs
K
lu
w
er
H
ea
lt
h,
In
c.
A
ll
ri
gh
ts
re
se
rv
ed
.
IS
S
N
:0
00
3-
49
32
/1
5/
00
00
0-
00
01
D
O
I:
10
.1
09
7/
S
L
A
.0
00
00
00
00
00
01
19
7
Pa
nd
ey
an
d
co
ll
ea
gu
es
re
fe
r
to
st
ud
ie
s
w
it
h
w
ea
ke
rd
es
ig
ns
.I
n
th
e
st
ud
y
by
S
ol
om
on
et
al
,3
th
e
ef
fe
ct
of
sy
st
em
at
ic
ly
m
ph
ad
en
ec
-
to
m
y
w
as
st
ra
ti
fi
ed
fo
r
pa
th
ol
og
ic
al
N
-s
ta
ge
(p
N
0
vs
pN
+)
,
w
hi
ch
ca
rr
ie
s
th
e
po
te
nt
ia
l
bi
as
of
st
ag
e
m
ig
ra
ti
on
.
In
th
e
st
ud
ie
s
by
A
lt
or
ki
et
al
4
an
d
Po
rt
al
e
et
al
,5
on
ly
a
sm
al
l
m
in
or
it
y
un
de
rw
en
t
ne
oa
dj
uv
an
t
th
er
-
ap
y,
w
hi
ch
is
ex
ac
tly
th
e
m
at
te
rt
ha
ti
s
at
st
ak
e.
T
he
ad
va
nt
ag
e
of
th
e
st
ud
y
by
Po
rt
al
e
et
al
is
th
at
it
co
m
pa
re
d
su
rg
ic
al
ap
pr
oa
ch
es
(e
n
bl
oc
vs
tr
an
sh
ia
ta
l)
,b
ut
th
e
de
si
gn
of
th
e
tr
ia
lw
as
no
tr
an
do
m
iz
ed
.
W
e
ag
re
e
th
at
se
co
nd
ar
y
an
al
ys
es
w
it
hi
n
a
ra
nd
om
iz
ed
tr
ia
l
ca
n
m
er
el
y
ge
ne
r-
at
e
ne
w
hy
po
th
es
es
.
W
e
ne
ed
co
nfi
rm
at
io
n
fr
om
ob
se
rv
at
io
na
l
st
ud
ie
s,
an
d
id
ea
lly
ra
n-
do
m
iz
ed
co
nt
ro
ll
ed
tr
ia
ls
,t
o
ex
cl
ud
e
po
te
nt
ia
l
bi
as
es
su
ch
as
st
ag
e
m
ig
ra
ti
on
.
R
et
ro
sp
ec
-
tiv
e
an
al
ys
es
on
th
e
ex
te
nt
of
ly
m
ph
ad
en
ec
-
to
m
y
fr
om
ob
se
rv
at
io
na
l
da
ta
m
ay
ha
ve
on
ly
li
m
it
ed
va
lu
e
be
ca
us
e
va
ri
ou
s
se
le
ct
io
n
bi
-
as
es
m
ay
pl
ay
up
.G
ro
up
s
pr
ob
ab
ly
di
ff
er
fo
r
m
an
y
m
or
e
va
ri
ab
le
s
(t
um
or
ty
pe
,
di
ag
no
s-
ti
c
w
or
ku
p,
in
cl
us
io
n
an
d
ex
cl
us
io
n
cr
it
er
ia
,
et
c)
,b
es
id
es
th
e
ex
te
nt
of
ly
m
ph
ad
en
ec
to
m
y.
A
se
co
nd
ar
y
an
al
ys
is
of
a
ra
nd
om
iz
ed
co
n-
tr
ol
le
d
tr
ia
ls
up
pl
ie
s
a
hi
gh
er
le
ve
lo
fe
vi
de
nc
e
th
an
a
re
tr
os
pe
ct
iv
e
co
m
pa
ri
so
n.
In
th
e
su
rg
er
y-
al
on
e
er
a,
w
e
ha
ve
pr
ev
i-
ou
sl
y
pe
rf
or
m
ed
a
ra
nd
om
iz
ed
co
nt
ro
ll
ed
tr
ia
l
co
m
pa
ri
ng
tr
an
sh
ia
ta
l
re
se
ct
io
n
w
it
h
li
m
it
ed
ly
m
ph
ad
en
ec
to
m
y
ve
rs
us
tr
an
st
ho
ra
ci
c
re
se
c-
ti
on
w
it
h
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y.
6
T
he
m
ea
n
nu
m
be
r
of
re
m
ov
ed
ly
m
ph
no
de
s
do
u-
bl
ed
af
te
r
ex
te
nd
ed
re
se
ct
io
n
(f
ro
m
16
±
9
to
31
±
14
no
de
s)
,a
nd
th
er
e
w
as
a
no
ns
ig
ni
fi
ca
nt
tr
en
d
to
w
ar
d
im
pr
ov
ed
lo
ng
-t
er
m
su
rv
iv
al
.I
n
li
ne
w
it
h
th
is
,
th
e
pr
es
en
t
st
ud
y
su
pp
or
ts
a
po
te
nt
ia
lt
he
ra
pe
ut
ic
be
ne
fi
to
fe
xt
en
de
d
ly
m
-
ph
ad
en
ec
to
m
y
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p.
To
qu
an
ti
fy
th
e
th
er
ap
eu
ti
c
im
pa
ct
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
r
pa
ti
en
ts
af
-
te
rn
eo
ad
ju
va
nt
tr
ea
tm
en
t,
w
e
ne
ed
a
ra
nd
om
-
iz
ed
co
nt
ro
ll
ed
tr
ia
li
n
w
hi
ch
pa
ti
en
ts
re
ce
iv
e
nC
R
T,
fo
ll
ow
ed
by
a
li
m
it
ed
tr
an
sh
ia
ta
lo
re
x-
te
nd
ed
tr
an
st
ho
ra
ci
c
re
se
ct
io
n.
B
ut
th
e
cu
r-
re
nt
ev
id
en
ce
fr
om
ou
r
st
ud
y
su
gg
es
ts
th
at
th
is
im
pa
ct
is
le
ss
im
po
rt
an
t
th
an
th
at
fr
om
th
e
su
rg
er
y-
al
on
e
er
a.
A
.K
oe
n
T
al
sm
a,
M
D
B
as
P.
L
.W
ij
nh
ov
en
,M
D
,P
hD
D
ep
ar
tm
en
to
f
S
ur
ge
ry
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
E
w
ou
t
W
.S
te
ye
rb
er
g,
P
hD
D
ep
ar
tm
en
to
f
P
ub
li
c
H
ea
lt
h
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
J.
Ja
n
B
.v
an
L
an
sc
ho
t,
M
D
P
hD
D
ep
ar
tm
en
to
f
S
ur
ge
ry
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
R
EF
ER
EN
C
ES
1.
Ta
ls
m
a
A
K
,S
ha
pi
ro
J,
L
oo
m
an
C
W
N
,e
ta
l.
Ly
m
ph
no
de
re
tr
ie
va
l
du
ri
ng
es
op
ha
ge
ct
om
y
w
it
h
an
d
w
it
ho
ut
ne
oa
dj
uv
an
t
ch
em
or
ad
io
th
er
ap
y.
P
ro
gn
os
-
ti
c
an
d
th
er
ap
eu
ti
c
im
pa
ct
on
su
rv
iv
al
.
A
nn
Su
rg
.
20
14
;2
60
:7
86
–7
93
.
2.
va
n
H
ag
en
P
,
H
ul
sh
of
M
C
,
va
n
L
an
sc
ho
t
JJ
,
et
al
.
P
re
op
er
at
iv
e
ch
em
or
ad
io
th
er
ap
y
fo
r
es
op
ha
ge
al
or
ju
nc
ti
on
al
ca
nc
er
.
N
E
ng
l
J
M
ed
.
20
12
;3
66
:2
07
4–
20
84
.
3.
S
ol
om
on
N
,Z
hu
ge
Y
,C
he
un
g
M
,e
ta
l.
T
he
ro
le
s
of
ne
oa
dj
uv
an
tr
ad
io
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
in
th
e
tr
ea
tm
en
t
of
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a.
A
nn
Su
rg
O
nc
ol
.2
01
0;
17
:7
91
–8
03
.
4.
A
lt
or
ki
N
,
K
en
t
M
,
Po
rt
J.
T
hr
ee
fi
el
d
ly
m
ph
no
de
di
ss
ec
ti
on
fo
r
sq
ua
m
ou
s
ce
ll
an
d
ad
en
oc
ar
-
ci
no
m
a
of
th
e
es
op
ha
gu
s.
A
nn
Su
rg
.
20
02
;2
36
:
17
7–
18
3.
5.
Po
rt
al
e
G
,H
ag
en
JA
,P
et
er
s
JH
,e
ta
l.
M
od
er
n
5-
ye
ar
su
rv
iv
al
of
re
se
ct
ab
le
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a:
si
ng
le
in
st
it
ut
io
n
ex
pe
ri
en
ce
w
it
h
26
3
pa
ti
en
ts
.J
A
m
C
ol
lS
ur
g.
20
06
;2
02
:5
88
–5
96
.
6.
H
ul
sc
he
r
JB
F
,
V
an
S
an
di
ck
JW
,
D
e
B
oe
r
A
G
E
M
,
et
al
.
E
xt
en
de
d
tr
an
st
ho
ra
ci
c
re
se
ct
io
n
co
m
-
pa
re
d
w
it
h
li
m
it
ed
tr
an
sh
ia
ta
l
re
se
ct
io
n
fo
r
ad
e-
no
ca
rc
in
om
a
of
th
e
es
op
ha
gu
s.
N
E
ng
l
J
M
ed
.
20
02
;3
47
:1
66
2–
16
69
.
Co
py
rig
ht
©
20
15
W
o
lte
rs
Kl
uw
e
r
H
ea
lth
,I
nc
.U
na
ut
ho
riz
e
d
re
pr
od
uc
tio
n
o
ft
hi
s
a
rti
cl
e
is
pr
oh
ib
ite
d.
An
na
ls
of
Su
rg
er
y
 Volu
m
e
00
,N
um
be
r
00
,
20
15
w
w
w
.a
nn
al
so
fs
ur
ge
ry
.c
om
|
1
209846-L-bw-Talsma
97
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy
5
R
E
S
P
O
N
S
E
T
O
L
E
T
T
E
R
Re
p
ly
to
Le
tt
er
:
“N
eo
ad
ju
va
nt
Th
er
ap
y
an
d
Ly
m
p
ha
de
ne
ct
om
y
in
Es
op
ha
ge
al
C
an
ce
r
Bo
th
A
re
Es
se
nt
ia
lt
o
M
ax
im
iz
e
Su
rv
iv
al
Be
ne
fit
”
R
ep
ly
:
W
e
th
an
k
D
r
Pa
nd
ey
an
d
co
ll
ea
gu
es
fo
r
th
ei
r
in
si
gh
tf
ul
co
m
m
en
ts
an
d
th
e
op
-
po
rt
un
it
y
to
cl
ar
if
y
a
nu
m
be
r
of
po
in
ts
fr
om
ou
r
ar
ti
cl
e.
1
T
he
ir
m
ai
n
po
in
t
of
cr
it
ic
is
m
is
th
at
th
e
nu
m
be
r
of
re
m
ov
ed
ly
m
ph
no
de
s
is
on
ly
a
su
rr
og
at
e
m
ar
ke
r
fo
r
sy
st
em
at
ic
ly
m
-
ph
ad
en
ec
to
m
y.
In
de
ed
,w
e
ha
ve
ad
dr
es
se
d
th
is
is
su
e
in
th
e
di
sc
us
si
on
.
A
n
ad
eq
ua
te
ly
m
-
ph
ad
en
ec
to
m
y
is
al
so
de
te
rm
in
ed
by
th
e
re
l-
ev
an
ce
of
th
e
re
m
ov
ed
ly
m
ph
no
de
st
at
io
ns
an
d
he
nc
e
th
e
su
rg
ic
al
ap
pr
oa
ch
.
O
ne
ha
s
to
re
m
ov
e
th
e
re
le
va
nt
ly
m
ph
no
de
s
to
ha
ve
an
im
pa
ct
on
su
rv
iv
al
.
O
ur
st
ud
y
ha
s
a
st
ro
ng
de
si
gn
be
-
ca
us
e
it
is
ba
se
d
on
th
e
C
R
O
S
S
tr
ia
l.2
In
th
e
C
R
O
S
S
tr
ia
l,
pa
ti
en
ts
w
er
e
ra
nd
om
-
iz
ed
be
tw
ee
n
su
rg
er
y
al
on
e
an
d
ne
oa
dj
u-
va
nt
ch
em
or
ad
io
th
er
ap
y
(n
C
R
T
)p
lu
s
su
rg
er
y.
T
he
re
fo
re
,w
e
ca
n
co
nc
lu
de
th
at
af
te
r
su
rg
er
y
al
on
e
a
hi
gh
er
nu
m
be
ro
fr
es
ec
te
d
no
de
s
w
er
e
as
so
ci
at
ed
w
it
h
su
rv
iv
al
w
he
re
as
th
is
as
so
-
ci
at
io
n
w
as
lo
st
in
a
co
m
pa
ra
bl
e
gr
ou
p
of
pa
ti
en
ts
w
ho
un
de
rw
en
t
su
rg
er
y
af
te
r
nC
R
T.
T
he
ra
nd
om
iz
at
io
n
w
as
st
ra
ti
fi
ed
fo
r
tr
ea
t-
m
en
t
ce
nt
er
,
cl
in
ic
al
N
-s
ta
ge
an
d
hi
st
ol
og
y,
w
hi
ch
m
ak
es
as
ym
m
et
ry
be
tw
ee
n
bo
th
tr
ea
t-
m
en
ta
rm
s
in
,f
or
ex
am
pl
e,
di
se
as
e
ex
te
ns
io
n
at
ba
se
li
ne
,s
ur
gi
ca
lt
ec
hn
iq
ue
or
ly
m
ph
no
de
ex
am
in
at
io
n
by
th
e
pa
th
ol
og
y
de
pa
rt
m
en
tu
n-
li
ke
ly
.
M
or
eo
ve
r,
st
at
is
ti
ca
l
ad
ju
st
m
en
ts
ex
-
cl
ud
ed
th
es
e
ch
ar
ac
te
ri
st
ic
s
as
an
ex
pl
an
at
io
n
of
th
e
ob
se
rv
ed
as
so
ci
at
io
ns
.
D
is
cl
os
ur
e:
T
he
au
th
or
s
de
cl
ar
e
no
co
nfl
ic
ts
of
in
te
re
st
.
C
op
yr
ig
ht
C�
20
15
W
ol
te
rs
K
lu
w
er
H
ea
lt
h,
In
c.
A
ll
ri
gh
ts
re
se
rv
ed
.
IS
S
N
:0
00
3-
49
32
/1
5/
00
00
0-
00
01
D
O
I:
10
.1
09
7/
S
L
A
.0
00
00
00
00
00
01
19
7
Pa
nd
ey
an
d
co
ll
ea
gu
es
re
fe
r
to
st
ud
ie
s
w
it
h
w
ea
ke
rd
es
ig
ns
.I
n
th
e
st
ud
y
by
S
ol
om
on
et
al
,3
th
e
ef
fe
ct
of
sy
st
em
at
ic
ly
m
ph
ad
en
ec
-
to
m
y
w
as
st
ra
ti
fi
ed
fo
r
pa
th
ol
og
ic
al
N
-s
ta
ge
(p
N
0
vs
pN
+)
,
w
hi
ch
ca
rr
ie
s
th
e
po
te
nt
ia
l
bi
as
of
st
ag
e
m
ig
ra
ti
on
.
In
th
e
st
ud
ie
s
by
A
lt
or
ki
et
al
4
an
d
Po
rt
al
e
et
al
,5
on
ly
a
sm
al
l
m
in
or
it
y
un
de
rw
en
t
ne
oa
dj
uv
an
t
th
er
-
ap
y,
w
hi
ch
is
ex
ac
tly
th
e
m
at
te
rt
ha
ti
s
at
st
ak
e.
T
he
ad
va
nt
ag
e
of
th
e
st
ud
y
by
Po
rt
al
e
et
al
is
th
at
it
co
m
pa
re
d
su
rg
ic
al
ap
pr
oa
ch
es
(e
n
bl
oc
vs
tr
an
sh
ia
ta
l)
,b
ut
th
e
de
si
gn
of
th
e
tr
ia
lw
as
no
tr
an
do
m
iz
ed
.
W
e
ag
re
e
th
at
se
co
nd
ar
y
an
al
ys
es
w
it
hi
n
a
ra
nd
om
iz
ed
tr
ia
l
ca
n
m
er
el
y
ge
ne
r-
at
e
ne
w
hy
po
th
es
es
.
W
e
ne
ed
co
nfi
rm
at
io
n
fr
om
ob
se
rv
at
io
na
l
st
ud
ie
s,
an
d
id
ea
lly
ra
n-
do
m
iz
ed
co
nt
ro
ll
ed
tr
ia
ls
,t
o
ex
cl
ud
e
po
te
nt
ia
l
bi
as
es
su
ch
as
st
ag
e
m
ig
ra
ti
on
.
R
et
ro
sp
ec
-
tiv
e
an
al
ys
es
on
th
e
ex
te
nt
of
ly
m
ph
ad
en
ec
-
to
m
y
fr
om
ob
se
rv
at
io
na
l
da
ta
m
ay
ha
ve
on
ly
li
m
it
ed
va
lu
e
be
ca
us
e
va
ri
ou
s
se
le
ct
io
n
bi
-
as
es
m
ay
pl
ay
up
.G
ro
up
s
pr
ob
ab
ly
di
ff
er
fo
r
m
an
y
m
or
e
va
ri
ab
le
s
(t
um
or
ty
pe
,
di
ag
no
s-
ti
c
w
or
ku
p,
in
cl
us
io
n
an
d
ex
cl
us
io
n
cr
it
er
ia
,
et
c)
,b
es
id
es
th
e
ex
te
nt
of
ly
m
ph
ad
en
ec
to
m
y.
A
se
co
nd
ar
y
an
al
ys
is
of
a
ra
nd
om
iz
ed
co
n-
tr
ol
le
d
tr
ia
ls
up
pl
ie
s
a
hi
gh
er
le
ve
lo
fe
vi
de
nc
e
th
an
a
re
tr
os
pe
ct
iv
e
co
m
pa
ri
so
n.
In
th
e
su
rg
er
y-
al
on
e
er
a,
w
e
ha
ve
pr
ev
i-
ou
sl
y
pe
rf
or
m
ed
a
ra
nd
om
iz
ed
co
nt
ro
ll
ed
tr
ia
l
co
m
pa
ri
ng
tr
an
sh
ia
ta
l
re
se
ct
io
n
w
it
h
li
m
it
ed
ly
m
ph
ad
en
ec
to
m
y
ve
rs
us
tr
an
st
ho
ra
ci
c
re
se
c-
ti
on
w
it
h
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y.
6
T
he
m
ea
n
nu
m
be
r
of
re
m
ov
ed
ly
m
ph
no
de
s
do
u-
bl
ed
af
te
r
ex
te
nd
ed
re
se
ct
io
n
(f
ro
m
16
±
9
to
31
±
14
no
de
s)
,a
nd
th
er
e
w
as
a
no
ns
ig
ni
fi
ca
nt
tr
en
d
to
w
ar
d
im
pr
ov
ed
lo
ng
-t
er
m
su
rv
iv
al
.I
n
li
ne
w
it
h
th
is
,
th
e
pr
es
en
t
st
ud
y
su
pp
or
ts
a
po
te
nt
ia
lt
he
ra
pe
ut
ic
be
ne
fi
to
fe
xt
en
de
d
ly
m
-
ph
ad
en
ec
to
m
y
in
th
e
su
rg
er
y-
al
on
e
gr
ou
p.
To
qu
an
ti
fy
th
e
th
er
ap
eu
ti
c
im
pa
ct
of
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
fo
r
pa
ti
en
ts
af
-
te
rn
eo
ad
ju
va
nt
tr
ea
tm
en
t,
w
e
ne
ed
a
ra
nd
om
-
iz
ed
co
nt
ro
ll
ed
tr
ia
li
n
w
hi
ch
pa
ti
en
ts
re
ce
iv
e
nC
R
T,
fo
ll
ow
ed
by
a
li
m
it
ed
tr
an
sh
ia
ta
lo
re
x-
te
nd
ed
tr
an
st
ho
ra
ci
c
re
se
ct
io
n.
B
ut
th
e
cu
r-
re
nt
ev
id
en
ce
fr
om
ou
r
st
ud
y
su
gg
es
ts
th
at
th
is
im
pa
ct
is
le
ss
im
po
rt
an
t
th
an
th
at
fr
om
th
e
su
rg
er
y-
al
on
e
er
a.
A
.K
oe
n
T
al
sm
a,
M
D
B
as
P.
L
.W
ij
nh
ov
en
,M
D
,P
hD
D
ep
ar
tm
en
to
f
S
ur
ge
ry
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
E
w
ou
t
W
.S
te
ye
rb
er
g,
P
hD
D
ep
ar
tm
en
to
f
P
ub
li
c
H
ea
lt
h
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
J.
Ja
n
B
.v
an
L
an
sc
ho
t,
M
D
P
hD
D
ep
ar
tm
en
to
f
S
ur
ge
ry
E
ra
sm
us
-M
C
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
R
EF
ER
EN
C
ES
1.
Ta
ls
m
a
A
K
,S
ha
pi
ro
J,
L
oo
m
an
C
W
N
,e
ta
l.
Ly
m
ph
no
de
re
tr
ie
va
l
du
ri
ng
es
op
ha
ge
ct
om
y
w
it
h
an
d
w
it
ho
ut
ne
oa
dj
uv
an
t
ch
em
or
ad
io
th
er
ap
y.
P
ro
gn
os
-
ti
c
an
d
th
er
ap
eu
ti
c
im
pa
ct
on
su
rv
iv
al
.
A
nn
Su
rg
.
20
14
;2
60
:7
86
–7
93
.
2.
va
n
H
ag
en
P
,
H
ul
sh
of
M
C
,
va
n
L
an
sc
ho
t
JJ
,
et
al
.
P
re
op
er
at
iv
e
ch
em
or
ad
io
th
er
ap
y
fo
r
es
op
ha
ge
al
or
ju
nc
ti
on
al
ca
nc
er
.
N
E
ng
l
J
M
ed
.
20
12
;3
66
:2
07
4–
20
84
.
3.
S
ol
om
on
N
,Z
hu
ge
Y
,C
he
un
g
M
,e
ta
l.
T
he
ro
le
s
of
ne
oa
dj
uv
an
tr
ad
io
th
er
ap
y
an
d
ly
m
ph
ad
en
ec
to
m
y
in
th
e
tr
ea
tm
en
t
of
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a.
A
nn
Su
rg
O
nc
ol
.2
01
0;
17
:7
91
–8
03
.
4.
A
lt
or
ki
N
,
K
en
t
M
,
Po
rt
J.
T
hr
ee
fi
el
d
ly
m
ph
no
de
di
ss
ec
ti
on
fo
r
sq
ua
m
ou
s
ce
ll
an
d
ad
en
oc
ar
-
ci
no
m
a
of
th
e
es
op
ha
gu
s.
A
nn
Su
rg
.
20
02
;2
36
:
17
7–
18
3.
5.
Po
rt
al
e
G
,H
ag
en
JA
,P
et
er
s
JH
,e
ta
l.
M
od
er
n
5-
ye
ar
su
rv
iv
al
of
re
se
ct
ab
le
es
op
ha
ge
al
ad
en
oc
ar
ci
no
m
a:
si
ng
le
in
st
it
ut
io
n
ex
pe
ri
en
ce
w
it
h
26
3
pa
ti
en
ts
.J
A
m
C
ol
lS
ur
g.
20
06
;2
02
:5
88
–5
96
.
6.
H
ul
sc
he
r
JB
F
,
V
an
S
an
di
ck
JW
,
D
e
B
oe
r
A
G
E
M
,
et
al
.
E
xt
en
de
d
tr
an
st
ho
ra
ci
c
re
se
ct
io
n
co
m
-
pa
re
d
w
it
h
li
m
it
ed
tr
an
sh
ia
ta
l
re
se
ct
io
n
fo
r
ad
e-
no
ca
rc
in
om
a
of
th
e
es
op
ha
gu
s.
N
E
ng
l
J
M
ed
.
20
02
;3
47
:1
66
2–
16
69
.
Co
py
rig
ht
©
20
15
W
o
lte
rs
Kl
uw
e
r
H
ea
lth
,I
nc
.U
na
ut
ho
riz
e
d
re
pr
od
uc
tio
n
o
ft
hi
s
a
rti
cl
e
is
pr
oh
ib
ite
d.
An
na
ls
of
Su
rg
er
y
 Volu
m
e
00
,N
um
be
r
00
,
20
15
w
w
w
.a
nn
al
so
fs
ur
ge
ry
.c
om
|
1
209846-L-bw-Talsma
98
Letters of correspondenceChapter 5
5
L
E
T
T
E
R
T
O
T
H
E
E
D
IT
O
R
Im
p
ac
t
of
N
eo
ad
ju
va
nt
C
he
m
or
ad
ia
tio
n
on
Ly
m
p
h
N
od
e
St
at
us
in
Es
op
ha
ge
al
C
an
ce
r:
Po
st
ho
c
A
na
ly
si
s
of
a
Ra
nd
om
iz
ed
C
on
tr
ol
le
d
Tr
ia
l
To
th
e
E
di
to
r:
W
e
ha
ve
re
ad
w
it
h
gr
ea
t
in
te
re
st
th
e
re
-
ce
nt
ar
ti
cl
e
by
R
ob
b
et
al
in
A
nn
al
s
of
Su
rg
er
y.
1
T
he
Fr
en
ch
st
ud
y
gr
ou
p
el
eg
an
tly
re
an
al
yz
ed
da
ta
of
th
e
F
F
C
D
99
01
tr
ia
l.2
T
hi
s
ra
nd
om
iz
ed
cl
in
ic
al
tr
ia
l
co
m
pa
re
d
su
rv
iv
al
af
te
rn
eo
ad
ju
va
nt
ch
em
or
ad
io
th
er
ap
y
(n
C
R
T
)
fo
ll
ow
ed
by
su
rg
er
y
w
it
h
su
rg
er
y
al
on
e
of
pa
-
ti
en
ts
w
it
h
es
op
ha
ge
al
sq
ua
m
ou
s
ce
ll
ca
rc
i-
no
m
a.
T
he
au
th
or
s
sh
ow
th
at
th
e
nu
m
be
r
of
re
se
ct
ed
ly
m
ph
no
de
s
an
d
th
e
nu
m
be
r
of
po
s-
it
iv
e
no
de
s
id
en
ti
fi
ed
ar
e
re
du
ce
d
af
te
r
nC
R
T
co
m
pa
re
d
w
it
h
su
rg
er
y
al
on
e.
P
re
vi
ou
s
st
ud
ie
s
ha
ve
sh
ow
n
th
at
m
ax
-
im
iz
in
g
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
is
st
il
l
re
le
va
nt
fo
r
im
pr
ov
in
g
ou
tc
om
e
af
te
r
nC
R
T,
3
,4
w
he
re
as
ot
he
rc
oh
or
ta
nd
po
pu
la
ti
on
ba
se
d
st
ud
ie
s
ha
ve
co
nc
lu
de
d
th
e
op
po
si
te
.5
–8
T
he
st
ud
y
by
R
ob
b
et
al
is
th
e
se
co
nd
st
ud
y
us
-
in
g
da
ta
fr
om
a
ca
re
fu
lly
co
nd
uc
te
d
ra
nd
om
-
iz
ed
co
nt
ro
ll
ed
cl
in
ic
al
tr
ia
la
nd
in
di
ca
te
s
th
at
th
er
e
is
no
as
so
ci
at
io
n
be
tw
ee
n
th
e
to
ta
ln
um
-
be
r
of
re
se
ct
ed
no
de
s
an
d
su
rv
iv
al
.A
n
ea
rl
ie
r
po
st
ho
c
an
al
ys
is
of
th
e
D
ut
ch
ra
nd
om
iz
ed
C
R
O
S
S
tr
ia
lp
ub
li
sh
ed
in
A
nn
al
s
of
Su
rg
er
y9
sh
ow
ed
si
m
il
ar
re
su
lt
s.
D
is
cl
os
ur
e:
N
o
so
ur
ce
s
of
fu
nd
in
g
ha
ve
be
en
re
ce
iv
ed
re
la
te
d
to
th
is
in
ve
st
ig
at
io
n.
N
o
po
te
nt
ia
l
co
m
pe
t-
in
g
in
te
re
st
s
ex
is
tf
or
al
la
ut
ho
rs
.
C
op
yr
ig
ht
C�
20
15
W
ol
te
rs
K
lu
w
er
H
ea
lt
h,
In
c.
A
ll
ri
gh
ts
re
se
rv
ed
.
IS
S
N
:0
00
3-
49
32
/1
5/
00
00
0-
00
01
D
O
I:
10
.1
09
7/
S
L
A
.0
00
00
00
00
00
01
35
8
In
ou
r
op
in
io
n,
th
e
as
se
rt
io
n
m
ad
e
by
th
e
au
th
or
s
th
at
th
ei
r
re
su
lt
s
do
no
t
ch
al
-
le
ng
e
th
e
in
di
ca
ti
on
fo
r
m
ax
im
iz
at
io
n
of
ly
m
ph
no
de
di
ss
ec
ti
on
du
ri
ng
es
op
ha
ge
ct
om
y
is
,
ho
w
ev
er
,
de
ba
ta
bl
e.
T
he
an
al
ys
is
of
th
e
C
R
O
S
S
tr
ia
l
sh
ow
ed
2
im
po
rt
an
t
fi
nd
in
gs
:
(1
)
af
te
r
nC
R
T,
th
er
e
w
as
no
as
so
ci
at
io
n
be
-
tw
ee
n
th
e
nu
m
be
r
of
re
se
ct
ed
ly
m
ph
no
de
s
an
d
su
rv
iv
al
;t
hi
s
w
as
in
sh
ar
p
co
nt
ra
st
to
th
e
gr
ou
p
of
pa
ti
en
ts
in
th
at
tr
ia
l
w
ho
un
de
rw
en
t
su
rg
er
y
al
on
e;
an
d
(2
)
af
te
r
nC
R
T,
th
er
e
w
as
no
as
so
ci
at
io
n
be
tw
ee
n
th
e
to
ta
l
nu
m
be
r
of
re
se
ct
ed
ly
m
ph
no
de
s
an
d
th
e
nu
m
be
r
of
po
s-
it
iv
e
no
de
s.
In
ou
rv
ie
w
th
es
e
fi
nd
in
gs
su
gg
es
t
th
at
an
ex
te
nd
ed
ly
m
ph
ad
en
ec
to
m
y
is
ne
it
he
r
ne
ce
ss
ar
y
fo
r
th
er
ap
eu
ti
c
no
r
fo
r
pr
og
no
st
ic
re
as
on
s.
It
w
ou
ld
be
of
gr
ea
ti
nt
er
es
ti
fR
ob
b
et
al
co
ul
d
al
so
pr
es
en
tt
he
ir
da
ta
on
th
e
po
te
nt
ia
l
as
so
ci
at
io
n
be
tw
ee
n
th
e
nu
m
be
r
of
re
se
ct
ed
no
de
s
an
d
th
e
nu
m
be
r
of
po
si
tiv
e
no
de
s.
U
lt
im
at
el
y,
to
pr
op
er
ly
ad
dr
es
s
th
e
im
-
pa
ct
of
su
rg
ic
al
ap
pr
oa
ch
on
ly
m
ph
no
de
re
-
tr
ie
va
l
an
d
su
rv
iv
al
,
a
ne
w
ra
nd
om
iz
ed
tr
ia
l
sh
ou
ld
be
ca
rr
ie
d
ou
t
co
m
pa
ri
ng
a
tr
an
-
sh
ia
ta
l
an
d
tr
an
st
ho
ra
ci
c
ap
pr
oa
ch
in
th
e
er
a
of
nC
R
T,
pr
ef
er
ab
ly
fo
cu
si
ng
on
tr
ul
y
es
op
ha
ge
al
(S
ie
w
er
tt
yp
e-
1)
ca
nc
er
s.
10
K
oe
n
T
al
sm
a,
M
D
,M
Sc
B
as
W
ij
nh
ov
en
,M
D
,P
hD
Ja
n
va
n
L
an
sc
ho
t,
M
D
,P
hD
M
ar
k
va
n
B
er
ge
H
en
eg
ou
w
en
,M
D
,P
hD
D
ep
ar
tm
en
to
f
S
ur
ge
ry
S
ui
te
H
-8
12
,E
ra
sm
us
M
ed
ic
al
C
en
te
r
R
ot
te
rd
am
,T
he
N
et
he
rl
an
ds
ko
en
ta
ls
m
a@
ho
tm
ai
l.c
om
R
EF
ER
EN
C
ES
1.
R
ob
b
W
B
,
D
ah
an
L
,
M
or
ne
x
F
,
et
al
.
Im
pa
ct
of
ne
oa
dj
uv
an
t
ch
em
or
ad
ia
ti
on
on
ly
m
ph
no
de
st
at
us
in
es
op
ha
ge
al
ca
nc
er
:
po
st
ho
c
an
al
y-
si
s
of
a
ra
nd
om
iz
ed
co
nt
ro
ll
ed
tr
ia
l.
A
nn
Su
rg
.
20
15
;2
61
:9
02
–9
08
.
2.
M
ar
ie
tt
e
C
,
D
ah
an
L
,
M
or
ne
x
F
,
et
al
.
S
ur
ge
ry
al
on
e
ve
rs
us
ch
em
or
ad
io
th
er
ap
y
fo
ll
ow
ed
by
su
rg
er
y
fo
r
st
ag
e
I
an
d
II
es
op
ha
ge
al
ca
nc
er
:
fi
na
l
an
al
ys
is
of
ra
nd
om
iz
ed
co
nt
ro
ll
ed
ph
as
e
II
I
tr
ia
l
F
F
C
D
99
01
.
J
C
li
n
O
nc
ol
.
20
14
;3
2:
24
16
–2
42
2.
3.
S
ol
om
on
N
,Z
hu
ge
Y
,C
he
un
g
M
,e
ta
l.
T
he
ro
le
s
of
ne
oa
dj
uv
an
t
ra
di
ot
he
ra
py
an
d
ly
m
ph
ad
en
ec
-
to
m
y
in
th
e
tr
ea
tm
en
t
of
es
op
ha
ge
al
ad
en
oc
ar
ci
-
no
m
a.
A
nn
Su
rg
O
nc
ol
.2
01
0;
17
:7
91
–8
03
.
4.
To
rg
er
se
n
Z
,
S
un
da
ra
m
A
,
H
os
hi
no
M
,
et
al
.
P
ro
gn
os
ti
c
im
pl
ic
at
io
ns
of
ly
m
ph
ad
en
ec
to
m
y
in
es
op
ha
ge
al
ca
nc
er
af
te
r
ne
o-
ad
ju
va
nt
th
er
ap
y:
a
si
ng
le
ce
nt
er
ex
pe
ri
en
ce
.
J
G
as
tr
oi
nt
es
t
Su
rg
.
20
11
;1
5:
17
69
–1
77
6.
5.
V
al
lb
o¨h
m
er
D
,H
o¨l
sc
he
r
A
H
,D
eM
ee
st
er
S
,e
t
al
.
A
m
ul
ti
ce
nt
er
st
ud
y
of
su
rv
iv
al
af
te
r
ne
oa
dj
u-
va
nt
ra
di
ot
he
ra
py
/c
he
m
ot
he
ra
py
an
d
es
op
ha
ge
c-
to
m
y
fo
r
yp
T
0N
0M
0R
0
es
op
ha
ge
al
ca
nc
er
.
A
nn
Su
rg
.2
01
0;
25
2:
74
4–
74
9.
6.
C
ha
o
Y
K
,
L
iu
H
P
,
H
si
eh
M
J,
et
al
.
Im
pa
ct
of
th
e
nu
m
be
r
of
ly
m
ph
no
de
s
sa
m
pl
ed
on
ou
tc
om
e
in
yp
T
0N
0
es
op
ha
ge
al
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a
pa
ti
en
ts
.J
Su
rg
O
nc
ol
.2
01
2;
10
6:
43
6–
44
0.
7.
S
is
ic
L
,
B
la
nk
S
,
W
ei
ch
er
t
W
,
et
al
.
P
ro
gn
os
ti
c
im
pa
ct
of
ly
m
ph
no
de
in
vo
lv
e
m
en
ta
nd
th
e
ex
te
nt
of
ly
m
ph
ad
en
ec
to
m
y
(L
A
D
)i
n
ad
en
oc
ar
ci
no
m
a
of
th
e
es
op
ha
go
ga
st
ri
c
ju
nc
ti
on
(A
E
G
).
L
an
ge
nb
ec
ks
A
rc
h
Su
rg
.2
01
3;
39
8:
97
3–
98
1.
8.
S
hr
id
ha
r
R
,
H
of
fe
S
E
,
A
lm
ha
nn
a
K
,
et
al
.
Ly
m
ph
no
de
ha
rv
es
t
in
es
op
ha
ge
al
ca
nc
er
af
te
r
ne
oa
dj
uv
an
tc
he
m
or
ad
io
th
er
ap
y.
A
nn
Su
rg
O
nc
ol
.
20
13
;2
0:
30
38
–3
04
3.
9.
Ta
ls
m
a
A
K
,S
ha
pi
ro
J,
L
oo
m
an
C
W
,e
ta
l.
Ly
m
ph
no
de
re
tr
ie
va
l
du
ri
ng
es
op
ha
ge
ct
om
y
w
it
h
an
d
w
it
ho
ut
ne
oa
dj
uv
an
t
ch
em
or
ad
io
th
er
ap
y:
pr
og
-
no
st
ic
an
d
th
er
ap
eu
ti
c
im
pa
ct
on
su
rv
iv
al
.
A
nn
Su
rg
.2
01
4;
26
0:
78
6–
79
2;
di
sc
us
si
on
79
2–
79
3.
10
.
O
m
lo
o
JM
T
,
L
ag
ar
de
S
M
,
H
ul
sc
he
r
JF
B
,
et
al
.
E
xt
en
de
d
tr
an
st
ho
ra
ci
c
re
se
ct
io
n
co
m
pa
re
d
w
it
h
li
m
it
ed
tr
an
sh
ia
ta
l
re
se
ct
io
n
fo
r
ad
en
oc
ar
ci
-
no
m
a
of
th
e
m
id
/d
is
ta
l
es
op
ha
gu
s:
fi
ve
-y
ea
r
su
r-
vi
va
l
of
a
ra
nd
om
iz
ed
cl
in
ic
al
tr
ia
l.
A
nn
Su
rg
.
20
07
;2
46
:9
92
–1
00
1.
Co
py
rig
ht
©
20
15
W
o
lte
rs
Kl
uw
e
r
H
ea
lth
,I
nc
.U
na
ut
ho
riz
e
d
re
pr
od
uc
tio
n
o
ft
hi
s
a
rti
cl
e
is
pr
oh
ib
ite
d.
An
na
ls
of
Su
rg
er
y
 Volu
m
e
00
,N
um
be
r
00
,
20
15
w
w
w
.a
nn
al
so
fs
ur
ge
ry
.c
om
|
1
209846-L-bw-Talsma
9 9
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy
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AbSTRACT
Objective
To describe causes of death in the first year after esophagectomy and determine the time 
frame that should be used for measurement of quality of surgery. A case-mix adjustment 
model was developed for the comparison between hospitals.
Summary background data
It is debated over which time period postoperative mortality should be measured as a per-
formance indicator. 
methods
Cause of death was identified for patients in a tertiary referral hospital who died within one 
year after surgery and classified as surgery related or not surgery related. Sensitivity and 
specificity for detecting deaths related to surgery were calculated for different periods of 
follow-up.  Case-mix adjustment models for 30DM, IHM and 90DM were developed. 
Results
In total 1,282 patients underwent esophagectomy. 30DM was 2.9%, IHM was 5.1% and 
90DM was 7%. Beyond 30 days a substantial number of deaths was related to the opera-
tion, especially due to anastomotic leakage. Post-discharge non-oncological mortality was 
most frequently caused by sudden death. One in five patients died because of recurrent 
disease, being the most important threat in the first year after surgery. The 30DM had a 
sensitivity for detecting surgery related deaths of 33% and a specificity of 100%. The 90DM 
had a sensitivity of 74% and a specificity of 96%. 
Conclusions
A period of postoperative follow-up longer than 30 days needs to be considered when 
comparing surgical performance between institutes. In the case mix adjustment model for 
90DM, no other variables have to be taken into account compared to those involved in 
30DM. 
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InTROdUCTIOn
There is an increasing interest in performance indicators as instruments for comparing qual-
ity of care between institutions. For surgical procedures postoperative mortality rates are 
generally used. Currently it is unclear which definition of postoperative mortality best re-
flects surgical quality of care. Being such a crucial statistic, its definition warrants in-depth 
consideration. The 30-day operative mortality (30DM) and the in-hospital mortality (IHM) 
after esophageal resection are well documented and vary from 4% for specialised centers 
to > 10% for nationwide registries [1, 2]. Few studies report on mortality beyond 30 days. 
Damhuis et al. however showed in the Dutch Cancer Registry that 43% of in-hospital deaths 
after surgery for esophageal cancer occurred 30 days or more after the operation [3]. In that 
study, the reported figures were unadjusted for patient and tumor related characteristics and 
causes of death were unknown. 
Using a longer time period after the operation for defining postoperative mortality may 
therefore provide a better definition of quality of surgery [4]. Extending the mortality period 
beyond 30 days has the advantage that patients who die because of surgery related com-
plications outside the hospital are included as well. On the other hand, patients who die 
because of recurrent disease are also ‘erroneously’ included at an increased rate as the 
postoperative period is prolonged.  However, it should be underlined that the quality of sur-
gical care in the treatment of esophageal cancer is not reflected by short-term morbidity and 
mortality only. Good surgical technique with meticulous, radical resection and lymph node 
dissection will result in better long-term oncological outcome, by some believed to be at the 
expense of perhaps somewhat worse short term non-oncological results. 
From the literature it is unclear how many additional deaths are captured if the time 
window of postoperative mortality is expanded after 30 days and outside the hospital and 
whether this is relevant for comparing surgical performance.  An exact cut-off value that 
defines a period of surgery related deaths has not been established. Some authors have 
suggested 90DM but this is as arbitrary as 30DM and has not been supported by solid data. 
Little attention has been paid in the literature to the detailed description of causes of death 
in the first year after esophageal resection.
The aim of the present study was to describe causes of death beyond the traditional 30 
days after esophageal resection; (2) to determine which time frame should be used to meas-
ure postoperative (non-oncological) mortality as a proxy of quality of surgery for esophageal 
cancer; and (3) to develop a case-mix adjustment model for comparison of postoperative 
mortality after esophageal resection between hospitals.
mEThOdS
Patients who underwent esophagectomy with curative intent for carcinoma of the esopha-
gus or esophago-gastric junction (EGJ; Siewert type 1 and 2) between January 1991 and 
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October 2011 were identified from a prospectively collected database. This cohort repre-
sents patients at the Erasmus MC University Medical Center (Rotterdam, the Netherlands), 
a tertiary referral and high-volume hospital. Excluded were patients who underwent an ex-
ploratory laparotomy/thoracotomy, additional organ resections (other than spleen) and a 
follow-up time less than 365 days.
All patients underwent a standard diagnostic work-up including endoscopy with histo-
logical biopsies, endoscopic ultrasound (EUS), CT-scan of chest and abdomen and external 
ultrasonography of the neck.  A PET scan was not routinely performed during the study pe-
riod. Some patients received neoadjuvant chemo(radio)therapy in the context of randomised 
controlled trials [2, 5]. In some cases, induction chemoradiotherapy or chemotherapy was 
given to patients with either a cT4-tumor without distant metastases or in patients with gross 
involvement of coeliac trunk lymph nodes who were not considered elegible for primary 
surgical therapy. The pathological staging of the tumor was based on the 7th edition of the 
TNM staging system [6]. Cardiovascular comorbidity was defined as a history of ischaemic 
heart disease, abnormal electrocardiogram findings or a diminished left ventricular ejection 
fraction. Pulmonary comorbidity was defined as a history of chronic pulmonary disease. 
Substantial preoperative weight loss was defined as loss exceeding 10% within 6 months 
before surgery. Esophagectomy was performed through a transhiatal or transthoracic surgi-
cal approach. Both techniques have been described elsewhere [7]. 
definition of outcome measures
The primary outcome measure for this study was postoperative mortality. This was defined 
as 30-day mortality (30DM), in-hospital mortality (IHM) and 90-day mortality (90DM). Thirty- 
and 90-day mortality were defined as death within 30 or 90 days respectively after date of 
surgery, and in-hospital mortality was defined as death at any time during the postoperative 
hospital stay. Deaths were counted as having occurred after discharge if patients survived 
the first hospital admission, including patients that were transported to a different hospital. 
Death during re-admission was counted as having occurred out of hospital, because it hap-
pened after the index admission. After discharge, surviving patients were followed at regular 
intervals at the outpatient clinic until five years after the operation. Last follow-up checkpoint 
was November 1st 2012.
 
Causes of death
The methodology of Waljee et al. [8] was used for classifying systematically and reliably the 
‘seminal’ cause of death in all patients who died within one year after surgery. One reviewer 
(AKT; corresponding author), after having identified in the medical files all complications 
that occurred during a patient’s postoperative course, chose the complication that most 
contributed to the patient’s death. In case of doubt, the patient’s history was discussed with 
one of the surgical co-authors (BPLW or JJBvL). Patients with a radiologically or pathologi-
cally proven recurrence of disease were counted as having died because of an oncological 
reason. Patients who died due to  worsening clinical performance without a radiologically or 
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pathologically proven recurrence of disease were counted in the category “Failure to thrive”. 
General practitioners were contacted if cause of death could not be determined from the 
patients’ paper and electronic files. Death certificates from the Central Bureau of Statistics 
were not used. The seminal complication is defined as the first event leading to the chain of 
subsequent complications that culminated in a patient’s death. Based on clinical relevance 
and frequency of occurrence, fatal events were identified and categorised into nine of the 
following entities: 1. anastomotic leakage with sepsis (incl. mediastinitis and esophago-tra-
cheal fistula); 2. progression of disease (due to either systemic or locoregional recurrence); 
3. pneumonia or any other pulmonary event (aspiration, acute respiratory distress syndrome 
etc.); 4. failure to wean from mechanical ventilation; 5. sudden death (at home or during 
admission without prodromal symptoms e.g. myocardial infarction, pulmonary embolus); 6. 
peroperative complication (haemorrhage, stroke, myocardial infarction); 7. medical compli-
cation other than pneumonia (stroke, renal failure, hepatic failure); 8. failure to thrive without 
evidence of progressive disease; or 9. abdominal sepis (not related to 1., e.g. diverticulitis, 
pancreatitis). Based on these descriptions, the seminal cause of death for each patient was 
grouped in two broad categories: (in)directly surgically or medically related to the operation 
versus recurrence of disease. Surgical complications included: Anastomotic leakage / me-
diastinitis, Per-/intraoperative surgical complications (hemorrhage) and Abdominal sepsis. 
Medical complications included (Aspiration) Pneumonia or other pulmonary event, Failure 
to wean, Sudden death, Per-/intraoperative non-surgical complications (stroke, cardiac), 
Stroke, Renal failure, Failure to thrive. Oncological reasons of death included: Progression/
recurrence of disease (locoregional recurrence, distant metastases). Patients who died after 
worsening clinical performance without a radiologically or pathologically proven recurrence 
of disease were counted in the category “Failure to thrive”. Patients with gross recurrence 
of disease were counted as having died because of progression of disease. Patients with 
minimal recurrence who died because of an intercurrent event were counted as having died 
because of that event.
Statistical analysis
Postoperative death was used as the outcome variable. Multiple imputation was performed 
for missing predictor values. To determine which timeframe would include the maximal per-
centage of deaths related to surgery and would exclude the maximal percentage of deaths 
due to recurrent disease, sensitivity and specificity were calculated for different periods of 
follow-up and a ROC curve was drawn. Logistic regression models were used to determine 
risk factors for the following outcomes as dependent variables: 30DM, IHM, and 90DM. 
Non-linearity was assessed for continuous predictors, such as age. Variables with a p-value 
< 0.15 in the univariable model were considered to be possible independent predictors 
and subsequently entered into the multivariable model. Two-tailed p<0.05 was considered 
statistically significant. All analyses were performed using SPSS version 19.0 (SPSS Inc, 
Chicago, IL, USA) and R (R statistical software , Vienna, Austria).
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RESUlTS
Clinicopathological characteristics
Between January 1991 and October 2011, 1,286 patients underwent esophageal resection 
for carcinoma.  Three patients were excluded because of additional resections (pulmonary 
wedge, wide local excision of GIST in gastric tube). One patient was excluded because 
of loss to follow up. The clinical characteristics of the resulting 1,282 patients in the co-
hort are shown in Table 1. Median age was 63 years and most of the patients were male. 
Median length of stay  in the hospital was 15 days. The majority of patients had advanced 
disease (pT3-4 and/or lymph node metastases). Most esophagectomies (71.5%) were done 
for adenocarcinomas of the distal esophagus or EGJ. Transhiatal resection with gastric tube 
reconstruction was the preferred surgical approach, especially in the earlier parts of the 
study period. A minority had significant medical comorbidity. One patient was excluded from 
regression analysis, because the tumor was not taken out due to a fatal myocardial infarction 
during surgery.
definiton dependent mortality
The 30DM, IHM and 90DM rates of patients were 2.9%, 5.1% and 7.0% respectively (Fig-
ure 1). Overall, 53 deaths (4.1%) occurred between 30 and 90 days postoperatively and 
29% of the total cohort did not survive the first year after surgery. The unadjusted mortality 
rates did not significantly change during the study period (data not shown).
Causes of death
For all patients who died in the hospital as well as for most patients who died after discharge, 
the single most important event that lead to death could be derived from the medical files. In 
all other cases, the general practitioner was contacted. For 15 patients, we contacted family 
members to evaluate the clinical condition of these patients in the weeks before death. For 
five patients we could not by all means identify cause of death.
The distribution and causes of deaths by time period and moment of discharge are 
shown in Table 2 and Supplementary Figure 1. Of the 37 patients who died within 30 days 
after surgery, the most common cause was anastomotic leakage or sudden death. However, 
anastomotic leakage could still result in a fatal outcome after 30 days as well. Esophago-tra-
cheal fistula as a manifestation of anastomotic leakage was fatal in almost all cases. There 
were ten patients who died between 30 and 90 days after surgery because of recurrent 
disease, all with haematogenous metastases that had not been detected during primary 
diagnostic work-up. After 90 days, cancer related death was heavily dominating with one in 
five patients dying due to progression of disease during the first year. Development of res-
piratory failure occurred in the majority of all septic fatal complications, but pneumonia and 
failure to wean were identified as the seminal complication leading to death in 22 patients. 
Most patients who could not be weaned from the ventilator survived longer than 30 days, 
but not beyond 90 days. In 14 of the 24 patients who died because of ‘sudden death’, this 
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happened after discharge. Five patients died of a complication during surgery, two among 
these because of fatal intraoperative haemorrhage, the source of bleeding being the aorta 
in both cases. Other causes of death that were encountered were stroke, renal failure and 
failure to thrive. This last group of patients with failure to thrive deceased in nursery homes. 
Abdominal sepsis (leakage of jejunal feeding tube, diverticulitis and pancreatitis) contributed 
to in-hospital mortality in 7 patients. Only fifteen of the 71 patients who died in the hospital 
were autopsied.
ROC analysis
The distribution of causes of death over time after surgery is shown graphically in Figure 2. 
To determine which timeframe would include the maximal percentage of deaths related to 
surgery and would exclude the maximal percentage of deaths due to recurrence, sensitivity 
and specificity were calculated for different periods of follow-up (Figure 3). For deaths med-
ically or technically related to surgery (surgical deaths), 33% would be captured at 30 days, 
whereas 74% would be captured at 90 days. Note from the resulting ROC curve in Figure 3 
that in  this study the time point of 105 days after surgery is the threshold that is found when 
the sum of sensitivity and specificity are maximized (sensitivity 79% and specificity 94 %).
Case mix adjustment models
In the univariable analysis it was found that age, gender, tumor location, surgical approach, 
reconstruction type, resection margin involvement, history of cardiovascular disease and 
substantial preoperative weight loss were significant predictors of both 30-day and 90-
day mortality. For age, the odds ratio (OR) for every year increment after 60 years was 
calculated, because the effect was non-linear before that age. For 30-day mortality there 
was a trend for additional variables (i.e. neoadjuvant therapy, history of pulmonary disease, 
diabetes or stroke/TIA) which reached significance for 90-day mortality. Transhiatal eso-
phagectomy was associated with a lower 90DM rate compared to a transthoracic surgical 
approach (6.0% and 9.7% respectively). In univariable analysis for IHM the following vari-
ables were significantly associated: age, gender, neoadjuvant therapy, surgical approach, 
reconstruction type and history of cardiovascular or pulmonary disease or  stroke/TIA. Year 
of operation was not univariably associated to survival for any of these short term outcomes. 
Stratified analysis of 30DM, IHM and 90DM by multivariable logistic regressions and the 
resulting case-mix adjusted models are summarized in Table 3. To identify risk factors for 
death after discharge, logistic regression was also conducted using death after discharge 
due to a surgically related cause as the dependent variable. This showed that patients with 
advanced age, positive resection margin and longer hospital stay are at an increased risk of 
dying early after discharge (data not shown).
209846-L-bw-Talsma
108
Chapter 6
6
dISCUSSIOn
In this study 30DM, IHM and 90DM rates were investigated in a large cohort of patients who 
underwent esophagectomy at a high-volume tertiary referral center. It confirmed the earlier 
finding that 30DM does not completely reflect the postoperative mortality risk. A substantial 
number of patients died beyond 30 days of surgery: 30DM was 2.7 % and 90DM 7.0 %. 
The definition of IHM has often been criticized for being dependent on length of stay and 
discharge practices, but has the advantage that it includes fatal complications that can 
be treated temporarily and beyond 30 or 90 days. A composite measure of both IHM and 
90DM, that is traditionally used in the US provides a more complete picture and was 7.4% 
in the present study. 
In the present study we were able to identify and further categorize cause of death 
for almost every patient in the first year after surgery and, therefore, to determine whether 
death was due to surgical or medical complications of the operation versus death due to 
recurrence/progression of cancer. A substantial number of deaths between 30 and 90 days 
after surgery were due to complications related to surgery with anastomotic complications 
and sudden death being the most frequent causes. Extending the follow-up beyond 90 days 
after surgery resulted mainly in the inclusion of more patients who died of recurrent disease 
as opposed to medical or technical complications related to surgery. This was not different 
for to two surgical approaches. Esophageal cancer surgeons should realize that they have 
to compare both the short term and the long term outcomes of their patients with the bench-
mark as both aspects are relevant for comparing surgical performance. Both surgery related 
deaths and cancer recurrence related deaths are reflections of surgical quality of care. 
Less radical surgical resections will generally result in lower postoperative morbidity and 
mortality, but will give less favourable oncological outcomes. The ROC curve shown in this 
study can be used to select an optimal threshold balancing the inherent tradeoffs that exist 
between sensitivity and sensitivity for surgery related deaths for all possible follow up peri-
ods.  Depending on the focus (e.g. surgical safety or oncological performance and patient 
selection), one has to choose between evaluating the optimal threshold by maximizing the 
sum of sensitivity and specificity or give different weights to sensitivity and specificity. In this 
study ROC analysis showed that postoperative day 105 after surgery was the time point that 
best discriminated between surgery related deaths and cancer recurrence related deaths. 
From an oncological point of view, 1-year survival rate provides more useful data than 
immediate postoperative mortality [4]. In the present data, 1-year survival rate was only 71% 
suggesting that apart from more effective neoadjuvant therapy and more radical resection 
further refinement is required in the selection of patients who will sufficiently benefit from 
potentially curative but aggressive surgery. 
Respiratory failure is a major problem after esophagectomy. Several studies have re-
ported that about half of the in-hospital deaths after esophagectomy is due to pneumonia 
[9-11]. Although some kind of respiratory failure was present in almost all fatal events in the 
present study, pulmonary complications were the direct, ‘seminal’ cause of death in one 
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in four patients who died in the hospital. In the present study, more fatal pulmonary events 
(including impossibility to wean from mechanical ventilator) occurred in patients who un-
derwent a transthoracic surgical approach compared to those who underwent a transhiatal 
approach (33.4 % of all deaths before 90 days after a transthoracic approach were due 
to pulmonary complications versus 10.8 % of deaths after transhiatal approach). The per-
centage of deaths due to fatal anastomotic leakage or sudden death was not different for 
the two approaches. Also of interest is the group of patients who died at home because of 
a sudden death. It would be interesting to subdivide these causes into cardiac events and 
pulmonary embolisms, but unfortunately in the great majority no autopsy reports were avail-
able. In a separate analysis it was found that patients with advanced age, positive resection 
margins and longer length of hospital stay are at an increased risk of suddenly dying after 
discharge, perhaps suggesting that at least some of these patients might have benefitted 
from prolonged thromboprophylaxis. 
Even after agreement on a uniform definition of postoperative mortality, direct comparison of 
crude mortality rates between hospitals can be misleading as they do not take into account 
the case-mix difference, i.e. the differences in physiological condition and tumor stages of 
patients. Sophisticated models have been developed for prediction of 30DM [12, 13] and 
IHM11, [14-17] after esophageal surgery, but models for 90DM have been mostly based 
on large multi-institutional databases with only few parameters available [18]. In the pres-
ent study a large number of prospectively collected variables were available to construct 
a model for 90DM that allows individual centers to compare their results with others as a 
means towards quality improvement. Age, gender, surgical approach, resection margin in-
volvement, history of cardiovascular disease and substantial preoperative weight loss were 
independent predictive factors for death within 90 days after esophagectomy. Interestingly, 
in 90DM the same predictors were involved as in 30DM, confirming our previous research 
[15, 16]. In patients older than 75 years of age, the 90-day mortality rate was 17.1%. In pre-
vious publications, some authors claim that such extensive surgery ought to be considered 
very carefully in this high age group [13, 19]. With respect to surgical approach it has been 
shown previously that there is a 5-year survival benefit for the transthoracic technique in 
some patients [7, 20]. In the multicenter trial comparing surgical approaches, mortality was 
4 % aftrer transthoracic resection and 2 % after transhiatal resection, but this difference 
was not statistically significant. In the present study that included 1,282 patients, the two-
fold increased risk of dying was statistically significant.  Moreover, in the present observa-
tional study a selection bias might play a role because patients with larger tumors might 
more frequently have undergone a transthoracic surgical approach. Incomplete resection as 
a risk factor for 30DM, IHM and 90DM is probably a reflection of high tumor load and more 
extensive and aggressive surgery. Of the patients who died within 90 days after surgery in 
this study, 40% underwent an irradical resection. This was reported in a Japanese study 
as well [11]. The present study reproduced the finding of previous authors that substantial 
preoperative weight loss is associated with increased mortality and early recurrence [12, 
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21, 22]. Some previous reports suggest higher morbidity [23] for patients after chemo(radio)
therapy, while others do not [24]. Only a randomized controlled trial can cancel out the valid-
ity issues of ‘confounding by indication’ that occurs in observational studies like the present 
study. There have been various reasons for the administration of preoperative therapy in this 
study population. Some patients received neoadjuvant chemotherapy [5] or neoadjuvant 
chemoradiotherapy [2]  in the context of RCTs, thus excluding selection bias. Other patients 
received induction chemotherapy outside RCTs because of advanced tumors which were 
considered inoperable at first presentation and would only proceed to surgery in case of a 
favourable tumor response. In that subgroup of patients a selection bias was introduced, 
with relatively unfavourable patients receiving induction therapy. It has been repeatedly 
shown that esophageal cancers which are insensitive to neoadjuvant therapy are associated 
with poor survival. Unfortunately, there were too many missing values in the present study to 
analyze the potential relation between tumor regression grade and (timing of) cancer death. 
The present study has some limitations, including the retrospective accumulation and 
addition of some variables to our prospectively collected database. The cause of sudden 
death was unknown in some of the late mortalities. The strength of the study, on the other 
hand, was the limited number of missing data on cause of death, for example unequivocally 
due to surgery or cancer progression. The results presented in this study are from a single 
institution and thus may not be broadly applicable. The mortality rates reported can vary with 
other reports in high volume centers for the reason that short-term outcome event rates are 
relatively low. This shows, besides issues of definition and case-mix correction, another  el-
ement of complexity in comparing surgical performance, i.e the problem of sample size [25].
In conclusion, this study shows that patients undergoing esophagectomy for cancer con-
tinue to have a surgery associated mortality risk after 30 days and after discharge, with 
anastomotic leakage and sudden death being the most frequent causes of death. The case-
mix factors associated with 90DM do not differ significantly from those involved in 30DM. 
Future studies should investigate if these findings have implications for ranking hospital 
performance by using data on both mortality definitions. Despite careful preoperative selec-
tion, the most severe threat for esophageal cancer patients in the first year after potentially 
curative surgery is still cancer recurrence. It would be helpful if hospital performance in 
esophageal surgery would include 90DM along with 1-year survival reflecting the quality of 
both the diagnostic and the therapeutic process.
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TABLE 1. Clinicopathological Characteristics of 1282
Patients Who Underwent Surgical Resection for or EGJ
Carcinoma
Age (yr) 63 (19–89)
Sex Male 988 (77)
Female 294 (23)
Length of hospital stay (d) 15 (0–186)
Tumor category
(pathology)
ypT0 or no residue after
endoscopic resection
96 (7.5)
HGD, Tis or T1 229 (17.8)
T2 197 (15.4)
T3 746 (58.1)
T4 13 (1.0)
Node category based on
TNM7∗
N0 623 (48.6)
N1 352 (27.4)
N2 187 (14.6)
N3 119 (9.3)
Tumor type Squamous cell carcinoma 349 (27.3)
Adenocarcinoma 917 (71.5)
Undifferentiated 16 (1.2)
Grade of differentiation Good 128 (10.0)
Moderate 566 (44.2)
Poor 545 (42.5)
Unknown 43 (3.4)
Tumor location Proximal 1/3 21 (1.6)
Middle 1/3 161 (12.6)
Lower 1/3 554 (43.2)
EGJ 546 (42.6)
Neoadjuvant therapy 468 (36.5)
Surgical approach Transhiatal 941 (73.3)
Transthoracic 341 (26.7)
Reconstruction type Gastric tube 1237 (96.5)
Colonic interposition 40 (3.1)
No reconstruction 5 (0.4)
Resection margin
involvement
R0 960 (74.8)
R1, R2 (any margin) 321 (25.0)
Comorbidity Cardiovascular disease 290 (22.6)
Pulmonary disease 117 (13.8)
Diabetes 106 (8.3)
Stroke/TIA 66 (5.1)
Weight loss >10% before
surgery
Yes 763 (59.5)
Unknown 15 (1.2)
Period of surgery
1991–1995 266
1996–2000 283
2001–2005 360
2006–2011 373
Data shown are mean (SD) or median (range) or number (prevalence percentage);
the sum of numbers may not equal 1282 because in 1 patient, the tumor was not taken
out.
∗Node category according to the seventh edition TNM-staging system: N0
(no positive nodes), N1 (1–2 positive nodes), N2 (3–6 positive nodes), and N3 (>6
positive nodes).
R0 indicates resection margin microscopically tumor-free, >1 mm; R1, resection
margin microscopically <1 mm; R2, macroscopically residual tumor; EGJ, esopha-
gogastric junction; HGD, high-grade dysplasia.
in the weeks before death. For 5 patients we could not by all means
identify the cause of death.
The distribution and causes of deaths by time period and mo-
ment of discharge are shown in Table 2 and Supplemental Digital
Content, Figure 1 available at http://links.lww.com/SLA/A528. Of
the 37 patients who died within 30 days after surgery, the most com-
mon cause was anastomotic leakage or sudden death. However, anas-
tomotic leakage could still result in a fatal outcome after 30 days
as well. Esophagotracheal fistula as a manifestation of anastomotic
leakage was fatal in almost all cases. There were 10 patients who died
FIGURE 1. Thirty-day, 90-day, 365-day, and in-hospital mor-
tality rates (%) in a cohort of 1282 patients who underwent
esophageal cancer resection (see Supplemental Digital Con-
tent, Figure 1 available at http://links.lww.com/SLA/A528).
The distribution and causes of death by time period.
between 30 and 90 days after surgery because of recurrent disease,
all with hematogenous metastases that had not been detected during
primary diagnostic workup. After 90 days, cancer-related death was
heavily dominating with 1 in 5 patients dying due to progression of
disease during the first year. Development of respiratory failure oc-
curred in themajority of all septic fatal complications, but pneumonia
and failure to wean were identified as the seminal complication lead-
ing to death in 22 patients. Most patients who could not be weaned
from the ventilator survived longer than 30 days, but not beyond 90
days. In 14 of the 24 patients who died because of “sudden death,” this
happened after discharge. Five patients died of a complication during
surgery, 2 among these because of fatal intraoperative hemorrhage,
the source of bleeding being the aorta in both cases. Other causes
of death that were encountered were stroke, renal failure, and failure
to thrive. This last group of patients with failure to thrive deceased
in nursing homes. Abdominal sepsis (leakage of the jejunal feeding
tube, diverticulitis, and pancreatitis) contributed to in-hospital mor-
tality in 7 patients. Only 15 of the 71 patients who died in the hospital
were autopsied.
ROC Analysis
The distribution of causes of death over time after surgery is
shown graphically in Figure 2. To determine which timeframe would
include the maximal percentage of deaths related to surgery and
would exclude the maximal percentage of deaths due to recurrence,
sensitivity and specificity were calculated for different periods of
follow-up (Fig. 3). For deaths medically or technically related to
surgery (surgical deaths), 33%would be captured at 30 days, whereas
74% would be captured at 90 days. Note from the resulting ROC
curve in Figure 3 that in this study the time point of 105 days after
surgery is the threshold that is found when the sum of sensitivity and
specificity are maximized (sensitivity 79% and specificity 94%).
Case-Mix Adjustment Models
In the univariable analysis, it was found that age, sex, tumor
location, surgical approach, reconstruction type, resection margin
involvement, history of cardiovascular disease, and substantial pre-
operative weight loss were significant predictors of both 30-day and
90-day mortality. For age, the odds ratio for every year increment
after 60 years was calculated, because the effect was nonlinear be-
fore that age. For 30-day mortality, there was a trend for additional
variables (ie, neoadjuvant therapy, history of pulmonary disease, di-
abetes, or stroke/transient ischemic attack) that reached significance
for 90-day mortality. Transhiatal esophagectomy was associated with
a lower 90DM rate compared to a transthoracic surgical approach
(6.0% and 9.7%, respectively). In univariable analysis for IHM the
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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TABLE 2. The Distribution and Causes of Death by Time Period and Moment of Discharge
30DM 30–90DM 90–365DM
Causes of Death In-hospital
After
discharge In-hospital
After
discharge In-hospital
After
discharge 1–5 yr M
Cause of death
Surgically related to operation 15 1 17 1 4 8
Medically related to operation 18 2 13 12 16
Oncological 0 2 8 1 249 355
Unknown 1 4 55
Description
Anastomotic
leakage/mediastinitis
11 1 14 1 2 6∗
Progression of disease 2 8 249 355
(Aspiration) pneumonia or
other pulmonary event
5 4 1 1 4
Failure to wean 1 6
Sudden death, eg, myocardial
infarction, pulmonary
embolism
9 2 1 5 7
Peri-/intraoperative
compli ation
Surgical bleeding 2 1∗
Medical, stroke, 2
Cardiac failure 1
Medical complication other
than pneumonia, eg, stroke,
renal failure
1 2 3 5
Failure to thrive without
evidence of progressive
disease (nursery home)
2
Abdominal sepsis 2 3 1 2 1∗
Total 34 3 32 21 5 277 410
Cumulative mortality ra e 37/1282 = 2.9% 90/1282 = 7.0% 372/1282 = 29% 782/1282 = 61%
∗Including fatal complications secondary to reconstruction surgery after cervical esophageal deviati n.
FIGURE 2. The distribution of causes of death
over time after surgery.
Copyright © 2014 Lippincott Willia s & Wilkins. Unauthorized reproduction of this article is prohibited.
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FIGURE 3. ROC curve for detection of surgery-
related deaths calculated for different time
frames after surgery.
following variables were significantly associated: age, sex, neoad-
juvant therapy, surgical approach, reconstruction type, and history
of cardiovascular or pulmonary disease or stroke/transient ischemic
attack. Year of operation was not univariably associated to survival
for any of these short-term outcomes. Stratified analysis of 30DM,
IHM, and 90DM by multivariable logistic regressions and the result-
ing case-mix adjusted models are summarized in Table 3. To identify
risk factors for death after discharge, logistic regression was also con-
ducted using death after discharge due to a surgically related cause as
the dependent variable. This showed that patients with advanced age,
positive resection margin, and longer hospital stay are at an increased
risk of dying early after discharge (data not shown).
DISCUSSION
In this study 30DM, IHM, and 90DM rates were investigated
in a large cohort of patients who underwent esophagectomy at a high-
volume tertiary referral center. It confirmed the earlier finding that
30DM does not completely reflect the postoperative mortality risk.
A substantial number of patients died beyond 30 days of surgery:
30DM was 2.7% and 90DM 7.0%. The definition of IHM has often
been criticized for being dependent on length of stay and discharge
practices, but has the advantage that it includes fatal complications
that can be treated temporarily and beyond 30 or 90 days. A composite
measure of both IHM and 90DM, that is traditionally used in the
United States provides a more complete picture and was 7.4% in this
study.
In this study, we were able to identify and further categorize
cause of death for almost every patient in the first year after surgery
and, therefore, to determine whether death was due to surgical or
medical complications of the operation versus death due to recur-
rence/progression of cancer. A substantial number of deaths between
30 and 90 days after surgery were due to complications related to
surgery with anastomotic complications and sudden death being the
most frequent causes. Extending the follow-up beyond 90 days after
surgery resulted mainly in the inclusion of more number of patients
who died of recurrent disease as opposed tomedical or technical com-
plications related to surgery. This was not different for to 2 surgical
approaches. Esophageal cancer surgeons should realize that they have
to compare both the short-term and the long-term outcomes of their
patients with the benchmark as both aspects are relevant for com-
paring surgical performance. Both surgery-related deaths and cancer
recurrence-related deaths are reflections of surgical quality of care.
Less radical surgical resectionswill generally result in lower postoper-
ative morbidity and mortality, but will give less favorable oncological
outcomes. The ROC curve shown in this study can be used to select an
optimal threshold balancing the inherent tradeoffs that exist between
sensitivity and sensitivity for surgery-related deaths for all possible
follow-up periods. Depending on the focus (eg, surgical safety or
oncological performance and patient selection), one has to choose
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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figure 3
Receiver Operating Characteristic (ROC) Curve for detection of surgery related deaths calculated 
for different time frames after surgery.
Chapter 6
Time 
frame
missed 
surgery re-
lated deaths 
(fn*)
Included 
oncological 
deaths (fP)
Sensitivity 
(=TP/
TP+fn)
Specificity 
(=Tn/
fP + Tn)
30 days 71 0 33% 100%
90 days 28 10 74% 96%
105 days 23 16 79% 94%
*FN i dica es false negative; FP, false positive; TP, true positive; TN, true negative.
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Supplementary figure 1
The distribution and causes of death by time period
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AbSTRACT
background
Survival after oesophagectomy for cancer seems to be improving. This study aimed to iden-
tify the most important contributors to this change.
methods
Patients who underwent oesophagectomy from 1999 to 2010 were extracted from the 
Netherlands Cancer Registry. Four time periods were compared: 1999–2001 (period 1), 
2002–2004 (period 2), 2005–2007 (period 3) and 2008-2010 (period 4). Hospital type, 
tumour location, tumour type, tumour differentiation, neoadjuvant therapy, operation type, 
(y)pT category, involvement of surgical resection margins, number of removed lymph nodes 
and number of involved lymph nodes were investigated in relation to trends in survival using 
multivariable analysis.
Results
A total of 4382 patients were identified. Two-year overall survival rates improved from 49.3 
per cent in period 1 to 58.4, 56.2 and 61.0 per cent in periods 2, 3 and 4 respectively (P 
< 0.001). Multivariable survival analysis revealed that the improvement in survival between 
periods 3 and 4 was related to the introduction of neoadjuvant therapy. The improvement in 
survival between periods 1 and 2 could not completely be explained by the factors studied. 
The number of examined lymph nodes increased, especially between periods 2 and 3, but 
this increase was not associated with the improvement in survival. 
Conclusion
The observed increase in long-term survival after surgery for oesophageal cancer between 
1999 and 2010 in the Netherlands is difficult to explain fully, although the recent increase 
seems to be partly attributable to the introduction of neoadjuvant therapy.
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InTROdUCTIOn 
A rising incidence in oesophageal cancer is largely explained by increased numbers of 
adenocarcinomas [1–4]. A population-based study in the Netherlands recently reported an 
increase in long-term survival after surgery for oesophageal cancer [3]. Many factors might 
be responsible for this improvement including surgical approach [5,6], introduction of mul-
timodal treatment including chemotherapy and chemoradiotherapy (CRT) [7–9], and better 
perioperative care [10]. The extent of surgical lymphadenectomy may also be important, as 
the number of removed lymph nodes can be considered as an indicator of surgical perfor-
mance, given its association with overall survival [11]. Improved survival might also be due 
to more favourable patient and tumour characteristics, including the impact of endoscopic 
surveillance for Barrett’s oesophagus and increased public awareness of disease. Novel 
clinical staging modalities (such as PET) and the introduction of specialist multidisciplinary 
teams are thought to have improved selection of patients for curative surgery [12]. Centrali-
zation of oesophageal surgery in specialized units in the Netherlands also took place in the 
past 10 years, influencing many of the above issues [13].
Although each of these factors has been investigated in relation to survival after oe-
sophagectomy, the impact of combination of these improvements on survival at a popula-
tion-based level is largely unknown. The aim of the present study was to identify patient, tu-
mour and treatment characteristics contributing to the observed trend for increased survival 
after oesophagectomy for cancer in the Netherlands. It was hypothesized at the outset that 
neoadjuvant CRT and better-quality surgery (as demonstrated by higher lymph node yields) 
would be the main factors responsible for this improvement.
mEThOdS
The Netherlands Cancer Registry (NCR) collects data on all patients diagnosed with cancer 
in the Netherlands, based on notification of all newly diagnosed malignancies by the nation-
al automated pathological archive and of additional hospital discharge diagnoses. Com-
pleteness is estimated to be at least 95 per cent [14]. For the present study, patients who 
underwent oesophagectomy for primary oesophageal cancer without evidence of distant 
metastases between 1999 and 2010 (ICD-O code C15) were identified. Because the pres-
ent study focused only on patients who underwent an oesophagectomy, and type of surgery 
and surgical approach were not yet registered routinely during the first half of the study, 
cardia tumours were excluded to make sure that patients who underwent gastrectomy were 
not included. Patients with cervical oesophageal tumours that constitute a distinct clinical 
entity with a different surgical technique and those who received neoadjuvant radiotherapy 
alone were also excluded.
Information on diagnosis, staging and treatment was extracted routinely from the med-
ical records by specially trained administrators of the NCR. Stage distribution was revised 
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to the seventh edition of the TNM system of the International Union Against Cancer (UICC) 
[15]. Tumour location was categorized as follows: lower oesophagus and oesophagogastric 
junction (C15.5), middle oesophagus (C15.4) or unspecified (C15.8, C15.9). Tumour, insti-
tution and patient-related characteristics included age, sex, date of diagnosis, type hospital 
in which surgery was performed, tumour location, tumour type, tumour differentiation, neo-
adjuvant therapy, operation type, (y)pT category, involvement of surgical resection margins, 
number of removed lymph nodes and number of involved lymph nodes. Because of confi-
dentiality regulations, information regarding hospitals was available only at an aggregated 
level. University hospitals are defined as hospitals affiliated with a teaching and research 
institution. Hospital type was defined by the hospital of diagnosis before 2005, and by the 
hospital of surgery thereafter. In the early years of the study some variables (hospital type, 
operation type, involvement of surgical resection margins) were not registered routinely by 
all regional data centres. In these instances variables were scored as ‘missing’. During sta-
tistical testing for time trends, these missing values were excluded from the analysis, with no 
imputation. Any results that could not be ascertained from the pathology reports or medical 
records were marked as ‘not specified’. Vital status was obtained by annual computerized 
linkage with the automated national civil registry and included information up to 1 December 
2012.
Statistical analysis
The study was divided into four intervals of 3 years: 1999–2001 (period 1), 2002–2004 
(period 2), 2005–2007 (period 3) and 2008–2010 (period 4). Differences in patient, tu-
mour and treatment characteristics between the time periods were tested using a  t test or 
Kruskal–Wallis test for continuous variables or by means of a X2 test for proportions. Overall 
survival was defined as the time interval between date of diagnosis and date of death (event) 
or 1 December 2012 (censored). Owing to privacy regulations, the specific date of surgery 
was not available to the investigators and postoperative mortality could not be reported. 
Survival curves for the four intervals were calculated by the Kaplan–Meier method and com-
pared by log rank test. Because follow-up data were available only until December 2012, 
5-year follow-up was not feasible for period 4 and so 2-year survival rates are reported. Of 
the patients diagnosed in the period 2008–2010 who were alive at the census date, 40.8 
per cent had less than 2 years of follow-up. 
Unadjusted and adjusted hazard ratios (HRs) were compared between the four peri-
ods using Cox analysis, with 1999–2001 as the reference category. In the adjusted analysis, 
adjustment was made for each variable found to be associated with time. When specific 
variables directed the adjusted HRs towards 1, this explained (part of) the time trend for 
improved survival. The change in X2 value for the variable ‘period of surgery’ (representing 
how much predictive information the variable gained or lost after adjustment) was compared 
between unadjusted and adjusted models. A final model consisted of all variables that were 
identified as significant predictors from a stepwise Cox regression model, in which the var-
iables with least significant P values were dropped at each step, stopping when all values 
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were significant, defined by a threshold P value of 0.050. Because of co-linearity between 
the variables neoadjuvant therapy, tumour differentiation, (y)pT category and involvement of 
surgical resection margins, only neoadjuvant therapy was used in the final model. All analy-
ses were carried out using SPSS® version 19.0 (IBM, Armonk, New York, USA) and R (R 
Foundation for Statistical Computing, Vienna, Austria).
RESUlTS
From 1999 until 2010, 4756 patients were identified from the NCR. After exclusion of 87 
patients with proximal oesophageal tumours and 287 who had neoadjuvant radiotherapy 
alone, 4382 patients were included in the study.  The number of oesophagectomies in-
creased from 793 in period 1 to 1373 in period 4, mainly in non-university teaching hospitals 
(Table 1). Age and sex distributions remained stable over time.  The use of neoadjuvant CRT 
increased from 2008, meaning that tumour differentiation could not always be reported for 
patients in period 4. At the beginning of the study, the preferred surgical approach was tran-
shiatal oesophagectomy, whereas by the end one-half of the patients underwent a transtho-
racic surgical approach. The percentage of patients with tumour-positive surgical resection 
margins decreased with time from 15.9 per cent in period 1 to 10.0 per cent in period 4. 
The median number of removed nodes increased from 8 in period 1 to 15 in period 4, but 
especially between periods 2 and 3, and a higher proportion of patients was diagnosed with 
node-negative disease ((y)pN0; 40.9  per cent in period 1 and 53.7  per cent in period 4). 
 
Associations between patient, tumour and treatment characteristics and survival
Median follow-up of censored patients was 48 months. Six-month mortality (death within 
6 months after date of diagnosis) for periods 1 to 4 was 12.8, 9.3, 7.5 and 6.1 per cent, 
respectively (Table S1, supporting information). The 2-year survival rate improved from 49.3 
per cent in period 1 to 58.4, 56.2 and 61.0 per cent in periods 2, 3 and 4 respectively (P 
< 0.001) (Fig. 1 and Table 2). Younger age and female sex were associated with improved 
survival. Univariable estimates for survival also showed improved survival for patients who 
underwent surgery in a university hospital (5-year survival rate 38.5 per cent) compared 
with non-university teaching hospitals (30.2 per cent; P < 0.001) and non-teaching hospi-
tals (23.4 per cent; P < 0.001). Tumour type, tumour location and surgical approach were 
not related to survival. An increased number of removed nodes was associated with better 
outcome, but this improvement was largely confined to the group of patients with at least 19 
removed lymph nodes. Number of involved lymph nodes was associated with survival; there 
were almost no survivors if more than three positive nodes were identified.
Relative contributors to improved survival
Unadjusted Cox proportional hazards analysis showed a significant improvement in survival 
between periods 1 and 2 (HR 1.00 versus 0.85; P < 0.001), and between periods 3 and 4 
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(HR 0.86 versus 0.71; P < 0.001) (Table 3). These improvements remained after adjusting 
for hospital type, number of removed nodes, tumour differentiation, tumour type and num-
ber of involved nodes. However, when adjustment was made for neoadjuvant therapy, there 
was no longer a significant improvement in survival improvement between periods 3 and 4 
(model 4; HR 0.86 versus 0.80; P = 0.117). Neoadjuvant therapy accounted for more than 
half of the improvement in survival between the two latter periods (X2 value decreased from 
34 to 15) (Table 3). In the final model, period 4 was no longer associated with improved 
survival, indicating that the combined variables (age, sex, time period of surgery, hospital 
type, neoadjuvant therapy, number of removed nodes and number of involved nodes) could 
negate the improvement in survival in the final period (HR 0.71 in model 1 versus 0.91 in final 
model), whereas these variables were not able to fully explain the improvement in survival 
from period 1 to period 2 (HR 0.86 in model 1 versus 0.85 in the final model) (Table 3). 
dISCUSSIOn
The present population-based study shows that long-term survival rates after oesophagec-
tomy for cancer have improved substantially in the past decade. The factors explaining this 
trend were investigated by adjusting for possible changes in tumour histology and differenti-
ation, patient demographics, and changes in surgical and medical treatment. 
It was difficult to dissect out the contribution of the different variables separately given 
the changes in treatment strategies and epidemiology that have occurred simultaneously. 
Nevertheless, the increased use of neoadjuvant therapy explained almost half of the im-
proved survival observed in the study period, especially between period 3 (2005–2007) 
and period 4 (2008–2010). Different neoadjuvant treatment regimens were used during the 
study period, including chemotherapy, which was popularized in the earlier years [8]. From 
2004 to 2008, a large Dutch multicentre trial [9] showed an absolute survival benefit of 13 
per cent at 5 years in patients who underwent preoperative CRT; although the final results 
of this trial were published in 2012, neoadjuvant therapy had already been implemented at a 
nationwide level from 2008 onwards, as demonstrated in Table 1. The present results mirror 
the findings of this randomized trial, with an absolute improvement in 5-year survival of 14 
per cent in patients who underwent neoadjuvant CRT (Table 2) and an R0 resection rate 
of 87  per cent (data not shown). After neoadjuvant CRT no viable tumour cells could be 
identified in the pathology specimen in 203 (25.4 per cent) of 799 patients.
The number of surgical resections almost doubled during the study interval. This prob-
ably reflected the rising incidence in adenocarcinoma, but does not easily explain the im-
proved long-term survival, as tumour type was not related to survival in the present study; 
this is different from previous findings [16,17], but similar to the results of a recent Surveil-
lance, Epidemiology, and End Results (SEER) analysis [18]. Time trends in resection rates 
should be interpreted cautiously, because patient selection for surgery might reflect chang-
es in diagnostics, overall treatment strategy or changes in the classification of tumours. 
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When pT and ypT categories were combined, no significant change in tumour category was 
seen over time. It is more likely that, as a result of neoadjuvant therapy, a greater proportion 
of initially more advanced tumours was treated surgically in recent years. Another explana-
tion for the increasing number of oesophageal resections might have been classification of 
some gastro-oesophageal junctional tumours as oesophageal rather than gastric cancers. 
At most this can have had only a small effect as the increase in oesophageal resection rates 
was only partly offset by a decrease in gastrectomies, the latter largely being thought to 
reflect a decreasing gastric cancer incidence and improved preoperative staging [3]. The 
increase in number of resections in the Netherlands has mainly taken place in university 
and non-university teaching hospitals, a phenomenon that has been described before [13]. 
Since 2008, a yearly minimum of ten oesophagectomies per year, and in 2011 a minimum 
of 20 per hospital, was enforced by the Dutch Health Care Inspectorate. It has been shown 
that centralization improves patient selection, perioperative care, surgical experience and 
decreases ‘failure to rescue’[19]. Although type of hospital was clearly associated with 
survival here, multivariable analysis showed that it did not contribute significantly to the ob-
served trend of improved survival with time. 
A shift towards more transthoracic resections was evident, but not associated with 
survival. This is in line with the findings of a randomized clinical trial [6] and a meta-analysis 
[20] comparing transhiatal and transthoracic oesophagectomy. The initial hypothesis that 
better nodal clearance might be associated with survival was confirmed in the present data. 
There was a significant improvement in nodal clearance from period 1 to period 3, although 
survival improvement was only seen between periods 1 and 2. The finding that survival 
did not change during period 2 and period 3 is noteworthy because many treatment and 
tumour-related variables changed at about this time (such as number of removed lymph 
nodes, tumour type and operation type). The number of nodes might be one of the factors 
contributing to the improved survival between periods 1 and 2, along with the introduction of 
the first centralization projects. The exact association between number of nodes and survival 
in the era of multimodal therapy is unclear as regressional changes are seen in lymph nodes 
after preoperative CRT. 
The present study has several limitations.  The analysis was limited by the clinicopatho-
logical data available. Missing data, especially for many patients in the earlier cohorts, meant 
that only a proportion of patients was left for studying the effects of variables. In the final 
model, the variable ‘time period’ was still a significant predictor of survival after adjusting for 
all the known variables. It has to be acknowledged, however, that stage, grade and involve-
ment of surgical resection margins were not included in this model because of co-linearity 
of these variables with neoadjuvant therapy. Despite a limited study period of 12 years, small 
changes in case mix may have occurred over time, but this could not be examined as infor-
mation on co-morbidity and performance status was not available. 
Patient selection may also have biased these results. One possible explanation for 
the observed increase in survival is that patients undergoing resection in the latter periods 
represent a group with an earlier clinical stage, as demonstrated previously [21]. Improved 
209846-L-bw-Talsma
130
Chapter 7
7
staging allowing the exclusion of occult metastatic disease by sophisticated diagnostics, 
and enhanced multidisciplinary treatment algorithms have previously been associated with 
survival [22,23], and may have had some effect, but  the rising number of oesophagectomies 
over time would seem to contradict more careful patient selection. Although resectability 
rates for patients with newly diagnosed oesophageal cancer are not reported by the availa-
ble registry, this trend might indicate a more aggressive surgical practice possibly instigated 
by the recent national volume standards in the Netherlands.  In the present study, a potential 
shift in pathological staging across the different periods was impossible to analyse accu-
rately because of the gradual increase in the use of neoadjuvant therapy. The present study 
only documented long-term survival. Because of privacy regulations only date of diagnosis 
was available. Therefore, short-term mortality related to surgery and/or neoadjuvant therapy 
could not be studied. Six-month mortality (as counted from date of diagnosis) for periods 1 
to 4 was 12.8, 9.3, 7.5 and 6.1 per cent respectively, perhaps implying lower treatment-re-
lated mortality over time, although there is confounding here as a result of the increase in 
time between diagnosis and completion of surgical treatment.  Other studies indicated that 
the postoperative 30-day mortality rate was 5.2 per cent around 2000 [24] and 4 per cent 
in 2010 [9]. Changes in postoperative mortality are not likely to explain the improved survival 
during the present study, as survival curves only diverged with longer follow-up (Fig. 1). 
Finally, owing to the chosen dates for the cohorts, 5-year survival cannot be reported for the 
most recent period (2008–2010). 
Survival after oesophagectomy for cancer improved substantially between 1999 and 
2010 in the Netherlands. Reasons for this improvement are probably multifactorial but, of all 
the studied prognostic variables that changed during the study interval, the introduction of 
neoadjuvant therapy was the most important. 
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figure 1
Kaplan–Meier overall survival curves for patients who underwent oesophagectomy for cancer ac-
cording to time interval: 1999–2001 (period 1), 2002–2004 (period 2), 2005–2007 (period 3) and 
2008–2010 (period 4). P <0·001 (overall, 2005–2007 versus 2008–2010, and 1999–2001 versus
2002–2004) (log rank test)
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fUTURE PERSPECTIvES
The rising incidence of adenocarcinoma in the West is impressive. If the yearly increase 
stays at the current level, the incidence of oesophageal cancer will potentially surpass that 
of colon cancer in the future. Much improvement has been achieved by oesophageal cancer 
research during the last decades. However, there are many remaining battles to win and 
some of these will be discussed in this chapter.
future perspectives on surgery
Although, also in the near future, surgical treatment will be the mainstay of treatment for po-
tentially curable disease, there will be further important advances in nonsurgical therapies. 
The direction will be towards organ-sparing options in situations where that is oncologically 
safe and appropriate.
Definitive chemoradiotherapy (dCRT) is expected to be increasingly performed, even 
in patients with resectable oesophageal cancer. Resection will then be only considered 
for incomplete responders or patients with local or regional recurrence. The trials by Stahl 
and Bedenne which compared dCRT versus neoadjuvant chemoradiotherapy (nCRT) plus 
surgery have already led to a paradigm shift in the management of squamous cell carcinoma 
in some countries [1,2]. In the future, this algorithm may also be applicable to patients with 
adenocarcinoma because of better nonsurgcial treatment regimens.
In the future, waiting a longer period after neoadjuvant therapy will be more frequently ap-
plied, thereby offering the possibility of patient recovery, increasing the chance of properly 
assessing a complete clinical response and, hence, a better patient selection for surgery.
Surgery might be increasingly regarded as ‘adjuvant’ to the other treatment strategies. 
Local recurrence is still not uncommon after dCRT, thus suggesting the potential need of 
‘salvage’ surgery in patients receiving this treatment. Previous studies have reported sal-
vage oesophagectomies to result in long-term survival in a subset of patients [3]. However, 
the data are ambiguous regarding the mortality, morbidity, and length of hospital stay after 
these procedures. Future research should be devoted to salvage oesophagectomies in or-
der to obtain more evidence on surgical and oncological safety.
Without doubt, minimally invasive surgery will further evolve, which has been proven to be 
superior to open surgery regarding postoperative pulmonary complication rate, short-term 
quality of life [4] with comparable short-term oncological outcome parameters. Besides the 
need for studies reporting long-term outcomes of minimally invasive surgery, there are some 
other important questions to answer in the future. The future surgical debate will focus on 
the best technique, which will probably be a composition of different ingredients: minimally 
invasive versus transhiatal versus open oesophagectomy, regional lymph node sampling ver-
sus en bloc radical lymphadenectomy, and intrathoracic versus cervical oesophagogastric 
anastomoses. Evolving technology might allow image-guided surgery and also identification 
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of involved nodal groups.
Based on this thesis, an extended lymphadenectomy after neoadjuvant chemoradi-
otherapy (nCRT) is debatable, but further adequately powered large RCTs are needed 
to determine the appropriate extent of a lymphadenectomy during potentially curative oe-
sophagectomy after neoadjuvant treatment. It is an interesting discussion what the exact 
role is of minimally invasive surgery if a transhiatal approach with a limited mediastinal lymph 
node harvest is really sufficient after nCRT. However, when an intrathoracic oesophagogas-
tric anastomosis is preferred over a cervical anastomosis, a thoracoscopy/-tomy will still be 
indespensible. 
future perspectives on staging
Despite currently available techniques to stage oesophageal cancer (e.g. EUS, PET/CT), 
there is still a need for better patient selection. Especially better re-staging techniques after 
or during neoadjuvant therapy are needed in the future.  With the implementation of neoad-
juvant treatment, the traditional prognostic factors including tumour stage and grade have 
become less powerful as they change because of the therapy. It is increasingly evident that 
residual cancer present in the resected surgical specimen (especially in the removed lymph 
nodes) after preoperative therapy (particularly CRT) is the main determinant of the patient’s 
long-term outcome. The key issue of prognosis will therefore be response prediction. With 
future metabolic and target-specific imaging, tumour biology will be monitored during treat-
ment and patients will be categorized in a clinically more relevant manner than nowadays, 
i.e. based on the therapy that is likely to be effective, thus avoiding ineffective, toxic and 
expensive treatments. 
The conventional diagnostic modalities have their limitations in response prediction. 
EUS is limited by no-pass (due to tumour stenosis) in some patients and EUS-FNA is difficult 
to distinguish tumour from fibrosis. CT imaging has difficulties in distinguishing between 
viable tumour and treatment induced inflammatory tissue and fibrosis. However, the tech-
nical developments in serial PET scanning are particularly interesting because they also 
provide characteristics of the clinical biology of oesophageal cancer undergoing therapy. 
More research is needed before restaging with PET allows for treatment decisions e.g. on 
an organ-preserving strategy versus discontinuation of neoadjuvant therapy and proceeding 
to surgery. Several studies have already demonstrated that PET/CT may be more accurate 
than EUS-FNA and CT alone in the evaluation of therapeutic response to neoadjuvant CRT 
and the detection of residual tumour deposits [5, 6, 7]. Therefore, in the future, PET/CT will 
gain influence in initial staging because adequate comparison with a pretreatment PET/CT 
will be important for proper assessment of therapeutic response after CRT.
There are also new developments in the imaging quality of MRI suggesting a more im-
portant role in staging and restaging in the future. Recent pilot studies showed that functional 
MRI techniques might compensate for the limitations inherent to other imaging devices [8]. 
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Biological parameters will be also involved in the future of response prediction, adding 
power to conventional predictive modalities. Although some biomarkers are associated with 
pathologic response, currently these are not yet well established, especially because their 
specificity is too low for clinical implementation [9]. In the future, the combination of bio-
markers and tumour genetic profiles will reveal a better prediction of oncological outcome. 
Microarrays for gene expression will disclose important prognostic information.
Until now, there is insufficient evidence to allow for individualized selective lymphadenec-
tomy and sentinel lymph node navigation in oesophageal surgery. Although sentinel node 
navigation surgery is feasible, its application in the gastrointestinal tract is still controversial 
[10]. However, innovation including the development of new tracers can be expected which 
may improve the accuracy and reliability of SLN mapping in oesophageal cancer in the 
future. Since the magnitude of the operative insult experienced during a systematic lymphad-
enectomy is considerable, the introduction of sentinel node navigation surgery could thus 
reduce the mortality and morbidity in patients undergoing an oesophagectomy and preserve 
the patients’ quality of life.
Currently, the 8th edition of the Union for International Cancer Control – American Joint 
Committee on Cancer (UICC-AJCC) tumour, node, metastases (TNM) staging system is 
developed to provide an even more accurate staging system. The current 7th edition is 
based on data from patients treated with surgery alone. Response to neoadjuvant therapy 
should clearly be incorporated in the next edition. Based on the results of this thesis, re-in-
troduction of the location of nodal involvement in the staging system might be considered.
future perspectives on survival
Prevention of oesophageal cancer is of paramount importance. Better understanding on the 
specific causes underlying the development of especially adenocarcinoma will fuel preven-
tive strategies. In the first place, there is a great need to stop the obesity epidemic, which 
has been strongly related to developing oesophageal cancer [11].
Oesophageal cancer is commonly diagnosed at an advanced stage, resulting in poor prog-
nosis. Early detection offers possibilities to intervene in the disease progression at an earlier 
stage. More research should be devoted to improve surveillance of patients with Barrett’s 
metaplasia including individual risk stratification. Molecular studies are promising and vari-
ous genetic polymorphisms have already been identified [12].
Future improvements in long-term survival in oesophageal cancer can be expected from 
more sophisticated neoadjuvant and adjuvant treatment regimens. The results of the 
CROSS trial are consistent with a model in which systemic therapy reduces the risk of 
distant metastases, and combined CRT improves locoregional control, further increasing 
cure rate by reducing the risk of recurrence in patients without systemic disease, and by 
209846-L-bw-Talsma
145
Future perspectives
8
eliminating residual primary tumour cells as a source of potential subsequent dissemination 
[13]. The approach taken in the CROSS trial emphasizes the importance of controlling both 
systemic and locoregional disease. Further improvements are still desperately needed and 
may result from identifying molecular subtypes that are sensitive to targeted agents such 
as antibody and small molecule kinase inhibitors or immune modulators. Exploring individ-
ualized multimodal treatment is clearly the most promising strategy for further improving 
outcome of oesophageal cancer therapy.
Future research projects should also be devoted to the differences between squamous cell 
carcinoma (SCC) and adenocarcinoma (AC). Long-term survival rates between the two 
subtypes differ because of different responses to neoadjuvant therapy. For example, defin-
itive chemoradiotherapy is considered as an alternative to surgery for SCC but not for AC. 
The future of neoadjuvant therapy may therefore include different treatment strategies for the 
two histological subtypes, which requires further investigation.
Further improvement can be expected from the spin-off of the molecular revolution. An 
increasing number of studies try to identify the pathways that are up- or downregulated in 
oesophageal cancer or during neoadjuvant therapy in order to manipulate these pathways 
in the future [14].
In future research projects, quality of life (QoL) should become a more important endpoint. 
The functional outcome after oesophagectomy has only recently begun to attract appro-
priate attention. The functional disturbances after oesophagectomy are measured in terms 
of dysphagia, regurgitation, early satiety, and dumping symptoms which may be profound. 
Improved tools for the assessment of quality of life and functional outcome are needed to 
define a “success” after oesophagectomy or chemoradiotherapy (CRT) [15, 16]. It is too 
simple to conclude that by definition organ-preservering treatment strategies inherently offer 
a better quality of life when compared to surgical modalities. A recent study showed that 
oesophagectomy and definitive CRT provided comparable functional results at 24 months of 
follow-up, except for progressive decline in pulmonary function in the CRT group, likely the 
result of radiation pneumonitis [17].
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EnGlISh SUmmARy
This thesis includes studies that investigate different aspects of oesophageal cancer: surgical 
treatment, staging and survival after surgery. It is subdivided in three parts: Goals of surgical 
therapy for oesophageal cancer (Part I), Aspects of staging of oesophageal cancer based 
on lymph node involvement (Part II) and Aspects of survival in oesophageal surgery (Part III).
PART I: GOAlS Of SURGICAl ThERAPy fOR OESOPhAGEAl CAnCER
The treatment of patients with oesophageal cancer is complex and demands a multidiscipli-
nary approach, in which potential treatment strategies are tailored to the individual patient. 
Surgery is still the cornerstone of potentially curative treatment. Nevertheless, less than half 
of the patients actually can be offered surgical treatment. In the remaining patients surgery 
is futile at first presentation because of concurrent distant metastases.
Oesophagectomy is probably one of the most challenging procedures in surgery. Chapter 
2 covers the main goals that have been defined for ‘open’ oesophagectomy and are also ap-
plicable to the increasingly used minimally invasive oesophagectomy. The following issues 
are highlighted: resection margin involvement, pros and cons of limited versus extended 
lymphadenectomy, restoration of gastrointestinal continuity, morbidity and mortality. The im-
portance of auditing surgical quality is underlined. 
Special attention is paid to the role of lymphadenectomy as an introduction to the 
following chapters of the thesis. Although a transthoracic surgical approach is associated 
with an increased number of lymph nodes in the surgico-pathological specimen - which has 
previously been related to better survival in literature - a benefit of a transthoracic approach 
over a transhiatal approach has not unequivocally been shown in trials and reviews.
Finally, in chapter 2 a paragraph has been devoted to definitive chemoradiotherapy as 
an alternative for potentially curative resection.
PART II: ASPECTS Of STAGInG Of OESOPhAGEAl CAnCER bASEd On lymPh 
nOdE InvOlvEmEnT
Oesophageal cancer is an aggressive disease with a dismal prognosis. Five-year survival for 
the whole population with newly diagnosed oesophageal cancer is around 10%. The poor 
prognosis is related to the advanced stage of disease at presentation. Accurate staging of 
tumour extension is essential, not only locally (through the wall of the oesophagus) but also 
regionally (in the lymph nodes surrounding the oesophagus) and distantly (spread to other 
organs). Traditionally, staging of malignant tumours is based on the Tumour, Nodes, Metas-
tases (TNM-) classification.
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Preoperative clinical staging, which frequently encompasses a combination of investigations 
including endoscopy, endoscopic ultrasonography and (PET-)CT scanning, can detect that 
there are distant metastases making surgery futile. On the other hand clinical staging can 
also show that the disease is at a very early stage, which can potentially be cured by an 
endoscopic organ-preserving resection. 
In chapter 3 two research questions are addressed. In the first place, it was investi-
gated whether clinical staging could actually predict patients’ prognosis. A study population 
of 102 patients from Rotterdam and Cambridge was clinically staged by endoscopic ultra-
sonography (EUS). It was shown that EUS could identify lymph node metastases as well as 
their location (esp. whether the involved lymph nodes were located above, below or on both 
sides of the diaphragm). Moreover, it was pointed out that involved metastases identified on 
both sides of the diaphragm were associated with a relatively poor prognosis compared to 
patients in whom EUS had not identified involved lymph nodes or only at one side of the di-
aphragm. These results showed that preoperative EUS is valuable in the decision to embark 
upon a surgical resection or to choose for a palliative treatment instead.
Secondly, it was evaluated whether this prognostic impact of distribution of involved 
nodes relative to the diaphragm also exists when determined in the resected specimen as 
assessed by the pathologist (pathological staging). Some 327 patients who had undergone 
oesophagectomy for cancer were included, their pathology reports reviewed (including the 
location of lymph node involvement) and subsequently related to long-term survival. With 
this analysis it was shown that a combined staging system that incorporates both number 
and distribution of lymph nodes relative to the diaphragm refines prognostication after oe-
sophagectomy. This conclusion has the opportunity to counsel patients about their progno-
sis more precisely.
In the previous 6th edition of the TNM staging system (TNM6) no distinction was made 
between distant organ metastases and ‘non-regional’ lymph node metastases (e.g. celiac 
node involvement), which were both categorized as being M1. The exact definition of region-
al and non-regional was unclear and this principle has been abandoned in the most recent 
7th edition of the TNM staging system (TNM7). Furthermore TNM7 has acknowledged the 
importance of the number of involved nodes by subdividing the N-classification into N0 
to N3. The new staging system was built on data from thousands of oesophageal cancer 
patients in whom squamous cell carcinoma was predominant and surgical approach was 
most frequently transthoracic. In Chapter 4 the validation of TNM 7 is described in a Rot-
terdam cohort of 358 adenocarcinomas who underwent a transhiatal approach. This study 
indicated that the application of the 7th TNM staging system results in a better prognostic 
stratification of overall survival compared to the 6th edition. The fact that TNM7 also had 
a superior prognostic ability in this study population from a single high-volume institution 
with predominantly adenocarcinomas and a transhiatal approach supports its generaliza-
bility for different oesophageal cancer practices. Although patients underwent a transhiatal 
oesophagectomy with a modest lymph node harvest (median 11), the survival curves of the 
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different N-stages did not overlap in these data, which probably indicated that the lymph 
node sampling was valid and robust. Finally, it was concluded that patients with ‘non-region-
al’ lymph node metastases had a dismal prognosis, but still significantly better than patients 
with distant metastases.
During recent years it has been generally accepted that, in case of locally advanced dis-
ease, surgery alone is not able to cure the patient but should be accompanied by other mo-
dalities such as chemotherapy and radiotherapy. The Dutch randomised controlled CROSS 
trial showed that a multimodality treatment including surgery after neoadjuvant chemoradi-
otherapy increases long-term survival. A considerable percentage of patients even showed 
a pathologically complete response and a beneficial impact on lymph node metastases was 
also shown: more than half of the patients with involved lymph nodes in the surgery-alone 
arm could be nodally ‘sterilised’ by chemoradiotherapy. In Chapter 5 a study is described 
that was based upon the CROSS trial database. In this study, the positive impact of an 
extended lymphadenectomy on survival, as shown by other studies, could be reproduced 
for patients who underwent surgery alone. However, in the patients who underwent surgery 
after neoadjuvant chemoradiotherapy, the number of resected nodes was not associated 
with survival. These data question the indication for maximisation of lymoh node dissection 
after chemoradiotherapy for staging purposes as well as for therapeutic reasons. Whether 
a transhiatal approach suffices after chemoradiotherapy needs to be further investigated.
PART III: ASPECTS Of SURvIvAl In OESOPhAGEAl SURGERy
Resection of the oesophagus is associated with a relative high morbidity and even mortal-
ity. There is an increasing interest in performance indicators as instruments for comparing 
quality of care between institutions. The performance indicator that was studied in chapter 
6 is postoperative mortality. The medical files of patients who underwent oesophagectomy 
between 1991 and 2011 were reviewed and the patients were identified who died within 1 
year after surgery. Subsequently, the complication was chosen that contributed most to the 
patient’s death. This study shows that a substantial number of deaths after the traditional 
cut-off of 30 days after surgery could still be related to complications related to the proce-
dure such as anastomotic leakage and ‘sudden death’. On the other hand, extending the 
follow-up beyond 90 days after surgery resulted mainly in the inclusion of more patients who 
died of recurrent disease as opposed to medical or technical complications related to sur-
gery. Of course the early (surgery-related) as well as the late (oncological) outcomes are im-
portant when comparing quality of care. One of the conclusions was that it would be helpful 
if hospital performance in oesophageal surgery would include 90-day mortality along with 
1-year survival, thus reflecting the quality of both the diagnostic and the therapeutic process.
Although long-term survival for oesophageal cancer has improved during the past dec-
ades, surgery still does not guarantee survival and 5-year survival rarely exceeds 40%. 
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In Chapter 7 a study is described based on oesophageal cancer patients from the Dutch 
Cancer Registry between 1999 and 2010. A rise in the number of surgical resection, as has 
been shown in various cancer registries worldwide, was also reported in this study with an 
almost two-fold rise during the study period. Furthermore, the study confirmed a significant 
increase in long-term survival, especially between periods 1999-2001 and 2002-2004 and 
again between periods 2005-2007 and 2008-2010. The factors explaining these trends 
were investigated. Although a better survival was reported in academic and non-academ-
ic teaching hospitals as compared to non-teaching hospitals, centralisation of this type of 
surgery could not explain the improved prognosis. The increase in the number of transtho-
racic surgical approaches could neither account for it. The main conclusion was that the 
most recent improvement in survival could particularly be explained by the introduction of 
neoadjuvant chemoradiotherapy. Finally, the main conclusions of the randomised CROSS 
trial (i.e. the high proportion of patients with pathologically complete response and the rise 
in the microscopically radical resection rate) were corroborated in this national database on 
population-based level.
In Chapter 8 the most important future perspectives are described in view of the pre-
vious chapters.
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SUmmARy In dUTCh (nEdERlAndSE SAmEnvATTInG)
Dit proefschrift omvat onderzoeken die verschillende aspecten van slokdarmkanker be-
lichten: de chirurgische behandeling van de ziekte, de stadiëring en de overleving na een 
operatie. Het proefschrift bestaat uit drie delen: Deel 1 – Eindpunten van chirurgische be-
handeling van slokdarmkanker, Deel 2 - de stadiëring op basis van lymfekliermetastasen bij 
slokdarmkanker, en Deel 3 - overleving na een operatie voor slokdarmkanker.
dEEl 1 : EInddOElEn vAn ChIRURGISChE bEhAndElInG vAn SlOKdARmKAnKER
De behandeling van patiënten met slokdarmkanker is complex en vereist een multidiscipli-
naire aanpak, waarbij behandelingsstrategieën in toenemende mate zijn gericht op de indi-
viduele patiënt. Een operatieve ingreep blijft de belangrijkste pijler binnen de behandeling. 
Echter, van de patiënten bij wie de diagnose slokdarmkanker wordt gesteld, komt slechts 
minder dan de helft in aanmerking voor een behandeling waarbij genezing kan worden ver-
wacht. Een resectie van de slokdarm is alleen zinvol indien deze in opzet curatief kan zijn en 
er geen sprake is van ‘metastasen op afstand’. 
De slokdarmresectie wordt beschouwd als een van de meest uitdagende operaties voor de 
ervaren chirurg. In hoofdstuk 2 worden de belangrijkste einddoelen besproken zoals deze 
in de literatuur geformuleerd zijn voor de conventionele open slokdarmresectie, maar die 
feitelijk ook gelden voor de steeds frequenter toegepaste minimaal-invasieve slokdarmre-
sectie. Aan de orde komt het wetenschappelijk bewijs voor achtereenvolgens : het belang 
van tumorvrije chirurgische snijvlakken, de keuze voor een beperkte of juist meer uitgebreide 
lymfeklierdissectie, continuïteitsherstel van het spijsverteringskanaal en het beperken van 
postoperatieve complicaties en sterfte. 
De paragrafen over lymfeklierdissectie en chirurgische benadering zijn relatief uitge-
breid in hoofdstuk 2 als inleiding op de hierna volgende hoofdstukken. Een gecombineerde 
thoracale en abdominale benadering van de slokdarm resulteert in het algemeen in het hoog-
ste aantal lymfeklieren in het uiteindelijke operatie preparaat zoals beoordeeld door de patho-
loog, omdat hierbij ook de lymfeklierstations hoog in de thorax (=borstholte) kunnen worden 
verwijderd. In de literatuur is een hoger aantal verwijderde lymfeklieren in verband gebracht 
met een verbeterde overleving. Er is echter nooit een duidelijk voordeel onomstotelijk aange-
toond van een gecombineerde ten opzichte van een uitsluitend abdominale benadering. In 
meerdere onderzoeken werd geen verschil in overleving op lange termijn gevonden. 
Er is een aanzienlijke kans op complicaties en zelfs sterfte na een slokdarmresectie. 
Het belang van kwaliteitsregistraties wordt hierbij onderstreept. De relatief hoge morbiditeit 
en mortaliteit kunnen o.a. worden teruggevoerd op de anatomische ligging van de slokdarm 
naast de vitale structuren in de hals, de borstholte en buik (abdomen). Een operatie vanwe-
ge een slokdarmtumor wordt dan ook vaak uitgevoerd in minstens twee van deze gebieden, 
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afhankelijk van de lokalisatie van de tumor en de conditie van de patiënt. Soms kan de meer 
kwetsbare patiënt een ingrijpende toegang via de zijkant van de (rechter) borstholte worden 
bespaard door vanuit de buik het thoracaal gelegen deel van de slokdarm los te maken. 
Een thoracale benadering daarentegen biedt een beter zicht op de structuren, die ‘scherp’ 
van de slokdarm kunnen worden losgemaakt. Uiteraard dient na verwijdering van vrijwel 
de gehele slokdarm de continuïteit van het spijsverteringskanaal te worden hersteld. Vaak 
geschiedt dit met behulp van de zogenaamde ‘buismaag’ die met een naad wordt aangeslo-
ten op de resterende slokdarm hoog in de thorax of laag in de hals. O.a. vanwege de vaak 
gecompromitteerde bloedvoorziening in de top van de buismaag bestaat er ter plaatse van 
deze naad een risico op lekkage met grote negatieve gevolgen.
Tot slot is in hoofdstuk 2 een paragraaf gewijd aan definitieve chemoradiotherapie, die 
in sommige landen wordt beschouwd als een alternatief voor chirurgie maar in Nederland 
alleen wordt toegepast bij patiënten die te kwetsbaar zijn voor een operatie.
dEEl 2 : STAdIëRInG vAn lymfEKlIER mETASTASEn bIj SlOKdARmKAnKER
Slokdarmkanker is een agressieve ziekte met een slechte prognose. Voor de gehele popu-
latie patiënten die zich presenteert met een slokdarmtumor is de 5-jaarsoverleving ongeveer 
10%. De slechte prognose hangt samen met het gevorderde stadium waarin de tumor zich 
bevindt op het moment dat de patiënt zich presenteert met klachten van de  tumor, met 
name een bemoeilijkte passage van voedsel. Reeds in een vroeg stadium van de ziekte kan 
slokdarmkanker aanleiding geven tot uitzaaiingen (zgn. ‘metastasen’) naar plaatsen elders in 
het lichaam, bijvoorbeeld lymfeklieren of lever. Nauwgezette stadiëring van tumoruitbreiding, 
zowel lokaal (in de wand van de slokdarm) als regionaal (in de lymfeklieren in de nabijheid 
van de slokdarm) en op afstand (naar andere organen) is essentieel, omdat het ziektestadi-
um niet alleen de prognose maar ook de behandelingsstrategie sterk beinvloedt.
Onder “klinische stadiëring” wordt verstaan de serie onderzoeken (vaak een combi-
natie van endoscopie, endoscopische echografie en (PET-)CT onderzoek) die plaatsvindt 
vòòr de behandeling op basis waarvan wordt bepaald wat de juiste behandeling is voor de 
individuele patiënt. Stadiëring kan bijvoorbeeld uitwijzen dat er sprake is van metastasen 
in andere organen. In dat geval hebben patiënten geen baat bij een operatie. Resectie 
van de slokdarm wordt immers niet beschouwd als een adequate palliatieve behandeling. 
Anderzijds kan geconstateerd worden dat er sprake is van een zeer vroeg stadium van 
slokdarmcarcinoom, waardoor het potentieel curatief behandeld zou kunnen worden met 
endoscopische orgaan-sparende resectie. Traditioneel worden kwaadaardige tumoren ge-
stadieerd volgens de zogenaamde TNM classificatie. Het T(umor)-stadium representeert de 
diepte ingroei van de tumor in de wand van de slokdarm, het N(ode)-stadium representeert 
het aantal betrokken lymfeklieren en het M(etastase)-stadium representeert de aan- of afwe-
zigheid van metastasen op afstand. Het TNM stadium dat gebaseerd is op de preoperatieve 
stadiëring wordt aangegeven met het c(linical)TNM stadium. 
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In hoofdstuk 3 worden twee onderzoeksvragen behandeld. In de eerste plaats is 
onderzocht of klinische stadiëring daadwerkelijk in staat is de prognose van patiënten te 
voorspellen. Bij 102 patiënten uit Rotterdam en Cambridge werd onderzocht of er sprake 
was van lymfekliermetastasen middels een preoperatieve echografie vanuit het lumen van 
de slokdarm (endoscopische ultrasonografie; EUS), waarmee de wand van de slokdarm 
alsmede de lymfeklieren om de slokdarm heen kunnen worden beoordeeld. EUS bleek in 
staat te zijn om uitzaaiingen van het slokdarmcarcinoom aan te tonen in lymfeklieren aan bei-
de zijden van het middenrif. Bovendien bleek dit van voorspellende waarde te zijn voor een 
relatief korte overleving ten opzichte van patiënten bij wie EUS had uitgewezen dat er geen 
lymfekliermetastasen waren of ‘slechts’ aan één zijde van het middenrif. Dit betekent dat de 
EUS resultaten meegewogen kunnen worden bij de beslissing af te zien van een operatie en 
te kiezen voor een palliatieve behandeling.
Ten tweede werd onderzocht of deze prognostische betekenis van de verdeling van 
lymfekliermetastasen ten opzichte van het middenrif ook geldt bij onderzoek van het weef-
selpreparaat dat uiteindelijk na de operatie is verkregen (bestaande uit slokdarm, het boven-
ste deel van de maag en de omgevende lymfeklieren). Het bepalen van de tumor uitbreiding 
op basis van macroscopie en microscopie door de patholoog wordt “histopathologische 
stadiëring” genoemd. Deze wordt geclassificeerd volgens het p(athological)TNM stadium. 
Uit de pathologie verslagen van 327 patiënten werden zowel de lokalisatie als het aantal 
aangedane lymfeklieren geïnventariseerd en gerelateerd aan de overleving op lange termijn. 
Op deze manier kon worden aangetoond dat de ligging van de aangedane lymfeklieren ten 
opzichte van het middenrif prognostische informatie toevoegt aan de informatie betreffende 
het aantal aangedane lymfeklieren. Dit biedt de mogelijkheid de patiënt meer betrouwbaar 
te informeren over zijn of haar prognose. 
Het N-stadium wordt bepaald door lymfeklieruitzaaiingen die aanwezig kunnen zijn niet al-
leen in de buurt (‘regionaal’), maar ook op afstand van de tumor (‘niet-regionaal’). Voorheen 
werd ervan uitgegaan dat lymfeklieruitzaaiingen op ruimere afstand van de primaire tumor 
net zo’n slechte prognose hebben als orgaanmetastasen. In de 6e editie van de TNM clas-
sificatie (TNM 6) werd bijvoorbeeld geen onderscheid gemaakt tussen een levermetasta-
se of een ‘niet-regionale’ lymfeklier metastase – beide werden gestageerd als M1. Waar 
de grens lag tussen regionale metastasen en afstandsmetastasen voor lymfeklieren was 
echter niet erg duidelijk. Dit principe van ‘niet-regionale’ lymfeklieren is in de 7e editie van 
de TNM classificatie (TNM 7) verlaten. Bovendien is het N-stadium niet langer dichotoom 
(N0/N1), maar gebaseerd op het aantal gevonden lymfekliermetastasen (N0, N1, N2, N3). 
Deze meest recente editie is gebaseerd op een mondiaal bestand van duizenden slokdarm-
kanker patiënten, voor een belangrijk deel met plaveiselcelcarcinomen die transthoracaal 
werden verwijderd. De vraag was of deze resultaten konden worden gegeneraliseerd naar 
de Nederlandse situatie. hoofdstuk 4 beschrijft de validatie van TNM 7 in een Rotterdams 
cohort van 358 adenocarcinomen die uitsluitend transhiataal werden geopereerd. Ook in 
dit cohort bleek dat de overleving op lange termijn nauwkeuriger werd voorspeld door TNM 
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7 dan door de vorige TNM 6, hetgeen de generaliseerbaarheid onderstreept van de nieuwe 
editie van de TNM classificatie voor verschillende praktijkvoeringen wereldwijd. Ondanks 
het feit dat alle patiënten een transhiatale benadering ondergingen, met een relatief lage 
lymfeklieropbrengst, overlapten de overlevingscurves van N0, N1, N2 en N3 elkaar niet, 
waaruit de robuuste lymfeklierstadiëring van deze benadering blijkt. Bovendien kon worden 
geconcludeerd dat patiënten met ‘niet-regionale’ lymfeklieren weliswaar een slechte prog-
nose hebben, maar dat bij deze patiënten de overleving echter wel significant beter is dan 
bij patiënten met metastasen op afstand. 
In het algemeen wordt aangenomen dat als er sprake is van voortgeschreden ziekte (waarbij 
de tumor al door alle wandlagen heen is gegroeid en/of er sprake is van uitgebreide lymfe-
kliermetastasering) chirurgie alleen vaak een onvoldoende behandeling is en gecombineerd 
dient te worden met andere modaliteiten zoals chemotherapie en radiotherapie. De his-
topathologische uitbreiding van de tumor die wordt vastgesteld in het operatiepreparaat na 
een dergelijke voorbehandeling wordt aangeduid met het ypTNM stadium. Het Nederlandse 
gerandomiseerde CROSS onderzoek heeft aangetoond dat, om de kans op overleving zo 
groot mogelijk te maken, een operatie dient voorafgegaan te worden door chemoradiatie. 
Niet alleen was er sprake van een complete tumor-respons bij een aanzienlijk percentage 
patiënten, ook bleek uit dit onderzoek het gunstige effect op lymfekliermetastasen: ten op-
zichte van de patiënten in de chirurgie-alleen arm werd bij de patiënten die eerst chemora-
diatie ondergingen vaker ‘sterilisatie’ bereikt van de aangedane lymfeklieren. In hoofdstuk 
5 wordt een onderzoek beschreven binnen de studiepopulatie van het CROSS onderzoek. 
Het positieve effect van uitgebreide lymfeklierdissecties, zoals dat in de literatuur is beschre-
ven kon inderdaad worden gereproduceerd bij patiënten die alleen een operatie ondergin-
gen. Maar er was geen relatie tussen het aantal verwijderde lymfeklieren en de overleving 
bij de 159 patiënten die een gecombineerde behandeling ondergingen van chemoradiatie 
plus een operatie. De noodzaak van uitgebreide lymfeklierdissecties nà chemoradiatie is 
derhalve twijfelachtig geworden. Of dit ook betekent dat een transhiatale benadering na 
chemoradiatie volstaat dient verder te worden onderzocht.
dEEl 3 : OvERlEvInG nA EEn OPERATIE vOOR SlOKdARmKAnKER
Een slokdarm resectie heeft een aanzienlijk risisco op postoperatieve morbiditeit en zelfs 
mortaliteit. Om dergelijke zorguitkomsten tussen ziekenhuizen te kunnen vergelijken is er 
een toenemende interesse in zgn. prestatie indicatoren. De prestatie indicator die wordt 
beschreven in hoofdstuk 6 is postoperatieve sterfte. Van 1282 patiënten die tussen 1991 en 
2011 werden geopereerd werden naast de overlijdensdatum ook de specifieke doodsoor-
zaken gescoord. Een aanzienlijk deel van de overleden patiënten overleden na het traditio-
nele afkappunt van 30 dagen na de operatie, terwijl de doodsoorzaak desondanks nog wel 
moest worden toegeschreven aan een complicatie van de operatie, zoals een naadlekkage 
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of aan ‘sudden death’. Voor de definitie van postoperatieve sterfte bleek het meer valide te 
zijn om een tijdsperiode te gebruiken van 90 dagen in plaats van 30 dagen na de operatie. 
Overigens waren er geen verschillen tussen de voorspellende factoren van 30-dagen en 
90-dagen mortaliteit. Na het verstrijken van de 90-dagen periode werd het grootste aan-
deel van de sterfte verklaard door oncologische oorzaken, d.w.z. terugkeer van de ziekte. 
Uiteraard zijn zowel de vroege (operatie-gerelateerde) als de late (oncologische) uitkomsten 
beide van belang voor de vergelijking van de kwaliteit van zorg tussen ziekenhuizen. Het 
lijkt dan ook aangewezen bij kwaliteitsregistraties een combinatie van 90-dagen en 1-jaars 
mortaliteit in ogenschouw te nemen.
Hoewel de langetermijnoverleving voor slokdarmkanker door de jaren is toegenomen, biedt 
een operatie nog altijd geen garantie op genezing. De 5-jaars overleving na een in opzet 
curatieve slokdarmresectie is zelden hoger dan 40%. In hoofdstuk 7 wordt een onderzoek 
van slokdarmkanker patiënten beschreven uit de Nederlandse Kanker Registratie tussen 
1999 en 2010. Een toename in de incidentie (het aantal nieuwe gevallen per jaar) van het 
slokdarmcarcinoom, zoals deze door kankerregistraties over de gehele wereld wordt ge-
rapporteerd, werd ook in dit databestand gezien met een verdubbeling van het aantal slok-
darmresecties gedurende de onderzoeksperiode. Er bleek sprake van een verbetering in de 
overleving, met name tussen de periodes 1999-2001 en 2002-2004 en opnieuw tussen de 
periodes 2005-2007 en 2008-2010. De verklarende factoren voor deze verbeteringen wer-
den geanalyseerd. Hoewel in academische- en niet-academische opleidingsziekenhuizen 
een betere overleving werd gezien in vergelijking met niet-opleidingsziekenhuizen, kon de 
centralisatie van zorg de verbeterde overleving niet verklaren. Ook de toename in het aantal 
transthoracale chirurgische benaderingen was een onvoldoende verklaring. De meest re-
cente verbetering in prognose werd vooral verklaard door de introductie van neoadjuvante 
chemoradiatie. De belangrijkste resultaten van het gerandomiseerde CROSS onderzoek, 
waaronder het percentage patiënten met een complete pathologische respons en met een 
radicale resectie, konden in dit landelijke onderzoek op populatie niveau worden gerepro-
duceerd.
In hoofdstuk 8 worden de belangrijkste toekomstperspectieven geschetst in het licht 
van de beschreven onderzoeken.
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Dankwoord
Een proefschrift is geen solo actie. Veel mensen ben ik dank verschuldigd. Ze hebben mij 
op het goede spoor gezet of op het spoor gehouden. Ik moest slechts het zitvlees kweken.
Allereerst : lieve jobke. De Benedictijnen onderscheiden de kunst van beginnen en de kunst 
van ophouden.  Beide zijn nodig om een taak af te ronden. Beginnen is lastig maar goed te 
doen. Jij leerde mij de kunst van het ophouden. 
Prof. dr. j.j.b. van lanschot. U heeft mij in de gelegenheid gesteld dit proefschrift te schrij-
ven. Vierdejaars assistent inmiddels als mijn sein gaat : van Lanschot - of ik niet eens wat 
onderzoek moest gaan doen. Ik denk met plezier aan onze inspirerende ontmoetingen. Na 
een kliniek dag, soms zelfs dwars door Rotterdam: nog even snel naar 8-Zuid. Uw commen-
taar was altijd goed voorbereid zodat ik weer wijzer wegging. Onze samenwerking verliep 
gemakkelijk en bleek vruchtbaar. Dankzij uw ervaring en scherpe kritiek bleef het tempo 
erin. Schrijven is immers schrappen. U leerde mij de woorden van Blaise Pascal : “Ik schrijf 
je een lange brief, want ik heb geen tijd voor een korte.” Ik heb het als een voorrecht ervaren 
uw promovendus te zijn.
dr. b.P.l. wijnhoven. Beste Bas, je bent heel belangrijk geweest voor dit proefschrift. Je 
bezieling voor wetenschappelijk onderzoek is erg groot. Bovendien ben je zeer toegankelijk 
en geestig. Sterk in de kliniek, sterk in onderzoek en sterk op de operatiekamer. Rotterdam 
boft met zo’n opleider!
De leden van de promotie commissie dank ik voor hun bereidheid het proefschrift op zijn 
wetenschappelijke waarde te beoordelen.
Prof. dr. E.w. Steyerberg. Beste Ewout. Dank voor je scherpe vragen. Wat heb jij een talent 
om snel de quintessence van een onderzoek op te pikken.
Prof. dr. j. Plukker. Beste John, in een korte tijd heb ik veel van je geleerd in Groningen. 
Jouw ervaring is om jaloers op te zijn. Dank voor je komst naar Rotterdam.
Prof.dr. m.bruno, Prof. dr. v. lemmens, beste professoren, veel dank voor uw aanwezig-
heid en het beoordelen van mijn proefschrift.
Prof. dr. j.P.P. Pierie. Beste Pier, dank voor je aanwezigheid vandaag. Wat een voorrecht na 
veel met jou te hebben geopereerd, dat je nu vandaag plaats wilt nemen in de commissie. Ik 
heb veel van je opgestoken en je operatie-beeldspraak gaat nog dagelijks door mijn hoofd 
(‘valse verklevingen’, ‘omgekeerde embryogenese’, ‘chinees poppetje’, ‘bal in de regenpijp’ 
... en ga zo maar door).
Prof. dr. S. Griffin, Dear professor, I am very honoured that you were willing to come from 
Newcastle, UK, to Rotterdam to be a member of the committee.
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Dank ben ik ook verschuldigd aan alle patienten en familieleden die hebben meegwerkt 
aan de verschillende studies.
In het bijzonder wil ik bedanken : mijn voorgangers en mede-onderzoekers.  
Pieter van hagen, jij hebt me wegwijs gemaakt terwijl je het zelf ook vaak druk had. Je hebt 
veel talenten. Veel geluk in het vak!
joel Shapiro. Wie lost het slokdarm mysterie op? Zijn ‘de ringen van Shapiro’ misschien het 
begin van de oplossing ? Ik heb erg genoten van onze momenten puzzelen. Wat zaten we 
met rooie oortjes te luisteren naar de Europese crème de la crème in Athene. In het begin 
was het een beetje ‘de lamme helpt de blinde’, maar inmiddels weten we echt wel wat en 
zijn onze boekjes (bijna) af. Succes met je opleiding!
Ronald damhuis. Dank voor de fijne samenwerking en je snelle feedback. Jouw jarenlange 
ervaring bij de Nederlandse Kanker registratie is onmisbaar geweest. 
hester lingsma en Caspar looman van de afdeling Public Health van het Erasmus MC. 
Dank voor jullie bereidheid iedere keer weer te kijken naar mijn data analyses. Ondanks 
ons nivo-verschil voor wat betreft de statistiek, slaagden jullie erin het voor mij begrijpelijk 
houden.
brechtje Grotenhuis. Ik ben jou veel dank verschuldigd voor je voor-werk in het slokdarm 
onderzoek. Met jouw drive heb je een mooie carriere voor de boeg!
Alle overige medeauteurs wil ik hierbij hartelijk bedanken. 
Prof. dr. h.w. Tilanus. Beste professor, u bent een ‘eminence grise’. Dank voor uw humor 
en uw advies om te starten met onderzoek. Bovendien stond u ooit aan de basis van de 
dabases met verzamelde slokdarmkankerpatienten. 
Verder ook dr. C. Rosman, dr. m.I. van berge henegouwen, dr. m.C.w. Spaander,  en de 
leden van de  CROSS-studie groep.
I would also like to thank the investigators of the MRC Cancer Unit in Cambridge UK,  pro-
fessor R.C. fitzgerald, dr. n.R. Carroll, dr. R.h. hardwick, johnny Ong and Xinxye liu, 
for a very fruitful collaboration. 
Eric van de Stok en Gijsber hötte, bedankt voor jullie inspanningen aan de EUS-studie. 
Veel succes met jullie verdere opleiding!
Secretaresses en datamanagers uit het Erasmus MC verdienen ook zeker een woord van 
dank, met name Conny vollebregt, Carola Zandijk en Conny van dooren.
mijn opleiders van het Ikazia Ziekenhuis, Maasstad Ziekenhuis, Erasmus MC, Medisch 
Centrum Leeuwarden (MCL) en UMCG Groningen dank ik voor hun tijdsinvestering in mijn 
opleiding. 
Beste dr Ted den hoed, je hebt mij op de juiste momenten scherp gemaakt en keuzes laten 
maken. 
Beste dr wibo weidema, chirurg en artiest, dank voor je humor en voorspraak voor mijn 
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opleidingsplaats.  
Beste dr wouter vles, dank dat je me kwam scouten bij de interne. Al snel volgde een korte, 
maar veelbetekenende sollicitatie bij jou en Wibo op de poli.  Mijn eerste publicatie was toch 
eigenlijk van ons samen.
Beste dr Erwin van der harst, je hebt me geleerd om op de details te letten. 
Beste dr Rene Klaassen, bij jou heb ik heel veel laparoscopische vaardigheden opgedaan. 
Bovendien hebben we veel plezier gehad.
Beste dr h.f. (/herman) veen. Bedankt voor de inspiratie om chirurg te worden. Uw en-
thousiasme voor het vak (en de dingen eromheen!) werkte aanstekelijk. De operatie kamer 
is een theater en opereren een voorstelling.
Beste gastro-enterologisch en bariatrisch chirurgen van het MCL: Pier, hoff, Koopal, ma-
nusama, Apers, Totte en Emous. Jullie hebben mij een prachtige vervolgopleiding gebo-
den!
Beste gastro-enterologisch chirurgen van het UMCG, beste ‘CAB’ers’. In het bijzonder dr 
Klaas havenga en dr Sijbrand hofker, dank voor jullie toegankelijkheid en inspanning om 
van mij een beter chirurg te maken. johan en joris, jullie boekje is niet ver weg
Oud-huisgenoten en bovenal vrienden. In het bijzonder joel versteeg, maarten van welie 
(wat is het heerlijk slapen als iemand elders in de kamer zit te typen hè?) en bart van Zijl . 
Jullie deden soms zelfs oprecht een poging de lijn van het onderzoek te volgen! Studiemaat 
maarten bijl, wij delen de nieuwsgierigheid en liefde voor het vak. 
Al mijn mede-(oud-)assistenten uit het Ikazia, Erasmus en Maasstad Ziekenhuis. Ik voelde 
me altijd thuis in de club en ging met plezier naar mijn werk. Dank voor de gezellige uren. 
Overdag, ‘s avonds en ‘s nachts.
wondcongres bestuur. “The Wound Congress”. Wat een heerlijke tijd hebben wij in Rotter-
dam gehad. Ontzettend veel gelachen. “VAC it !”.
Collega chirurgen en assistenten in het UmCG. Dank voor het warme nest in het hoge 
Noorden en de leerzame opleidingstijd.
Schoonouders, schoonzusjes, jaap, marijke, janine en Esther. Sorry voor de keren dat ik 
een deadline moest halen tijdens familiebezoek! 
familie, vrienden, collega’s en al de mensen die ik niet heb genoemd. Bedankt voor 
jullie meeleven!
Mijn zwagers en schoonzus: louis, Geran, maarten en janneke. Bedankt voor jullie ener-
gie, positiviteit en gastvrijheid. Ik bewonder wat jullie betekenen voor onze familie.
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mijn ouders. Ik dank jullie hartelijk voor jullie steun en liefdevolle opvoeding. Jullie hebben 
me nieuwsgierigheid en brede interesse bij gebracht. Mama had dit graag mee willen ma-
ken en zou trots zijn geweest (“Je hebt een helder verstand”). Papa, u heeft me geleerd hoe 
belangrijk het is om te blijven zitten, dan is het schrijven vanzelf eens klaar. 
Lieve broer en zussen. laura, henk, Gieneke en bertie. Jullie zijn heel bijzonder voor me. 
Wat heeft het leven veel in petto. Vette en magere jaren. Vandaag is het oogsten geblazen. 
Tenslotte, boven alles, lieve jobke. Het leven is lichter met jou. Nog vele jaren zo door! Met 
onze lieve Sil!
Koen
Groningen, najaar 2015
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Aaldert Konraad (Koen) Talsma werd 
geboren op 26 augustus 1980 als jong-
ste van vijf kinderen. Hij groeide op in 
de omgeving van de Utrechtse Heuvel-
rug en Gelderse Vallei in Veenendaal. 
In 1998 begon Koen aan de studie ge-
neeskunde aan de Erasmus Universiteit 
in Rotterdam. Hij verwierf tijdens zijn 
studie een Master of Science titel in de 
Klinische Epidemiologie door een oplei-
ding aan zowel het Netherlands Institute 
for Health Sciences (NIHES) en de Har-
vard School of Public Health, Boston 
VS. Het Rotterdams Bataafsch Genoot-
schap der Proefondervindelijke Wijsbe-
geerte verleende hem een studieprijs in 
2006. Na een senior co-schap Interne 
Geneeskunde werd hij arts-assistent 
chirurgie in het Ikazia Ziekenhuis, waar 
hij begon aan de opleiding tot chirurg in 
2007 (opleiders dr. W.F. Weidema and dr. P.T. den Hoed). Overige ziekenhuizen waar Koen 
werd opgeleid waren: Erasmus MC / Daniel den Hoed (opleiders: prof.dr. J.N.M. IJzermans 
en dr. B.P.L. Wijnhoven) en het Maasstad Ziekenhuis (opleiders: dr. E.W. van der Harst en 
dr. R. Klaassen). Tijdens zijn opleidingstijd begon hij aan het promotieonderzoek dat heeft 
geresulteerd in dit proefschrift onder supervisie van prof.dr.J.J.B. van Lanschot (promo-
tor) en dr. B.P.L.Wijnhoven (copromotor). Nadat Koen in oktober 2013 Koen gecertificeerd 
gastro-enterologisch chirurg werd, startte hij met het fellowship gastro-intestinale chirurgie 
in Leeuwarden (2014; MCL-opleider: prof.dr. J.P.E.N. Pierie) en Groningen (2015; UM-
CG-opleider: dr. K. Havenga). Koen is tevens lid van de hoofdredactie van het Nederlands 
Tijdschrift voor Heelkunde. Hij is getrouwd met Jobke Thesing en vader van een zoon Sil.
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Many improvements have been made in the treatment of oesophageal 
cancer. Surgical techniques have been refined, multimodality treat-
ment has become the standard of care and nationwide quality audits 
have been introduced. Nevertheless, there are some persevering chal-
lenges in the treatment of oesophageal cancer and its complications: 
1. with current staging modalities, even after radical surgery, many pa-
tients suffer from early recurrence (“challenge to stage”) ; 2. more than 
half of the patients who undergo surgery will still die from oesophageal 
cancer  (“challenge to cure”) ;  3. complications after surgery cannot 
always be treated early and appropriately (“challenge to rescue”) ; 4. 
surgery alone, without preceding neoadjuvant therapy, too often has 
the disadvantage of involved surgical resection margins (“challenge 
to resect”); 5. there is a striking rise in the incidence of oesophageal 
adenocarcinoma, especially in the Western hemisphere, which is only 
partly understood (“challenge to prevent”).
This thesis includes clinical studies that address these issues which 
are still present in treating this devastating disease.
Koen Talsma
2011-2015 Rotterdam, Leeuwarden, Groningen
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